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ABSTRACT
Cystic fibrosis (CF) is the most frequent disease inherited in an autosomal recessive fashion within
the Caucasian population. Though CF is considered to be a monogenic disorder transmitted by
lesions in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the disease severity
is characterised by a high degree of variability. This thesis reports on two studies addressing the
relative impact of the CFTR mutation genotype and other inherited factors on the course of CF
disease.
Patients participating in the study "rare genotypes and atypical CF" were recruited from the
Hannover clinic. A total of 19 patients were investigated by intestinal current measurements (ICM),
nasal potential difference measurement (NPD) and a pilocarpine iontophoresis sweat test to assess
the basic defect, being defined as an impaired CFTR transmitted Cl
¯
conductance. Mutation analysis
of the CFTR gene was done by single strand conformation polymorphism analysis, direct
sequencing and Southern blotting. The two deletions CFTRdelEx2 and CFTRdelEx2,3 were
identified by analysis of genomic DNA. Different residual Cl
¯
conductances, distinguishable by their
sensitivity to DIDS and cAMP, were seen by ICM in patients participating in the study "rare
genotypes and atypical CF" but pancreatic sufficiency was found to be associated with a residual
current indicative of CFTR mediated Cl
¯
conductance. The diagnosis of CF was confirmed by
investigation of the basic defect for three patients presenting CF symptoms but lacking evidence for
two CFTR disease causing lesions as judged by extensive mutation screening and, in two of these
cases, sustained by the family history or genetic analysis within the family.
In the "European CF twin and sibling study", disease severity and intrapair discordance for more
than 300 patient pairs was quantified by combining nutritional (weight for height %, wfh%) and
pulmonary (FEV1%pred percentiles, FEVPerc) status. A significantly higher concordance of
monozygous twins in wfh% and FEVPerc compared to dizygous patient pairs indicated the impact of
non-CFTR genetics on the CF disease phenotype. 38 patient pairs, selected due to an extreme
phenotype while being homozygous for the most frequent CF causing allele ∆F508, were analysed at
candidate gene loci. The typing of polymorphic markers employing multiwell PCR reactions and
continuous direct blotting electrophoresis was optimised. Significant association of an allele at the
marker locus D12S889 with a milder clinical phenotype was detected. Hence, SCNN1A, encoding
for the α-subunit of the amiloride-sensitive sodium channel (ENaC) and located near D12S889,
might modulate CF disease. The analysis of markers within the CFTR linkage group pointed to the
existence of hitchhiking genes which modulate the course of CF disease and thus might be
responsible for a heterozygote advantage among CF carriers. A significant influence on wfh% was
detected at MetH and at D7S495 due to an association of alleles at these loci with a milder
phenotype. Candidate genes for the modulation of the nutritional status located within the
investigated region are the receptor tyrosine kinase MET, the paternally imprinted gene PEG1 and
the human homologue of the murine obesity gene LEP. An association with the phenotype
"discordance" in FEVPerc, indicative of a modulation mediated by a gene encoded in trans, was seen
at J3.11. This effect was attributed to a trans encoded factor acting on a responsive element linked to
J3.11, thereby regulating CFTR expression. At the loci D7S514 and D7S495, an association of
alleles with the phenotype "discordant" was seen in wfh%. As serum levels of leptin, encoded for by
the gene LEP located near D7S514 and D7S495, were shown to be in linkage to D2S1788, this
marker was analysed among CF twins and sibs. Sharing of alleles at D2S1788 was significantly
associated with higher concordance in wfh%. Summarising these findings gained by genetic analysis
of ∆F508 homozygous CF twins and siblings, evidence for a role of the ENaC and hitchhiking genes
near CFTR in modulating CF disease severity has been provided.
KEYWORDS: Genotype-Phenotype Relation
Association Study
Modulating Genes
ZUSAMMENFASSUNG
Cystische Fibrose (CF) wird durch Mutationen im "Cystic Fibrosis Transmembrane Conductance
Regulator" (CFTR) Gen ausgelöst und ist die häufigste autosomal rezessiv vererbte Erkrankung in der
kaukasischen Bevölkerung. CF wird als monogene Erkrankung angesehen, obwohl der Schweregrad der CF
durch eine hohe Variabilität gekennzeichnet ist. Diese Dissertation beschreibt Ergebnisse zweier Studien,
deren Ziel es ist, den relativen Einfluß des CFTR Mutationsgenotypes neben weiteren vererbten Faktoren
auf den Verlauf der Erkrankung zu erfassen.
19 Patienten der CF Klinik in Hannover wurden im Rahmen der Studie "Seltene Genotypen und atypische
CF" mithilfe der Messung der intestinalen Leitfähigkeit (ICM), der Nasalpotentialdifferenzmessung (NPD)
und dem Pilocarpin-Iontophorese Schweißtest hinsichtlich ihres Basisdefektes untersucht, der sich als
Störung der CFTR vermittelten Chloridleitfähigkeit manifestiert. Mutationsanalyse des CFTR Gens wurde
mithilfe der Analyse von Einzelstrangkonformationspolymorphismen, Direktsequenzierung und Southern-
Blot Verfahren durchgeführt. Die Deletionen CFTRDelEx2 und CFTRDelEx2,3 wurden auf genomischer
Ebene nachgewiesen. Verschiedene Restleitfähigkeiten, die aufgrund ihrer Sensitivität gegenüber DIDS und
cAMP unterschieden werden konnten, wurden mit ICM im Rahmen der Studie "Seltene Genotypen und
atypische CF" beobachtet. Pankreassuffizienz war dabei mit CFTR vermittelter Restleitfähigkeit assoziiert.
Durch die Analyse des Basisdefektes wurde die Diagnose der CF bei drei Patienten bestätigt, für die eine
Anwesenheit von krankheitsauslösenden Läsionen auf beiden CFTR Allelen nach ausführlicher
Mutationsanalyse unwahrscheinlich schien. Für zwei dieser Patienten wurde der genetische Befund durch
klinische oder genetische Analyse der Familie unterstützt.
Im Rahmen der "Europäischen CF Zwillings-und Geschwisterstudie" wurde für mehr als 300
Patientenpaare der Schweregrad der Erkankung und die Intrapaardiskordanz quantitativ durch einen aus
dem Ernährungsstatus (wfh%) und dem pulmonalen Status (FEVPerc) zusammengesetzten Parameter
beschrieben. Monozygote Zwillinge waren signifikant konkordanter in wfh% und FEVPerc als dizygote
Patientenpaare, so daß der Einfluß des genetischen Hintergrundes auf den Schweregrad der Erkrankung
nachgewiesen werden konnte. Aufgrund eines extremen klinischen Phänotyps wurden 38 Patientenpaare,
die für das häufigste CF verursachende Allel ∆F508 homozygot waren, zur Analyse von
Kandidatengenorten ausgewählt. Die Typisierung polymorpher Marker wurde mithilfe von Multiwell-PCR
Reaktionen und kontinuierlicher "Direct Blotting" Elektrophorese optimiert. Ein Allel des Marker Locus
D12S889 war mit einem milden klinischen Verlauf signifikant assoziiert. SCNN1A, das Gen welches für
die α−Untereinheit des Amilorid-sensitiven Natriumkanals codiert, liegt in der Nähe von D12S889 und
könnte daher als Modulator der Erkrankung CF eine Rolle spielen. Eine Analyse von Markern innerhalb
der CFTR Kopplungsgruppe ergab Hinweise auf die Existenz benachbarter Gene, die den Verlauf der CF
beeinflussen und daher auch für den Heterozygotenvorteil von CF Genträgern verantwortlich sein können.
Eine Assoziation von Allelen der Loci MetH und D7S495 mit einem milden Krankheitsbild konnte für
wfh% beschrieben werden. Kandidatengene dieser Region mit einer möglichen Funktion bei der
Modulation des Ernährungsstatus sind MET, PEG1 und LEP. Mit dem Phänotyp "diskordant" konnte eine
Assoziation eines J3.11 Allels in FEVPerc gezeigt werden. Dieser Effekt stellt einen Hinweis auf den
Einfluß eines in trans kodierten Gens dar und wurde auf einen regulatorischen Faktor zurückgeführt, der
durch ein an J3.11 gekoppeltes Element die Expression des CFTR Gens beeinflußt. Eine Assoziation von
Allelen der Loci D7S514 und D7S495 mit dem Phänotyp "diskordant" wurde in wfh% beobachtet. Da der
Serumspiegel von Leptin – einem durch das zwischen D7S514 und D7S495 liegende Gen LEP kodierten
Peptid – mit dem Marker D2S1788 in genetischer Kopplung steht, wurde D2S1788 bei den ausgewählten
Patientenpaaren typisiert. Ein signifikanter Zusammenhang zwischen der Zahl gemeinsamer D2S1788
Allele und der Konkordanz in wfh% wurde beobachtet. Zusammenfassend läßt sich aus den Ergebnissen
der Typisierung von ∆F508 homozygoten Zwillingen und Geschwistern ein modulierender Einfluß des
ENaC sowie mehrerer Gene aus der CFTR Kopplungsgruppe auf den Schweregrad der Erkrankung ableiten.
SCHLAGWÖRTER: Genotyp-Phänotyp-Beziehungen
Assoziationsstudie
Modulierende Gene
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INTRODUCTION
1    INTRODUCTION
Cystic fibrosis (CF) is the most common autosomal recessive disease within the Caucasian
population, exhibiting an incidence of 1 in 2500 births (Welsh et al. 1995, Davies et al. 1996). The
symptoms of the disorder are caused by an impaired function of exocrine glands in many organs,
predominantly within the gastrointestinal and respiratory tracts. Major manifestations of the disease
are a consequence of chronic obstruction: bronchitis and bronchiectasis (obstruction of the airways)
combined with chronic infection, pancreatic insufficiency (obstruction of the pancreatic duct),
meconium ileus (obstruction of the intestine), biliary cirrhosis (obstruction of the biliary duct) and
reduced fertility or infertility in both genders (obstruction within the reproductive organs) (Welsh et
al. 1995, Davies et al. 1996).
The diversity of symptoms associated with CF and the variety of disease conditions which
exhibit comparable features provide a challenge to diagnosis, especially when mild symptoms are
presented by the patient. Since the 1950s, an elevated concentration of Cl
¯
in the sweat is used to
discriminate CF from other disease conditions (Di Sant'Agnese et al. 1953, Gibson and Cooke
1958). The measurement of the ionic composition of sweat gland secretion is directly linked to the
basic defect in cystic fibrosis, which was recognised as impaired Cl
¯
permeability in sweat glands
(Schulz 1969). Other diagnostic methods relying on the basic defect have been developed and
employed clinically for respiratory tissue (potential difference measurements on the epithelium of the
lower nasal turbinate, NPD; Knowles et al. 1981) and intestinal tissue (short circuit current
measurement of rectal biopsies, ICM; Veeze et al. 1991).
1.1    Terminology of human genetics: an application to cystic
fibrosis
The field of human genetics examines the relationship between inherited factors (comprising the
genotype) and the characters or traits of an individual (defining the phenotype; Johannsen 1909). In the
case of cystic fibrosis, the gene which causes the disease when both chromosomal copies are
impaired has been identified in 1989 and termed the Cystic Fibrosis Transmembrane conductance
Regulator (CFTR) gene (Rommens et al. 1989).
1.1.1    Chromosomes and genes
The human genome is organised on pairs of homologous chromosomes, each of them harbouring
numerous genes. In the Guidelines for Human Gene Nomenclature (1997), a gene is defined as "a
DNA segment that contributes to phenotype/function". The localisation of a given gene can be
expressed in cytogenetic terms which are based on a band pattern generated by staining of the
chromosomal material that is specific for each of the different chromosomes. For instance, the CFTR
gene is localised at 7q31, an abbreviation for the gene's position at band 31 on chromosome 7 with q
referring to the longer of both chromosomal arms that are separated by the chromosome's centromer.
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1.1.2    The unidirectional flow of genetic information
The carrier of genetic information is desoxyribunucleic acid (DNA), a macromolecule consisting of a
linear sequence of nucleotides. The information content of the genome is encoded by the sequence of
the four different nucleotides A, G, C and T (an abbreviation of the monomer's bases adenine,
guanine, cytosine and thymidine) of the DNA molecule. Specific base pairing of A to T and G to C is
not only a key element for the maintenance of genetic information through replication of the DNA
molecule, but also for the expression of the genetic information in the form of a linear sequence of
amino acids through transcription and translation.
Transcription generates mRNA (messenger ribonucleic acid), formed by aligning
complementary bases to the DNA strand, thereby ensuring that the nucleotide sequence between
DNA and mRNA contains the same information. During translation of the nucleotide sequence to an
amino acid sequence, the successive bases of the mRNA are interpreted according to the rules of the
genetic code: a sequence of three contiguous bases, the codon, is translated to one out of a set of 20
amino acids. Each of the amino acids is linked to a specific tRNA (transfer ribonucleic acid)
molecule and specific base pairing between the three nucleotides of the mRNA codon and three
nucleotides of the tRNA anticodon again ensures that the gene's information is preserved in the gene-
product.
The CFTR gene sequence (Riordan et al. 1989) encompasses 240 000 bases (240 kb)
containing 27 sections of coding sequences in sizes ranging from 38 to 724 bases (so-called exons)
separated by much larger stretches of non-coding sequences (so-called introns). Both, exons and
introns, are transcribed into primary mRNA. However, while the nucleotide sequence of the CFTR
exons determines the amino acid sequence of the CFTR protein, introns are not translated but
contain signals that are vital to the expression of the CFTR gene, such as the splice site consensus
sequences at the exon/intron boundaries. In the splicing process, introns are excised from the primary
mRNA and exons are joined to form mRNA that consists of an uninterrupted coding sequence.
Translation of the transcribed exon sequences results in the chain of 1480 amino acids of the CFTR
protein.
1.1.3    Nomenclature of DNA sequence alterations
The sequence of the four different nucleotides A, G, C and T of the DNA molecule defines the
genetic information. Differences between two DNA sequences – so-called loci (Morgan et al. 1915)
– can be described as either a deletion, an insertion or an exchange of nucleotides. A change of the
DNA gives rise to alternative sequences at a locus which are called alleles (Bateson & Sounders
1902, Johannsen 1909). Rules for naming different alleles were published by a Nomenclature
Working Group in Human Mutation 11: 1-3 (1998).
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By comparing the CFTR gene sequences of CF patients and non-CF controls, numerous DNA
sequence variations have been described (available at: http://www.genet.sickkids.on.ca/cftr/). They
were classified as neutral polymorphisms if no influence on the CFTR protein was expected as a
consequence of the DNA sequence alteration or as mutations whenever an impairment of CFTR
function seemed likely.
Even though the terms "sequence alteration", "sequence variation" and "mutation" are all valid
to designate a change in the nucleic acid sequence, most human geneticists aim at a distinction
between sequence alterations that cause a change in phenotype – i.e. qualify as a cystic fibrosis
causing lesion of the CFTR gene – and sequence alterations which do not influence the phenotype.
Most frequently, this is based on comparisons of the amino acid sequences that will result from the
two alleles. In other cases, the decision of whether a sequence alteration is called a neutral
polymorphism instead of a mutation is based on the observation that both alleles occur on CF-
chromosomes as well as on non-CF chromosomes. Analogously, sequence alterations have been
classified as mutations if they were observed on a CF-chromosome, but not on non-CF
chromosomes.
1.1.3.1    Sequence alterations of the CFTR gene
The DNA sequence alterations are named according to their position with respect to the CFTR
coding sequence: nucleotide residues from the CFTR coding sequence and amino acids from the
CFTR protein are enumerated consecutively. A change of a nucleotide of the coding sequence is
then described as, for instance, 2694 T/G (Zielenski et al. 1991) to denote that the residue 2694 of
the CFTR coding sequence was found to be T or G. Since the genetic code is redundant, not all
nucleotide exchanges lead to a change of the amino acid sequence of the CFTR protein. In the case
of the neutral polymorphism 2694 T/G, the resulting CFTR protein is not altered by the exchange:
both resulting codons – ACT of the allele 2694T as well as ACG of the allele 2694G – encode for
the same amino acid threonine (T) at position 854 within the amino acid chain of the CFTR protein.
Other nucleotide alterations within the CFTR coding sequence result in an amino acid
exchange, such as the mutation E92K (Nunes et al. 1993) which refers to an exchange at position 92
of the amino acid sequence of glutamic acid (E) to lysine (K). E92K is the consequence of the
nucleotide exchange from G to A at position 406 of the DNA coding sequence. Hence, the codon 92
is changed from GAA, translated to glutamic acid from allele 406G, to AAA translated to lysine
from allele 406A. All sequence alterations that lead to an amino acid exchange are termed missense
mutations. If a nucleotide exchange leads to an exchange of an amino acid to a termination signal for
the translation machinery (so-called stop codon), the mutation is called a nonsense mutation. An
example is the CFTR mutation G542X (Kerem et al. 1990) where a nucleotide exchange leads to a
stop codon (X) instead of the amino acid glycine (G).
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The deletion of nucleotides from the CFTR gene sequence are described as frameshift mutations or
out-of-frame deletions when the reading frame of the CFTR coding sequence is disrupted due to a
deletion of one or two nucleotides from a codon due to a loss of 3n + 1 or 3n + 2 (n   )
nucleotides, respectively. The most frequent CFTR mutation in central European populations is an
in-frame-deletion of three nucleotides resulting in a CFTR protein that lacks the residue
phenylalanine (F) at position 508 within the amino acid sequence and is abbreviated  ∆F508.
Unless the full length genomic sequence is known, the nucleotides of the introns are not
enumerated . Consequently, nucleotide exchanges within the non-coding sequences are described in
relation to the nearest nucleotide of the coding sequence, e.g. the nucleotide exchange 1898+3A  G
(Ferrari et al. p.c.) which implies that the A following as a third nucleotide in wild type CFTR on the
nucleotide 1898 – the last residue of exon 12 of the CFTR gene – was found to be exchanged to a G
in the patient's CFTR gene. Nucleotide exchanges near the exon-intron junctions of the CFTR gene
may affect the splicing process by destroying the splice site consensus sequence and thus are called
splicing mutations. The first two nucleotides and the last two nucleotides of each intron are highly
conserved and nucleotide exchanges at these positions within the CFTR gene are considered to be a
disease-causing lesion. However, even at a position +5 the splicing mechanism can be affected, as
has been shown for the mutation 2789+5G  A (Highsmith et al. 1997). Nucleotide exchanges at less
conserved positions than +1, +2 or –1, – 2 are generally assumed to be associated with the
generation of wild-type mRNA and alternatively spliced transcript. In contrast to the alteration of a
present splice site as in the case of 2789+5G  A, the splicing mutation 3849+10kbC  T generates a
novel splice site consensus sequence in intron 19 of the CFTR gene. Processing of the altered
transcript was shown to yield a truncated CFTR protein as the newly inserted exon bears a stop
codon (Highsmith et al. 1994).
1.1.3.2    Dimorphic and polymorphic markers
For practical reasons, loci at which nucleotide sequence alterations occur that can easily be
monitored by standard procedures are called a "marker". Two types of markers are discriminated by
the number of alleles observed: single nucleotide polymorphisms (SNP) refer to an exchange of
single nucleotides. SNP loci are characterised by the occurrence of two alleles within the population
and thus are termed dimorphic markers. Insertions and deletions of more than one nucleotide are
observed at loci where short DNA sequence motifs are repeated and consequently, the number of
repeats varies between individuals. Most of these short tandem repeat polymorphisms – so-called
microsatellites – are characterised by the occurrence of more than two alleles within the population
and thus are termed polymorphic markers.
Most commonly used names of genetic markers contain little information with respect to the
nucleotide exchange involved. For instance, the intron polymorphism 4006-200A/G within the CFTR
intron 20 is known among researchers within the CF field as TUB20. Other dimorphic markers
frequently used in CF research are MetH, XV-2c, KM.19 and J3.11 which were named arbitrarily by
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the researchers and therefore, these abbreviations are non-conclusive for most other scientists.
Restriction enzymes that cleave DNA specifically near short sequence motifs such as TCGA
(recognised by TaqI), CTGCAG (recognised by PstI) or CCGG (recognised by MspI or HpaII) are
employed in the detection of these SNPs as the nucleotide exchange of the SNP alters a recognition
sequence for a restriction enzyme. The alleles are differentiated by the observations "sequence is not
cleaved" (defined as allele 1) or "sequence is cleaved" (defined as allele 2). SNPs that can be
detected with restriction enzymes are termed "restriction fragment length polymorphisms" (RFLPs).
The sequence that differs between the alleles 1 and 2 at a dimorphic marker locus can be inferred if
the restriction enzyme used for detection of the dimorphic marker is named, e.g. MetH/MspI, XV-
2c/TaqI, KM.19/PstI and J3.11/HpaII.
The genome database, a reference for information on the human genome accessible at
http://www.gdb.org, applies an unequivocal nomenclature for DNA loci: the letter D abbreviates the
source (DNA), followed by a number to denote the chromosomal assignment and a symbol to
indicate the complexity of the DNA segment, whereby S denotes a single copy segment. Finally, a
sequential number is assigned "to give uniqueness to the above characters" (Guidelines for Human
Gene Nomenclature 1997). For example, three repeat polymorphisms investigated within this thesis
are D7S495, D7S514 and D7S525. While the localisation of these markers on chromosome 7 can be
inferred based on their name in the D-nomenclature system, neither their subchromosomal
localisation nor the nucleotide sequence alterations that confer polymorphic character to these
sequences can be perceived. These three repeat polymorphisms are located near the CFTR gene in
the order 7cen – D7S525 – CFTR – D7S514 – D7S495 – 7qtel, whereby D7S525, D7S514 and
D7S495 have been assigned to the cytogenetic bands 7q22-7q31, 7q31-7q32 and 7q32-7q33,
respectively (Bouffard et al. 1997).
1.1.4    Genetic linkage
While alterations of the DNA sequence that are classified as a mutation infer a change of the gene
product's functionality, neutral polymorphisms do not influence a gene product by definition.
Nevertheless, the study of polymorphic sequences has several applications in human genetics as it
provides information on the genomic region defined by the location of the polymorphism on the
physical map.
Both sets of homologous chromosomes are passed from cell to cell at each mitosis (division of
somatic cells). A reduction to one set of homologous chromosomes takes place during the meiosis
which forms the gametes. Prior to the separation of two chromosomes of a homologous pair during
meiosis, sections of chromosomes are exchanged between the two homologous chromosomes in a
process called "crossing over" (Morgan & Cattrell 1912) which leads to recombination (Bridges &
Morgan 1923). Due to the recombination events, the genome of gametes that is passed to the next
generation contains combinations of chromosomal sections which do not exist in the parents' somatic
cells.
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The analysis of recombination events within families facilitates the construction of a genetic map
(Haldane 1919). Most polymorphisms were identified without knowledge about their chromosomal,
much less subchromosomal localisation. Recombination events between two loci were monitored by
analysing the inheritance of alleles of genetic markers at these two loci within a family. If the alleles
at both loci were not transmitted in parallel to the next generation, recombination has occurred.
Generally, recombination is expected to occur more frequently between loci that are located in a
larger physical distance. Thus, the observation of recombination events between two loci in many
families can be taken as an indication of a larger physical distance between them.
The term "genetic linkage" refers to loci which are not separated by a recombination event.
Alleles at two loci that are inherited in parallel are called "associated". If two alleles are associated
more frequently than expected due to the allele frequencies, they define a chromosomal region that is
in "linkage disequilibrium" (Kimura 1956). The combination of alleles at two or more linked loci is
called "haplotype" (Cepellini et al. 1967).
1.1.4.1    Mapping of the CFTR gene: linkage and association
Cystic fibrosis is often regarded as a model example among human geneticists of what is called
"reverse genetics". The CFTR gene, causing CF when present in a defective state on both
chromosomal copies, was identified by studying the transmission of chromosomal regions within
large family pedigrees wherein one or more of the members were affected by the disease. Monitoring
of the inheritance of chromosomal segments within these families was carried out by the analysis of
dimorphic markers.
Due to the fact that alleles at certain dimorphic loci such as MetH and J3.11 were transmitted
parallel to the disease in these families (Beaudet et al. 1986), researchers were able to conclude that
the disease-causing gene was localised near these markers: the inheritance of alleles at a marker locus
in parallel with the disease implies that no recombination has occurred between marker locus and
disease locus. Consequently, marker loci MetH and J3.11 and the CF disease locus were assumed to
be located near each other on the physical map, as the probability of observing a recombination event
between two loci increases with the physical distance between them. The identified chromosomal
region was further analysed by physical cloning and examination of the DNA sequences for candidate
genes (Rommens et al. 1989). The identification of the CFTR gene among the candidates was due to
its predicted biochemical properties based on the deduced amino acid sequence (Riordan et al 1989).
Analysis of the CFTR coding sequence in CF families provided another argument for the role of the
CFTR gene in CF disease: the three base pair deletion ∆F508 was found to be associated exclusively
with CF disease among CF families (Kerem et al. 1989a).
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1.1.4.2    An extragenic haplotype common to most CF chromosomes
In contrast to the situation 15 to 20 years ago, the physical map of the CFTR gene region is now known
in detail. At four loci near CFTR, the dimorphic markers MetH, XV-2c, KM.19 and J3.11 have been
studied within many populations (Estivill et al. 1987, Schmidtke et al. 1987). At these three markers,
located on the genetic map in the sequence 7cen–MetH–XV-2c–KM.19–CFTR–J3.11, an
association with CF of one out of the two possible alleles 1 or 2 has been observed. For instance, at
MetH 54% of normal chromosomes, but 70% of CF chromosomes, carried the allele 1. At J3.11,
43% of normal chromosomes but 60% of CF chromosomes carried the allele 1. The allelic
association is even more pronounced at the loci XV-2c and KM.19 which are closer to CFTR on the
physical map: 89% of CF chromosomes, but only 45% of normal chromosomes, carried the allele 1
at XV-2c and 88% of CF chromosomes, but only 27% of normal chromosomes, carried the allele 1
at KM.19. The resulting MetH – XV-2c – KM.19 – J3.11 haplotype 1-1-2-1 is frequent on CF-
chromosomes but rather rare on non-CF chromosomes. The allele sequence 1-1-2-1 at these loci is
known as the "CF haplotype". Thus, CF chromosomes bearing the same haplotype can be considered
to share a common chromosomal background.
1.2    The CFTR protein and the basic defect in CF
The CFTR gene codes for a protein of 1480 amino acids (Riordan et al. 1989) which was, due to
sequence similarities and structure predictions, recognised as a member of the ATP binding cassette
(ABC) transporter protein family. Like other ABC transporters, CFTR is composed of two cytosolic
nucleotide binding domains and two membrane spanning domains containing 6 transmembrane
helices. Unique to CFTR is the regulatory domain (R-domain). In addition to being able to transport
a substrate across a membrane, ABC transporters are known to impose regulation on other
membrane channels (reviewed by Higgins 1995). With respect to the modulation of the activity of
other ion channels by CFTR, articles on interaction with the outwardly rectifying Cl
¯
channel ORCC
(Egan et al. 1992, Gabriel et al. 1993), the amiloride-sensitive epithelial Na+ channel ENaC (Ismailov
et al. 1996, Stutts et al. 1997) and the K+ channel have been published (Loussouarn et al. 1996,
McNicholas et al. 1997).
The CFTR protein was identified as a cAMP regulated Cl
¯
channel expressed in the apical
membrane of epithelial cells (Denning et al. 1992a). The secretory properties transmitted by CFTR
are regulated by the β2 adrenergic pathway in exocrine tissues. The molecular pathology, connecting
the basic defect to the symptoms of the disease, is described comprehensively for the sweat gland
(Quinton 1990): the impermeability of the apical membrane of sweat duct cells results in a decreased
reabsorption of Cl
¯
and, parallel to this, a decreased reabsorption of the counterion Na+. Reduction
of NaCl absorption thus leads to elevated NaCl concentrations in sampled sweat.
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The most frequent disease-causing lesion within the CFTR gene is the in-frame deletion ∆F508
(European Working Group on Cystic Fibrosis Genetics 1990). The molecular phenotype of
∆F508  CFTR  protein  was  assessed  in  heterologous  expression  systems  (Cheng et al. 1990) and
in ∆F508 transgenic mice (French et al. 1996) as a maturation defect. The absence of apical CFTR
was also demonstrated for patient tissue in sweat glands (Kartner et al. 1992), but in nasal polyps no
difference between ∆F508 homozygous patients and non-CF controls was observed (Dupuit et al.
1995). Furthermore, missing or mislocalised CFTR was detected in non-CF lung biopsies (Brezillon
et al. 1997) and remodelled non-CF nasal epithelium (Brezillon et al. 1995), depending on the
dedifferentiation status of the tissue. The channel properties of ∆F508 CFTR were distinguishable
from wild type channels by a decreased open probability (Haws et al. 1996).
For organs other than the sweat gland, the link between the basic defect and the disease
symptoms is still not fully resolved. Basically, epithelial cells expressing defective CFTR have been
characterised by failure to respond to stimulation of secretion. The interdependence of ion and water
transport is thought to result in an altered composition of the fluid secreted by the epithelia of the
gastrointestinal, respiratory and reproductive tracts, which in turn leads to obstruction of the
excretory ducts of these organs. However, the vulnerability of CF lungs to opportunistic pathogens,
determining the life span of CF patients, cannot be explained solely on the basis of altered fluid
viscosity. Hypotheses aiming at an explanation of the impaired protection of CF airways were
focussed on the unspecific host defence: it has been suggested that a higher NaCl concentration in
the airway fluid, a condition presumed to exist in CF, impairs the antibacterial effect mediated by
epithelial beta-defensin-1 (Bensch et al. 1995, Goldmann et al. 1997).
Compared to the efforts spent on analysing the Cl
¯
transport properties of the protein, few
research groups focussed on functions of CFTR other than involvement in ion transport. CFTR was
reported to play a role in regulation of plasma membrane recycling (Bradbury et al. 1992), water
transport (Hasagawa et al. 1992), efflux of neutral amino acids (Rotoli et al. 1994), membrane
endocytosis (Spilmont et al. 1996), transport of glutathione adducts of pro-inflammatory agents
(Lallemand et al. 1997), HCO3¯ conductance (Illek et al. 1997), apoptosis (Maiuri et al. 1997) and
glutathione transport (Lindsdell et al. 1998).
In summary, the extent to which the disease symptoms can be derived from the basic defect
reflects the complexity of the tissue and the complexity of Cl
¯
conductances displayed by the
individual cell: for the absorptive duct of the sweat gland, expressing exclusively the CFTR
transmitted Cl
¯
conductance, the observed deviations between CF and non-CF individuals can be
explained solely on the basis of defective CFTR mediated Cl
¯
conductance. For organs like the lung,
displaying several cell types and expressing Cl
¯
conducting properties other than those mediated by
CFTR, the link between the pathophysiology of CF disease and the basic defect is not fully
understood.
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1.3    The role of the CFTR gene in disease
While the mode of inheritance for CF was in 1910 first assumed to be autosomal recessive based on
the analysis of a consanguineous family (Garrod et al. 1912), this mode of inheritance became a
generally accepted fact in the 1950s (Lowe 1949, Carter 1952). The disease is considered to be
monogenic due to a lack of evidence for the involvement of multiple loci (Scambler et al. 1985, Tsui
et al. 1985, Lander and Botstein 1986).
While no evidence for genetic heterogeneity was established, the impact of the allelic heterogeneity
at the CFTR locus has been shown to contribute to the phenotypic variation as demonstrated by an
association of CFTR spanning haplotypes with the pancreatic status (Kerem et al. 1989b) and sweat
sodium values (Witt et al. 1991). Even before detailed analysis of the CFTR gene allowed the
identification of more than 700 sequence variants (The Cystic Fibrosis Genetic Analysis Consortium
1998), the variability of the CF phenotype was attributed to allelic heterogeneity based on haplotype
analysis at the CFTR locus (Kerem et al. 1989a, Gasparini et al. 1990). Based on the patient's
pancreatic status, mutations are termed "mild" (e.g. A455E, R347P) or "severe" (e.g. ∆F508) with
pancreatic sufficiency resulting as a consequence of at least one "mild" CFTR mutation. However,
even for a group of patients homozygous for the most common CF mutation ∆F508, phenotypic
diversity has been noticed (Johansen et al. 1991, Lester et al. 1994).
The in-frame deletion ∆F508 accounts for 60-80% of CF chromosomes within European
populations (European Working Group on Cystic Fibrosis Genetics 1990). The comparatively high
frequency of the ∆F508 allele has been attributed to genetic drift or to an advantage of the
heterozygous state. A complex effect on the family size of CFTR mutation carriers was shown
(deVries et al. 1997) and a reproductive advantage of ∆F508 heterozygotes was demonstrated (Dahl
et al. 1998a). The benefit of the carrier state was ascribed to a longevity advantage due to resistance
to viral and bacterial pathogens (Stuart and Burton 1974, Shier 1979, Meindl 1987, Hollander 1982,
Cassano 1985, Rodman and Zamundio 1991, Gabriel et al. 1994, Pier et al. 1998).
Apart from disease-causing lesions, sequence variants are known within the CFTR gene. These
polymorphisms are termed neutral due to their occurrence in the non-CF population, but it has been
shown that polymorphic variants such as IVS8-6(T) and the missense variant M470V alter the
splicing of CFTR mRNA, the processing of CFTR protein and the electrophysiological properties of
the CFTR channel (Strong et al. 1993, Cuppens et al. 1998).
The role of CFTR in diseases other than CF is evident for congenital bilateral absence of the
vas deferens (CBAVD) as demonstrated by an increased frequency of CFTR mutant alleles among
CBAVD patients (Dumur et al. 1990b, Chillon et al. 1995). Similarly, it has also been suggested that
CFTR may play a role in allergy (Warner 1976), chronic bronchial hypersecretion (Dumur et al.
1990a), allergic bronchiopulmonary aspergillosis (Miller et al. 1996), disseminated bronchiectasis
(Pignatti et al. 1996), sinopulmonary disease of ill-defined etiology (Friedman et al. 1997), asthma
(Dahl et al. 1998b) and chronic pancreatitis (Sharer  et al. 1998).
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1.4    Analysis of complex inherited traits
Since the work of Mendel in 1865, reporting that characters are transmitted from generation to
generation due to independently assorted entities called genes, the genetic basis of phenotypic
diversity has been studied. It was realised that groups of genes are ordered linearly along
chromosomes and recombination events were taken as a measurement of the distance between genes
(Sturtevant 1913). The discovery of the molecular basis of inheritance subsequently enabled the
direct investigation of chromosomal sequences, and the analysis of the inheritance of DNA
polymorphisms facilitated the construction of genetic maps (Haldane 1919). Distance units on
genetic maps are based on observed recombination frequencies, assuming that the recombination
frequency between two loci will increase with distance. However, as recombination breakpoints are
not distributed equally throughout the genome, the relationship is not linear (e.g. accounted for by
Kosambi 1944) and consequently, genetic distances and physical distances between two loci are
different.
The genetic diversity is complex on the level of the isolated gene as well as within the 'gene
network' (reviewed by Tanksley 1993, Romeo and McKusick 1994, Frankel and Schork 1996).
Phenotypic variation based on isolated gene sequences occurs due to sequence variants (allelic
heterogeneity) which may express variability in their impact on the phenotype (penetrance) or mode
of transmission (dominant or recessive). Considering several gene loci, they can either interact
synergistically (epistasis) or act through independent pathways (genetic heterogeneity). Whether
interaction between genes will be recognised when studying a phenotypic trait depends on the
number of loci involved and on the impact of each gene (figure 1): the inheritance is perceived as
monogenic when one locus accounts for nearly all variations of the phenotypic trait studied. If the
trait is modified by few additional loci, the role of the extragenetic background will be noticed in
phenotypic variation. When many loci have a similar impact on the phenotype, the mode of
inheritance is recognised as polygenic.
1
FIGURE 1: MONOGENIC AND POLYGENIC INHERITANCE
The number of loci involved and the impact of each locus on the phenotype determines whether a trait is perceived as
monogenic, influenced by genetic background or polygenic.
— 10 —
IN
FL
U
EN
C
E 
O
F 
IN
D
IV
ID
U
A
L 
LO
C
I 
O
N
 P
H
EN
O
TY
PI
C 
CH
A
R
A
C
TE
R
NUMBER OF GENES SHAPING PHENOTYPE
Low
High
One Some Many
MONOGENIC 
INHERITANCE
POLYGENIC
 INHERITANCE
MAJOR GENE AND
INFLUENCE OF
GENETIC BACKGROUND
ANALYSIS OF COMPLEX INHERITED TRAITS
Strategies to determine the genetic basis of a trait have been applied successfully to map more than
500 genes to their chromosomal regions (Lander and Kruglyak 1995). Methods involved pursue two
different concepts, namely linkage and association (reviewed by Lander and Schork 1994). Linkage
studies rely on the observation of the inheritance of alleles and the transmission of a phenotypic
character within a pedigree. If an allele is transmitted in concordance with the phenotype, linkage
between the locus studied and the gene involved in determining the character is assumed.
Association studies compare allele frequencies between a group expressing a trait and a control
group. Allelic imbalance, e.g. an increased frequency for an allele in one group, is considered as an
indication of association between the locus studied and the gene responsible for shaping the trait.
Linkage and association methods detect the genetic distance between a marker and the gene
transmitting the phenotype under investigation. However, when either the influence of the gene on
the character studied is too small or the marker locus investigated is too far away from the gene of
interest, neither method will provide evidence for the gene's location. Both elements can be taken
into account by the study design: when analysing a quantitative trait, the influence of minor genes is
expected to be more pronounced at the extremes of the distribution (reviewed by Tanksley 1993)
and, consequently, selection of extreme phenotypes can increase the number of individuals who
either possess or lack the gene of interest (Risch and Zhang 1995). The selection of the marker locus
also varies: genome-wide screens, employing markers typically spaced in 20 cM intervals, cover the
entire genome but might miss a gene of interest due to the space between the loci tested.
Alternatively, markers can be placed with higher density in gene-rich regions of the genome
(Antonorakis 1994, Inglehearn 1997), thereby decreasing the distance between the marker locus
studied and the gene of interest when it is located within gene-rich regions. Finally, candidate genes,
selected due to a hypothesis on their involvement in shaping the phenotype, can be tested directly
when a sequence variant of sufficient informativeness is either intragenic or close to the candidate
gene.
1.5    Study designs and objectives
Within this thesis, results from two research trials investigating genotype-phenotype relations in CF
are presented: the study "Rare genotypes and atypical CF" analyses patients with uncommon CFTR
alleles while the "European CF Twin and Sibling study", carried out under the auspices of the
European Working Group on Cystic Fibrosis, is focussed on the most common CFTR allele ∆F508.
Both trials were designed as collaborative studies between the CF centers of Rotterdam, The
Netherlands and Hannover, Germany. Recruitment of patients for the European CF Twin and
Sibling study involved CF clinics in Austria, Belgium, France, Germany, Italy, the United Kingdom,
Spain, Sweden, Switzerland and The Netherlands. Investigation of patient pairs was conducted in
Hannover, Germany; Innsbruck, Austria; London, United Kingdom; Rotterdam, The Netherlands
and Verona, Italy.
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For both studies, the investigation of the clinical phenotype – as evaluated in accordance with the
guidelines of the BIOMED genotype-phenotype workshop in 1994 by pulmonary function,
characterisation of nutritional status by weight and height, serum analysis and identification of
bacterial pathogens in sputum cultures – was combined with an investigation of the basic defect in
the sweat gland and in the major affected organs, that is the respiratory and intestinal tracts.
Respiratory tissue was analysed by nasal potential difference measurement (NPD) and rectal tissue
was analysed by intestinal current measurements (ICM). Both ICM and NPD are sensitive to the
basic defect in CF by assessing the chloride conductance defect transmitted by non-functional CFTR
protein. Expertise with these electrophysiological methods was provided by the CF research group in
Rotterdam, as was the equipment to measure NPD and ICM.
1.5.1    Rare genotypes and atypical CF: genotype-phenotype
correlation on a case-to-case basis
The term "atypical cystic fibrosis" refers to an uncommon manifestation of the disease CF. This can
appear as a general mild course of the disease or as a tissue specific expression – as described for
CBAVD – where helpful diagnostic methods such as sweat test and mutation analysis do not provide
clear evidence for CF. A patient, presenting mild disease symptoms and a close-to-normal sweat test,
might not be considered as a CF patient if the analysis of the CFTR gene does not sustain the
diagnosis. On the other hand, if the same patient is shown to carry two rare CFTR alleles with
unknown impact on the CFTR protein, he might be considered to be a CF patient even if the chain of
evidence between the molecular lesion within the CFTR gene and the disease symptoms presented is
far from being conclusive. Thus, a characterisation of the phenotype inflicted by uncommon CFTR
mutations and a characterisation of the CFTR gene in patients with atypical CF was attempted by the
study "Rare genotypes and atypical CF" with the aim of correlating CFTR genotype and CF
phenotype on a case-to-case basis.
CFTR mutation genotypes have been categorised in accordance with the anticipated effect of
the molecular lesion (reviewed by Zielenski and Tsui 1995): no CFTR protein is expected for most
nonsense mutations, partly impaired regulation or function has been suggested for some missense
mutations and reduced amounts of wild type CFTR protein can result from some splice site
mutations. Within the study "Rare genotypes and atypical CF", patients carrying uncommon CFTR
alleles that cover the broad spectrum with respect to the probability of residual CFTR activity were
investigated. A total of 19 patients were examined: 7 patients were homozygous for a non-∆F508
mutation, 7 patients carried at least one rare CFTR allele and five patients were suspected of bearing
at least one functional CFTR allele in spite of CF symptoms. Three of the patients analysed bear
sequence variations which have not previously been found within the CFTR gene: two novel
deletions are presented in chapter 3.1.1.1 and a novel intronic sequence variant is described in
chapter 3.1.1.2.
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A widely accepted approach to correlating genotype and phenotype in cystic fibrosis is based on
explaining the latter only on the basis of the former, i.e. on deriving the clinical outcome only from
the impaired chloride conductance of CFTR expressing epithelia and on deriving a defect in ion
conductance solely on the basis of the underlying CFTR genotype. This concept can only be
successfully applied to explain a patient's clinical state when the CFTR genotype is assumed to be
predictive for the basic defect in all affected tissues and, likewise, when the impaired chloride
conductance is assumed to be predictive for the clinical outcome. Two chapters of the thesis address
this issue: chapter 3.1.3.1 examines whether the basic defect in three tissues – namely the sweat
gland, the nasal tissue and the rectal tissue – correlates due to the CFTR defect transmitted to all
tissues or whether other, tissue specific ion channels diminish this correlation. Chapter 3.1.3.2
inspects whether the results from the basic defect measurements can be explained entirely on the
basis of the CFTR genotype and whether the disease severity can be based entirely on the observed –
if any – residual chloride conductance in investigated tissues.
1.5.2    European CF twin and sibling study: genotype-phenotype
correlation through patient pair cohorts
The variability of CF disease severity can be attributed to the CFTR genotype, epigenetic factors and
disease modulating genes. The "European Cystic Fibrosis Twin and Sibling Study" pursues a
classical approach to address the impact of each factor by investigating affected patient pairs. The
influence of epigenetic factors can be estimated by analysing monozygous twin pairs. Being
genetically identical, they can only vary in phenotype based on non-inherited factors. Dizygous CF
patient pairs harbour the same CFTR mutation, share mostly the same environment but only part of
their genetic background. Thus, when comparing monozygous twins and dizygous pairs with respect
to their intrapair variation – i.e. the difference between two siblings or twins of a pair in a phenotypic
character – the impact of the differences in the genetic background can be assessed. Furthermore, in
central European populations, approximately 70% of CF alleles bear the same CFTR mutation,
∆F508 (European Working Group on Cystic Fibrosis Genetics 1990). Consequently, 50% of all
patient pairs are homozygous for the same disease-causing lesion, a fact that facilitates analysis of
the disease severity in a group with a homogeneous mutation genotype in the major disease-causing
gene. CF is the only disease where a sufficient number of patient pairs that fulfil these criteria can be
recruited, due to the prevalence of one mutation genotype in a so-called monogenic disease that
follows an autosomal recessive trait.
For identifying a gene involved in shaping a complex trait, the extreme phenotypes —
presenting either an extremely mild or an extremely severe clinical picture — are considered to be
most informative. Three groups of pairs can be defined based on the phenotype of the individual (see
figure 2): discordant pairs, composed of two sibs with highly different phenotypes (DIS), concordant
pairs, consisting of two sibs with mild phenotypes (CON+), and concordant pairs, comprised of two
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sibs with severe phenotypes (CON-). When selecting CF twin and sibling pairs exhibiting extreme
phenotypes, the clinical phenotype, the basic defect — being accessible by nasal potential difference
and intestinal current measurement — and selected candidate gene loci composing part of the genetic
background were investigated. This thesis reports on the following results from the study: the
selection of CF twin and sibling pairs for analysis of selected candidate genes is described in chapter
2.2.1. Conclusions drawn from the clinical epidemiological data are shown in chapter 3.2.1. Results
of the ICM experiments are discussed in chapter 3.2.2. In chapter 3.2.3, the modulation of CF
disease severity by the genetic background is examined.
2
FIGURE 2: CONCORDANT AND DISCORDANT PATIENT PAIRS
The pathophysiology of CF provides numerous opportunities to make an "intelligent guess" about
the involvement of a gene product in the modulation of this disease. However, to test the hypotheses
with a genetic approach, the localisation of the gene must be known in order to select DNA markers
for an association study: in order to detect the influence of a functional polymorphism within a
candidate gene on the phenotype by analysis of a closely linked neutral polymorphism, marker locus
and candidate gene locus must be in linkage disequilibrium.
Within this thesis, the amiloride sensitive, epithelial sodium channel ENaC was analysed for its
role as a candidate gene. This sodium channel is a likely candidate for a modulation of CF disease
severity due to two observations: on the molecular level, an interaction of CFTR and the ENaC has
been demonstrated. Furthermore, a disease called pseudohypoaldosteronism type I (PHA) is caused
by mutations within the ENaC coding sequences. Some PHA patients share characteristic symptoms
with CF, e.g. an increased NaCl concentration in sweat. Results from the association study on
polymorphic markers near the ENaC coding sequences are reported in chapter  3.2.3.4.
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Besides candidate genes located anywhere in the genome, sequences near the CFTR gene might play
a role in the modulation of CF disease severity due to their physical location which results in a tight
linkage between the CF disease causing gene and flanking sequences, the so-called hitchhiking genes.
Hitchhiking genes have been the subject of discussions as to whether they might confer an advantage
to the chromosomal background shared by many mutant CFTR alleles, as indicated by the common
CF haplotype. 3.2.3.5 shows the results of the association study with markers localised near CFTR.
As will be illustrated in detail within chapter 3.2.3.6, the results obtained from markers within the
CFTR linkage group have pointed to a modulation mediated by the proopiomelanocorticoin gene
POMC that is most likely involved in the regulation of the expression of one CFTR hitchhiking gene.
An association study primarily detects an allelic imbalance, i.e. in the case of the "European
CF twin and sibling study" an overrepresentation of one allele at given marker locus among pairs
ranked DIS, CON+ or CON-. The modulation of the disease phenotype that can be inferred from an
allelic imbalance is directly accessible through clinical parameters that describe the disease severity.
Parameters that describe the pulmonary and the nutritional status were available for the ∆F508
homozygous patients typed. In chapter 3.2.3.7, the attempt to dissect whether a candidate gene
region influences the CF nutritional or the pulmonary state – or both – was made.
Finally, chapter 3.2.3.8 introduces hypotheses that might explain the observed results on the
genomic level. While the hypothesis is straightforward for the interpretation of the results gained on
markers near the ENaC coding sequences because a direct hypothesis facilitated the choice of the
ENaC as a candidate gene, more than one gene within the CFTR gene region serves as a likely
candidate for the modulation of the CF disease phenotype within a complex gene network.
1.5.3    Aim of the thesis
Cystic fibrosis is known as the most severe inherited disease that follows an autosomal recessive
trait. The course of the disease varies between "mild" and "severely affected". However, CF is a
lethal disease and the disease symptoms as well as the considerable therapeutic efforts definitely
reduce the patient's quality of life. Several implications for CF therapy arise from the fact that CF is
considered as a monogenic disease: most basic research of the last decade was focussed on the
CFTR transmitted defect, e.g. by somatic gene therapy (reviewed by Boucher 1999) or through
pharmacological approaches attempting to correct specific mRNA or protein defects of CFTR
mutants (reviewed by Zeitlin 1999). While substantiated by in vitro data and aiming at a permanent
cure for CF, both approaches have run into technical complications that might well jeopardise their
practicability in vivo. Besides CFTR directed interventions, therapeutic measures concentrate on
specific CF symptoms, e.g. antibiotic treatment of patients infected by Pseudomonas aeruginosa or
supplementation of pancreatic enzymes for pancreatic insufficient patients. While these therapeutic
regimes have considerably lengthened the patient's life span, the clinical outcome is characterised by
an interindividual variability of which the basis is poorly understood. Thus, it is of interest to the CF
community to identify the basis of disease variability, thereby enabling the identification of factors
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which (a) might be more amenable to therapeutic intervention or (b) have to be taken into account
when applying current therapeutic measures. However, a clinically significant impact on the CF
disease phenotype has to be verified. This thesis has the intention of evaluating whether besides the
CFTR gene the genetic background influences the severity of CF disease in a substantial manner.
The thesis reports on results from two clinical studies which have been introduced in detail within the
last chapters, viz the study "Rare genotypes and atypical cystic fibrosis" and the "European cystic
fibrosis twin and sibling study". While the former is focussed on a case-to-case-approach, the latter
is based on the study of patient pair cohorts. However, both studies aim at a correlation of the CF
disease phenotype to the underlying CFTR genotype, the extragenetic background and epigenetic
factors — three elements which can be considered to account for the variability of CF disease
severity that characterises this multi-organ disorder. The data obtained within each study are
discussed separately in chapter 3 of this thesis. The final section of this thesis, chapter 4, entitled
"Synopsis", is given over to a discussion that links the results from both studies. In an attempt to
summarise and draw conclusions from the two studies of this thesis as well as material published by
many authors in the field of CF research, four questions are addressed in chapters 4.1, 4.2, 4.3 and
4.4 concerning the relative impact of the relative impact of the CFTR genotype, the genetic
background and epigenetic factors on the course of CF disease.
CFTR genotype- the basis of CF disease phenotype?
For a disease that is considered to be monogenic, a straightforward genotype-phenotype correlation
is expected. If only one locus – the CFTR gene – plays a dominant role for the disorder CF, it should
be possible to predict the course of the disease on the basis of the disease-causing lesion. As CF is
characterised by allelic heterogeneity, it has been speculated that most of the variation observed
among CF patients results from compound heterozygous genotypes. Moreover, the basic defect of
impaired chloride conductance in CFTR expressing epithelia was often considered as the sole basis
of phenotypic variation since the impairment of CFTR function can be estimated from the underlying
disease causing lesion. The investigation of CF patients who are homozygous for rare CFTR
genotypes presents the opportunity to address the issue of whether different CFTR mutation
genotypes predispose to a presentation of specific trademarks in CF diagnosis and clinical prognosis
– i.e. the sweat chloride concentration, the pancreatic status or the severity of pulmonary disease.
This approach is targeted by the study "Rare genotypes and atypical cystic fibrosis" through an
analysis of the clinical picture and the basic defect in CF of non- ∆F508 homozygous patients.
CF disease variability- the basis of non-CFTR genetics?
If the variation of CF disease severity cannot be explained on the basis of the CFTR mutation
genotype, the remaining elements which can be held responsible are epigenetic factors and the
genetic background. Evidence for the relative impact of inherited vs non-inherited elements can only
be gained by comparing the intrapair variation of CF disease severity in monozygous twins to
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dizygous patient pairs: as monozygous twins are genetically identical, all variation observed when
comparing two twins of a pair has to result from epigenetic factors. The "European CF twin and
sibling study" is at present the only clinical study where information on the nutritional and pulmonary
status of a sufficient number of patient pairs has been collected to pursue this issue.
Advantage of CF carriers- none, CFTR transmitted or hitchhiking genes?
The frequency of CF causing alleles in the general population has often been the subject of debate as
to whether a selective advantage is associated with the carrier state. Alternatively, a random fixation
by genetic drift – a mechanism which does not rely on a hypothetical benefit of mutant CFTR alleles
– has been taken into account. If the maintenance of the allele frequency of CFTR mutants is based
on a selective advantage, two alternative interpretations are possible: it has been speculated that
mutant CFTR protein itself is advantageous by providing protection against viral and bacterial
infections. In contrast, genes at loci near CFTR which are transmitted in parallel to the mutant CFTR
allele – the hitchhiking genes – were considered to transmit a selective advantage. The latter is
sustained by the observation of a chromosomal background common to many frequent CFTR
mutations that is indicated by the CF haplotype. If a selective advantage is conveyed by sequences
adjacent to CFTR, their effect should be seen not only in carriers, but also in the affected patients
who harbour two CF alleles. In order to test the hypothesis as to whether CFTR flanking sequences
influence the CF disease phenotype and thus may be able to convey a heterozygote advantage, the
genomic region near CFTR was investigated in an association study on ∆F508 homozygous patient
pairs recruited for the "European CF twin and sibling study". As ∆F508 homozygous patient pairs
have to be considered as identical with respect to the CFTR gene itself, any association of alleles at
flanking loci with the disease phenotype has to be caused by hitchhiking genes.
CF- monogenic disease or complex trait?
The state of a monogenic disorder, by definition caused by one gene locus, is opposed by two
conditions, i.e. genetic heterogeneity and polygenic inheritance. While genetic heterogeneity infers
that the phenotype can be caused independently by two loci, polygenic inheritance indicates that
many different loci are simultaneously involved in shaping the trait. Neither of the studies this thesis
reports on, examines CF as a strictly monogenic disease. Within the study "Rare genotypes and
atypical cystic fibrosis" causes for CF other than two defective CFTR alleles are targeted by
investigating patients displaying CF symptoms while lacking evidence for – or even providing
evidence against – the presence of two disease-causing lesions within the CFTR gene. Whether CF
behaves as a monogenic disease or has to be considered as substantially influenced by the genetic
background is challenged by clinical data from the "European CF twin and sibling study".
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Unless described differently, all chemicals were purchased as p.a. substances from one of the
following companies: Boehringer (Mannheim), Fluka (Neu-Ulm), Merck (Darmstadt), Roth
(Karlsruhe), Serva (Heidelberg), Sigma (Deisenhofen). Composition of common reagents and buffers
supplied by the manufacturer of enzymes are listed in chapter 8.3.
2.1    Analysis of genotype
Most methods used within this thesis to analyse a genomic sequence rely on polymerase chain
reaction (PCR) methods, either to screen for and to identify a sequence variation of the CFTR gene
(chapter 2.1.2.1) or to identify alleles at a marker locus for multiple samples (chapter 2.1.2.2). A
deletion involving exoni2 and exoni3 of the CFTR gene was verified by Southern blotting (chapter
2.1.3).
2.1.1    DNA isolation
2.1.1.1    Preparation of high molecular weight DNA
High molecular weight DNA was isolated as described by Gross-Bellard et al. (1973). 5-10iml K-
EDTA blood, either fresh or thawed on ice after storage at –20°C, were incubated with 40iml lysis
buffer (50imM Tris-HCl, 109.5ig/l saccharose, 1%iw/v TritoniX-100) for 30' on ice. Nuclei of
lymphocytes were separated from cell fragments by centrifugation (15', 600i×ig). Upon incomplete
lysis of erythrocytes, detectable by the dark red colour of the pellet, the lysis procedure was
repeated. The pellet was treated with 5iml of 0.25img/ml proteinaseiK, 0.5%iw/v SDS in STE for 8
to 14ih at 56°C in a shaking water bath. Digested proteins and high molecular weight DNA were
separated by phenol/chloroform extraction: 3iml chloroform/isoamylalcohol (29:1) and 3iml phenol
were added to the digest. After cautious mixing for 15' and centrifugation (10', 600i×ig) the organic
phase collected at the bottom of the tube was carefully removed. This extraction step was repeated
once, followed by an extraction with 6iml chloroform to remove phenol remaining in the aqueous
phase. DNA was precipitated on ice by adding 1/10 of the volume of the aqueous phase of 3iM
sodium carbonate (pHi5.5) and 30-40iml of 70% ethanol precooled to -20°C. High molecular weight
DNA was transferred to an Eppendorf cup containing 1iml 70% ethanol and centrifuged (3',
12000i×ig). The supernatant was discarded and the pellet washed twice with 70% ethanol. After
dissolving DNA in 300iµl TE (4°C, 1iweek), a 1:25 dilution of the stock solution was prepared and
the DNA concentration determined by OD at 260inm.
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2.1.1.2    Chelex 100
A fast method yielding enough DNA to perform 20 to 40 PCR reactions was employed using
Chelexi100 (Walsh et al. 1991), a cation exchanger binding divalent metal ions which are known to
cause DNA degradation at higher temperatures in aqueous solution. 3-10iµl of K-EDTA blood were
shaken at room temperature for 30imin. After centrifugation at 13000i×ig the supernatant was
discarded and the pellet dissolved in 200 µl of a 5% w/v Chelexi100 suspension. The mixture was
incubated at 56°C for 30', vortexed for 10', incubated for 8' in a boiling water bath, vortexed for 10'
and again centrifuged at 13000i×ig. 5-10iµl of the supernatant were used as a template for PCR
reactions.
2.1.2    PCR methods
The polymerase chain reaction is used for amplification of DNA sequences. The specificity of the
reaction is ascertained by the precise binding of the primer molecules to their target sites adjacent to
the sequence of interest. All factors that determine the association and dissociation of
complementary DNA strands – base composition, salt concentration, temperature – have an
influence on the accuracy of the repetitive annealing procedure and thus on the formation of PCR
product.
The base composition of the primer molecules is largely dependent on the target sequence site.
However, the 3' end of a primer, being elongated during PCR reactions if bound to a template, is
preferably composed of a sequence unique to the chosen site and rare throughout the genome
studied. Griffais et al (1991) have provided an algorithm to assign primer locations on given DNA
sequences which takes the frequency of octamers throughout the genome into account, favouring
rare octamers on the primer's 3' end. Primer binding can be facilitated by providing counterions for
the negatively charged DNA backbone and thereby reducing the repulsion of phosphate groups. The
salt concentration within PCR reactions is modified by MgCl2 which is also a cofactor for the Taq
polymerase. Besides the buffer composition, the stringency of PCR reactions is controlled most
rigidly by the temperature conditions governing the annealing step of primer to template. This
includes the annealing temperature itself as well as the temperature gradient applied when cooling
from the denaturation step to the annealing temperature.
Apart from the thermodynamic conditions, the probability of a primer binding to its target site
as opposed to binding at any other site with sufficient sequence similarity will depend on the ratio of
unbound primer to DNA sequences available. This is influenced by the amount of DNA used as a
template and changes rapidly during PCR amplification because products that contain the primer
sequences are formed.
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The standard protocol using 400ing of DNA and 25ipmol of each primer in a 50µl reaction mix
containing 2imM MgCl2 and 200iµM of each dATP, dGTP, dCTP and dTTP was varied for different
applications. Less MgCl2 (1-1.5imM) and less dNTP's (50-100iµM) lower the product yield but
hinder the formation of unspecific primed by-products, which is used for amplifying SSCP-products
(chapter 2.1.2.1.1) and for PCR amplification of probes for Southern hybridisation (chapter 2.1.3).
The commercially available Taq polymerases differ in fidelity; consequently not all Taq
polymerases are suitable for all applications. To reduce the experimental costs, a polymerase without
proof reading activity was used when the size of the PCR product was analysed, such as RFLP and
microsatellite analysis (chapter 2.1.2.2). All methods relying on amplifying the exact sequence, such
as sequencing reactions (chapter 2.1.2.1.2), were performed with a Taq polymerase possessing an 5'
to 3' polymerisation dependent exonuclease activity (Dap Goldstar, Eurogentec). Details of the
reaction conditions used for amplification and primer sequences can be found in chapter .
2.1.2.1    Identification of sequence alterations
Sequence variants within a gene can be identified by direct sequencing of the complete coding
sequence. However, depending on the equipment available, it may be more cost-effective and less
time-consuming to screen the complete sequence for alterations and subsequently perform
sequencing only for those fragments which have provided evidence for a sequence variant.
The screening technique used within this thesis is the single strand conformation polymorphism
(SSCP) analysis (chapter 2.1.2.1.1). The fragment of interest, encompassing the respective exon and
its flanking intron sequences, was PCR amplified and the DNA strands separated by heat
denaturation. Rapid cooling to –20°C allowed each single strand to form secondary structures which
depend on the nucleotide sequence. When the sequence is changed, e.g. by a point mutation, the
resulting secondary structure will differ from the wild type molecule when the change has occurred
at a position responsible for the formation of a secondary structure. If both single strand
conformations — assumed by the wild type strand and the corresponding mutant strand — are
sufficiently different from each other to be separated on a non-denaturing polyacrylamide gel, the
resulting band shift will signal the presence of a mutant allele in a sample, thus leading to sequencing
of the fragment (chapter 2.1.2.1.2).
The size of the fragment studied and the gel conditions have been shown to influence the
resolution of the SSCP. Fragments of 100-150ibp have been reported to show the best results when
looking for band shifts in SSCP gels; low temperature (4°C to 10°C) and glycerol in the
polyacrylamide matrix stabilise single strand conformations. The sensitivity can be increased by using
two different restriction digests per analysed PCR fragment to increase the probability that a
nucleotide change is positioned within a sequence responsible for the formation of secondary
structures. An overall detection rate of 100% for 134 known CFTR mutations, screened under
optimised SSCP conditions, has been shown (Ravnak-Glacik et al. 1994).
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2.1.2.1.1    Analysis of single strand conformation polymorphisms
400ing of DNA, 25ipmol of each primer and 1iU of Invitaq polymerase (Invitek) were placed in a
total reaction volume of 50iµl reaction buffer (Invitek) containing 0.08imM dATP, dGTP, dCTP,
dTTP and 5-7imM MgCl2. The mixture was subjected to 20 cycles of PCR amplification beneath a
paraffin oil overlay of 30iµl. While incubating the reaction mixture at the annealing temperature,
20iµl were transferred on 1iµCi α33PdATP (Amersham) and 0.5iµl of 2imM dGTP, dCTP, dTTP and
amplified for additional 15 cycles beneath a paraffin oil overlay of 20iµl. The remaining 30iµl of the
unlabelled reaction mixture were also amplified for another 15 cycles and the products were
separated on a 2% agarose gel and stained with ethidium bromide to access the quality. The labelled
products were digested with restriction enzymes giving fragments of 150-200ibp. To obtain single
strands, the restriction digest was mixed 1:1 with loading buffer (0.2%iw/v of xylenecyanol and
bromphenolblue in formamid), heated to 95°C for 5imin and directly cooled in an aluminium block
precooled to –20°C. Separation of single strand conformations was carried out on a 40icm gel casted
with 0.2-0.4imm wedge spacers, the matrix containing 6% acrylamide / bisacrylamide 29:1 and 10%
glycerol in TBE. One glass plate was precoated with silane A-174 (BDH Chemicals) while the other
was precoated with repel silane (dimethyldichlorsilane, Merck). 
Electrophoresis was performed at 10°C with 1900iV for 7-9ih. After electrophoresis, the glass
plates were separated and the gel, adherent to the silane A-174 coated plate, fixed by incubation in
10% acetic acid for 1ih and subsequent drying for 2ih at 80°C. X-Omat AR (Kodak) films were
exposed to the surface of the dried gel from between 12 h to 3 idays.
2.1.2.1.2    Sequencing of PCR products
The fragment of interest was amplified in a 100iµl PCR reaction with 50ipmol of upstream and
50ipmol of downstream primer employing a polymerase with high fidelity (DapGoldstar polymerase,
Eurogentec). The quality of the PCR product was evaluated and the concentration of the product
was estimated by loading 10µl of the reaction mixture on a 2% agarose gel, then checking for by-
products and assessing the signal intensity after ethidium bromide staining. Unincorporated primers
were removed from the reaction mixture by ultrafiltration (Ultrafree-MC filter unit, Millipore)
according to the manufacturer's instructions. The filtrate was adjusted to 10-20iµl, depending on the
intensity of the ethidium bromide stained band of the unpurified PCR product. 5-10iµl of the purified
PCR product were amplified in an 100iµl reaction with 50ipmol of one primer only, resulting in an
excess of linearly amplified single stranded PCR product of one template strand. 10iµl of the
asymmetric product were checked for background smear or by-products by agarose gel
electrophoresis and the remaining 90iµl were purified with Ultrafree-MC filter units and the volume
of the filtrate was adjusted to 10-20iµl. Sequencing was performed manually with the Sequenase 2.0
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kit (United States Biochemical). 5-10iµl of purified asymmetrical product and 5ipmol of the primer
that was not used for the asymmetric amplification were mixed in a total volume of 20iµl reaction
buffer. Annealing was done in a PCR thermocycler programmed to 2imin 80°C and cooling to 40°C
within 30imin. Labelling with α33PdATP (Amersham) and termination were carried out according to
the manufacturer's instructions.
The products were separated on a 4%-6% acrylamide/bisacrylamide 29:1 gel with 50g urea
(Gibco BRL, electrophoresis grade) freshly dissolved to make a total volume of 25iml of acrylamide
solution in TBE. Electrophoresis was performed at 55°C with 1900V for 3-6h. The radioactive
labelled products were visualised as described in chapter  2.1.2.1.1, page 33.
2.1.2.2    Genotyping of polymorphisms in PCR multiwell plates
96 well PCR plates (multiwell plates) make it possible to process multiple DNA samples in parallel.
However, compared to the conventional set-up in single tubes with 50iµl reactions beneath an oil
overlay, several modifications became necessary as the standard protocol for several PCR reactions
failed to give rise to a product (figure 3a): conditions that have been shown to amplify a single band
within 50iµl tube reactions produced multiple by-products that are characteristic for a PCR with an
unbalanced primer to template relationship and high MgCl2 concentrations when used on multiwell
plates.
Evaporation during the reaction time is prevented in single tube reactions even without paraffin
oil overlay when used in a thermocycler with a heated lid. For multiwell plates, the following
approach was used (figure 3b): the outer wells were filled with 50µl of distilled water. After the
remaining inner 60 wells were set up for the PCR reaction, the outer rim of the multiwell plate was
coated with 1000iµl of molten 1% agarose by pipetting a continuous trail surrounding all wells and
pressing the lid on the still liquid agarose.
The stringency of the annealing process, in single tube reactions mostly regulated by the
annealing temperature, was adjusted by modification of the MgCl2 concentration (figure 3c). For a
reaction mixture containing 50ing of DNA, 15ipmol of upstream and 15ipmol of downstream primer
in a reaction buffer containing 20iµM dNTP's, products below 500ibp could be amplified with
0.8imM MgCl2 at annealing temperatures between 50°C and 60°C. The same reactions failed to give
a product at higher MgCl2 concentrations. Products of 1000ibp or larger were amplified with
2.5imM MgCl2 at annealing temperatures between 55°C and 65°C.
Multiwell plates were purchased from Greiner. Handling of solutions was done with an
Eppendorf eight channel pipette. A Hybaid thermocycler with a heated lid was used for PCR
reactions.
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FIGURE 3: GENOTYPING OF POLYMORPHISMS IN MULTIWELL PLATES
(a) Amplification in 96 well plate without agarose seal and outer wells filled with water as shown in (b). The PCR
conditions used to generate these products were previously optimised for single tube reaction. As is evident from
figure (a), these conditions were found to be unsatisfactory for multiwell PCR.
(b) PCR set-up with agarose seal and water within outer wells of PCR plate
(c) Conditions optimised for multiwell reactions: RFLP markers within the CFTR linkage group
The analyses of dimorphic markers were carried out in the set-up described in (b) which allows PCR amplification
of DNA in 60 wells per 96 well plate. To ensure that the patient's samples were PCR amplified and digested with
the restriction enzyme appropriately, 12 wells on each 96 well plate were used to amplify four sets of three controls
with known genotypes. The four sets of controls were used as follows: one set of three controls was tested prior to
digestion with the restriction enzyme in order to ensure that the DNA was PCR amplified (not shown). The
remaining three sets of controls were digested in parallel with the 48 samples of the CF patients and their parents
and products were separated on the same gel in order to facilitate the assignment of marker genotypes to the
samples based on the pattern seen for the controls.
Please note that most of the 48 samples give signals suitable for interpretation as can be estimated by comparison
with the controls. A detail that explains the interpretation of the genotypes 1-1, 1-2 and 2-2 for dimorphic markers
is shown in figure 5 on page 39.
LEFT: 48 samples and 9 controls analysed at MetH. Products after restriction digest separated on a 4% agarose gel.
Allele 1: 240 bp, allele 2 (two fragments):100 bp
MIDDLE: optimised MgCl2 concentration for PCR fragments of different size.  J3.11, MetH, TUB20, and KM.19 were
amplified with an annealing temperature of 55°C, XV-2c was amplified with an annealing temperature of 60°C
RIGHT: 48 samples and 9 controls analysed at XV-2c. Products after restriction digest separated on a 2% agarose gel.
Allele 1: 1000 bp, allele 2:600 bp and 400 bp
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2.1.2.2.1    Precoating of multiwell plates with DNA
Samples for typing were selected as described in chapter 2.2.1.4. The DNA was diluted in 96 well
PCR plates to enable handling of the samples with a multichannel pipette. For each well, the stock
solution of the sample was diluted by placing an aliquot of 1µg DNA at the bottom of the well.
100iµl of distilled water were added and the DNA dissolved and sheared with a multichannel pipette
set to 80iµl. 5µl of the dilution were used as template for a reaction. A set of 15 plates was prepared
and stored at 4°C.
2.1.2.2.2    Analysis of single nucleotide polymorphisms
The PCR was done with the set-up described in figure 3b. 30iµl of product were amplified using
0.3iU per well of Invitaq polymerase (Invitek) in a reaction mixture containing 50ing of DNA,
15ipmol of upstream and 15ipmol of downstream primer in a reaction buffer provided by the
manufacturer containing 20iµM dNTP's and 0.8imM to 2.5imM MgCl2. The PCR products were
digested on the multiwell plate used for PCR amplification by adding 10iµl of restriction mix
containing 2-10iU of the restriction enzyme (NE Biolabs) and 4iµl of the supplied 10i× incubation
buffer. The multiwell plates were incubated at the appropriate temperature after a fresh agarose seal,
as described in chapter 2.1.2.2, was placed on the outer rim of the multiwell plate to avoid
evaporation of samples. Products were separated on 2% or 4% agarose gels casted with wells
spaced suitably for multichannel pipette loading of samples. For application into the wells, 10iµl of a
40%iv/v glycerol buffer containing 0.05%iw/v of bromphenolblue and xylenecyanol were added to
the samples. 30iµl were loaded on the agarose gel, products separated by electrophoresis of 10iV/cm
and stained with ethidium bromide.
2.1.2.2.3    Analysis of simple sequence repeat polymorphisms
Nucleotide repeat polymorphisms were amplified using an asymmetric primer ratio of 5ipmol biotin
labelled primer and 25ipmol of unlabelled primer in an amplification volume of 15iµl containing
1iµM MgCl2, 20iµM dNTP's and 0.25iU / well Invitaq polymerase (Invitek) in the reaction buffer
supplied. PCR was carried out with an oil overlay of 10iµl in the set-up described in figure 3. 8iµl of
PCR product were transferred to a new multiwell plate and dried by incubation for 6ih at 40°C
without an agarose seal (see figure 3) in a thermocycler. Products were dissolved in 10iµl of
formamid containing 0.2%iw/v bromphenolblue and xylenecyanol. Prior to loading the products onto
the gel, DNA fragments were denatured by heating to 95°C for five minutes and subsequently
cooling the multiwell plates by placing each multiwell plate in a tight fitting form made of modelling
clay precooled to –20°C and embedding the assembly in ice.
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Amplified products were separated by direct blotting electrophoresis (Beck and Pohl 1984). The
apparatus (GATC, Konstanz) consists of a vertical electrophoresis gel – anode in upper buffer
chamber and cathode in lower buffer chamber – with a conveyor belt directly beneath the lower edge
of the acrylamide gel (figure 4a). A membrane is mounted on the conveyor belt and transported
beneath the lower edge of the acrylamide gel. Products that are separated on the gel exit the matrix
at the lower end and are directly transferred onto the membrane. The resolution depends on the
matrix used for separation but also on the velocity used for the transport of the membrane.
The direct blotter provides an opportunity for the processing of multiple samples in parallel: once a
set of products is blotted on the membrane, the gel can be used for the next set of samples. The
microsatellites described in this work had product lengths of 100-200ibp, providing a unique
occasion for the consecutive blotting of 210 PCR products on a membrane of 50icm in length within
5ih (figure 4b). One set of samples was loaded on the gel and separated by electrophoresis. When the
bromphenolblue marker reached the lower edge of the gel after 50imin, the electrophoresis was
stopped and a second set of samples was loaded. After restarting the electrophoresis, the products of
the first set of samples were transferred to the membrane while the second set of samples was
separated in the matrix. The blotting of the first set of samples was finished when the
bromphenolblue marker of the second set of samples has reached the lower edge of the acrylamide
gel. Then, electrophoresis and transport of the membrane was stopped and a third set of samples was
loaded. This continuous direct blotting was possible for five to seven consecutive sets of samples
with a length of 100-200ibp, equivalent to a time of five to seven hours electrophoresis.
The acrylamide gel was casted and mounted into the apparatus as described in the manufacturer's
manual. Microsatellites were separated with 3.5% to 4% acrylamide gels. The velocity of the
conveyor belt was set to 17icm/h when products were transferred to the membrane. Membranes
were dried and stored at 4°C until processing.
Biotinylated products were detected employing chemoluminescence detection. The membrane
was incubated on a horizontal shaker for 5imin in 100imM Tris pH 7.5 with 150imM NaCl, twice for
30-60imin in 100imM Tris pH 7.5 with 150imM NaCl containing 1.5%iw/v Blocking reagent
(Boehringer) and for 1-4ih in 100imM Tris pH 7.5 with 150imM NaCl containing 1.5% Blocking
reagent and 1iµl/10iml anti-Biotin Fab fragments, alkaline phosphate conjugate (Boehringer).
Detection was carried out after equilibrating the membrane in reaction buffer (100imM Tris pH 9.5
with 100imM NaCl and 50imM MgCl2) for 5imin. Next, the membrane was placed flat in a container
and the surface covered with reaction buffer containing 10%iv/v SapphireiII (Tropix) and
300iµi/i50iml CDPstar (Tropix) for 5imin. The solution was retained and the membrane briefly rinsed
in reaction buffer containing 1%iv/v SapphireiII and 30iµli/i50iml CDPstar. The membrane was
wrapped in plastic foil and immediately exposed to X-omat AR films (Kodak) for 1imin to 60imin.
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FIGURE 4: CONTINUOUS DIRECT BLOTTING ELECTROPHORESIS
(a) Direct blotting apparatus. The vertical electrophoresis gel is in contact with a conveyor belt at the lower edge of
the acrylamide matrix. A membrane is mounted on the conveyor belt and transported beneath the lower edge of the
acrylamide gel. Products separated on the gel exit the matrix and are directly transferred onto the membrane. The
resolution depends on the matrix used for separation but also on the velocity used for the transport of the membrane.
(b) Transfer of three out of five sets of 36 samples to the membrane in a continuous direct blotting electrophoresis
experiment.
(c) 180 samples of D2S1788, blotted with continuous DBE protocol. c: set of three control samples employed to
calibrate the size of the alleles between the successive sets. The 180 samples represent the total number of CF twins
and siblings and their parents analysed at polymorphic loci. A detail of samples 73-108 that demonstrates the
assignment of alleles is shown in figure 8 on page 43.
All time points given in this figure refer to minutes of electrophoresis time. The time needed for loading of the
samples at 45', 90', 135', 180' and 235' is not included in this time protocol.
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2.1.2.2.4    Marker analysis and interpretation
The PCR based study of genetic markers finds multiple implementations in human genetics: pedigree
analysis aids in genetic counselling, it may be used for identification of parentage and allows the
mapping of inherited traits. As all methods rely on the comparison of PCR generated signals between
different individuals, the key to all applications of marker analysis is the unequivocal assignment of
the allele's identity irrespective of the genomic source.
5
FIGURE 5: RFLP PATTERNS OF PON2
(a) PON2 sequence variant typed by DpnII digest of PCR product. The protocol by Adkins et al. (1993) was modified:
a mismatch in the forward primer was generated to destroy a second DpnII site within the amplified sequence (see
chapter 8.3) thus allowing easier discrimination of cleaved and uncleaved products on a 4% agarose gel.
LEFT: 54 samples separated after in-well digest as described in chapter 2.1.2.2.2
RIGHT: detail showing the three possible genotypes 1-1, 1-2 and 2-2 for this dimorphic marker
Single nucleotide polymorphisms (SLPs), typed as restriction fragment length polymorphism (RFLP)
when a site for an restriction endonuclease is either generated or destroyed upon nucleotide
exchange at the SLP locus, are analysed by digestion of the PCR product and separation of the
resulting fragments. The pattern can be interpreted unequivocally when the digested and the
undigested product are separable under the gel conditions used and when the homozygous condition
for the presence of a restriction site can be discriminated against the heterozygous state (figure  5).
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Microsatellites normally present more than two alleles and, consequently, more than three genotypes
can be observed. Furthermore, PCR amplification of repetitive sequences can give rise to by-
products which differ by even numbers of repeat units in size, as do alleles at a polymorphic locus.
The resulting pattern of alleles and by-products of both chromosomes studied can obscure the
underlying genotype. Within this thesis, repeat polymorphism patterns were interpreted in two steps
as described within the next two paragraphs: first, alleles and by-products were distinguished by
analysing genotypes within pedigrees (figures 6 and 7). Next, the size of alleles was calibrated in
arbitrary repeat units (ARU) by assigning a repeat unit of 10 to an allele and successively deducing
the size of smaller or larger alleles throughout the gel (figure 8).
All figures shown are electronic images generated from X-ray films. However, the interpretation of
band patterns was carried out solely on the basis of the autoradiograms and not of any photographic
or electronic copy thereof. The electronic images presented within this chapter were adjusted for
contrast and brightness to mimic the band pattern observed on the X-ray films after reproduction on
a high resolution ink jet printer.
Interpretation of repeat polymorphism patterns (I): Identification of alleles
The pattern observed depends upon the products generated by PCR, which in turn will depend on
the sequence of the repeat itself: repetitive sequences can be aligned asymmetrically by causing small
segments of one DNA strand to form a loop. However, only structures with sufficient stability during
the temperature conditions used for amplification that form a template-bound 3' end allowing
elongation by the Taq polymerase will lead to PCR product formation (PCR artefacts). Additionally,
the conditions used for separation of PCR products will determine the product pattern: sharp bands
are produced by DNA fragments of equal size and identical conformation. Incomplete denaturation
of products or reassembly of complementary sequences after denaturation, occurring especially when
high concentrations of product are loaded on the gel, can form smeared bands due to
inhomogeneous structural composition of the products (gel artefacts).
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FIGURE 6: PREDICTED PATTERNS OF MICROSATELLITE GENOTYPES
Genotype patterns expected for repeats amplifying with one band per allele (left) and two bands per allele (right).
Examples for both conditions are shown in figure  7, page 42:
D7S495 figure 7 (a), (b), (c) PCR amplification yielded one band per allele
D12S889 figure 7 (d), (e), (f) PCR amplification yielded two bands per allele
Within this thesis, polymorphic markers were studied using direct blotting electrophoresis enabling
simultaneous processing of 180 samples (see chapter 2.1.2.2.3 for details). This allowed the analysis
of band patterns for several families and monozygous twin pairs, having been PCR amplified and
separated under comparable conditions, thus being prone to similar PCR and gel artefacts.
First, the number of bands representing an allele was determined. It was assumed to be one
(observed for D7S495, βENaCGT and D7S525, respectively) unless more than two bands were
detected in nearly all lanes (observed for D12S889 and D7S514, respectively). Next, the resulting
pattern was predicted for genotypes composed of two alleles of identical size, two alleles differing by
one repeat unit in size, two alleles differing by three repeat units in size and genotypes with larger
size differences between the alleles (figure 6). Comparison of predicted patterns to genotypes
observed yielded rules used for the interpretation of all samples typed at that locus.
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7
FIGURE 7: BAND PATTERN OF TWO DINUCLEOTIDE REPEATS
Band patterns for 180 samples in (a) (locus D7S495) and (d) (locus D12S889) were generated by continuous direct
blotting electrophoresis as described in chapter 2.1.2.2.3.
D7S495 (b) pedigree showing two bands per allele (c) band patterns for different genotypes
D12S889 (e) pedigree showing one band per allele (f) band patterns for different genotypes
Figure (a)-(c): pattern as displayed in figure  6, page 41 for satellites amplifying with  one band per allele
Figure (d)-(f): pattern as displayed in figure  6, page 41 for satellites amplifying with  two bands per allele
See text for details.
Each microsatellite studied showed individual characteristics in terms of by-products and
background smear. Two examples are shown in figure 7: the dinucleotide repeat D7S495 was
predominantly amplified with one band per allele (shown by the pedigree in figure 7b) while the
dinucleotide repeat D12S889 continuously showed two bands per allele (as shown by the pedigree in
figure 7e). Consequently, as predicted by figure 6, the number of bands observed for genotypes
composed of two identical alleles or alleles differing one, two or more repeat units in size was
different for D7S495 and D12S889.
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Genotypes with size differences between the alleles of 0 to 5 repeat units are displayed in figure 7c
and figure 7f, for D7S495 and D12S889 respectively. The detail of figure 7f shows for D12S889 the
four band pattern predicted for a genotype composed of two alleles with a difference in size of 2
repeat units. D7S495 however, showed an exception to the pattern predicted for a repeat where an
allele is represented by one band only: whenever two alleles differing 2 repeat units in size were
observed (detail of figure 7c), three bands were obtained instead of the expected two bands. For all
D7S495 band triplets encountered within a pedigree, the pattern of inheritance was consistent with
the hypothesis of the largest and the smallest band being the allele1.
Interpretation of repeat polymorphism patterns (II): Assignment of arbitrary repeat units
Two alleles at a polymorphic locus are generally believed to be identical if they are of similar size. As
the allelic diversity at a polymorphic locus is assumed to result from omission or insertion of one or
more repeat units during DNA replication events, the size difference between any two alleles will be
an even number of repeat units. Consequently, as long as all alleles that have to be compared in size
are compared to the size of the same control allele(s), the natural dimension for sizing alleles at
microsatellite loci is "number of repeat units". These can be arbitrarily calibrated by defining the size
of a control allele for example as 10 arbitrary repeat units (ARU) (figure  8).
8
FIGURE 8: ASSIGNMENT OF ARBITRARY REPEAT UNITS (ARU)
(a) Separation of D2S1788 PCR samples in 35 lanes.
(b) Assignment of arbitrary repeat units 12-24 to bands of alleles and by-products of the samples displayed in (a).
     Desmiling lines are shown at   12   ,    19   and   22   arbitrary repeat units.
1 A speculative explanation for the dependence of observable by-products on the size difference between the alleles
typed is based on the observation that isolated D7S495 signals were accompanied by faint smears emerging
upwards and downwards from the focussed band. If two alleles are separated by 2 repeat units in size, the "upward
smear" of the lower band and the "downward smear" of the upper band would both be of equal size and might get
focussed during electrophoresis.
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2.1.3    Southern blotting
Southern blotting was performed to confirm a deletion of exon 2 and exon 3. EcoRI (NEBiolabs)
and HindIII (NEBiolabs) were used to digest genomic DNA. In the reaction buffer supplied, 10iµg
of DNA and 20 U of restriction enzyme were incubated overnight at 37°C. Restriction fragments
were separated on a 1% agarose gel (2iV/cm, 4°C, 16-18ih) and stained with ethidium bromide to
control for the loading of similar amounts of DNA in all lanes and the absence of non-specific
degradation. The DNA was denatured by incubation in 1.5iM NaCl 0.5iM NaOH for 2ih. Transfer of
DNA to a Hybond N+ membrane (Amersham) was carried out overnight with 0.4iM NaOH in a
capillary blot device.
The exoni2 and exoni3 probes, encompassing the respective exons and its flanking intron
sequences (Zielenski et al. 1991), were separately PCR amplified with a high fidelity polymerase
(DapGoldstar Polymerase, Eurogentec) in two consecutive rounds: 50ing of DNA were amplified
with a stringent protocol (annealing at 57°C-65°C and MgCl2 1.5imM or less) with 25ipmol of
upstream and downstream primer (see appendix 8.3.1 on page 171) in a reaction volume of 50iµl.
10iµl of the product were checked by agarose gel electrophoresis for absence of by-products. For
labelling with α32PdATP, 5iµl of the PCR product were used as the template for the second
amplification in 50iµl with 65°C annealing temperature and 1imM MgCl2. The probe was labelled in
a PCR reaction: 10ipmol of each primer, 1inmol dGTP, 1inmol dCTP, 1inmol dTTP, 25inmol MgCl2
and 2iµl 10i×ireactionibuffer provided by the supplier were mixed in a total volume of 8iµl and
placed on ice. 6iµl α32PdATP (5000iCi/mmol, Hartmann Analytic) and 6iµl of PCR product were
mixed in a separate tube. Both mixtures were combined, 2iU DapGoldstar Polymerase (Eurogentec)
were added and the mixture was immediately placed in a 95°C preheated block of a PCR
thermocycler. Labelling of the probe was carried out by PCR amplification with an annealing
temperature of 65°C for 30icycles. Unincorporated nucleotides were removed by ultrafiltration with
a Sephadex G-50 (Pharmacia) column. The volume of the filtrate was adjusted to 1500iµl.
The hybridisation concentration of the probe was optimised prior to analysis of patient material
on a set of control blots (figure 9). Next, the samples were processed using the optimised probe
concentration. Ionic composition of the hybridisation and washing solutions were identical for
control blots and sample blots: membranes were equilibrated at 67°C in a shaking water bath using
200iµl/cm2 of 5i×iSSC containing 1% Blocking reagent (Boehringer), 6% SDS and 100iµg/ml DNA
from fish sperm (Boehringer). For hybridisation, aliquots from 50µl to 500µl of the purified probe
were diluted in a final volume of 1iml with TE. The probes were denatured by 5' incubation in a
boiling water bath and cooled on ice. Each control blot was hybridised in a different hybridisation
bag with 200iµl/cm2 prehybridisation solution containing an aliquot of the probe. Hybridisation was
accomplished overnight at 65°C in a shaking water bath. After hybridisation, the membranes were
briefly rinsed in 2i×iSSC at 65°C (1iml/cm2 membrane), washed 5imin in 2i×iSSC at 65°C (2iml/cm2
membrane) and finally 5imin in 0.2i×iSSC at 65°C. The wet membranes were sealed in plastic foil
and exposed to X-Omat-AR films (Kodak) for 18ih up to 14idays.
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FIGURE 9: SIGNAL TO NOISE RATIO FOR DIFFERENT PCR GENERATED PROBES
The signal to noise ration was depending on (a) the concentration of the template used for the PCR labelling reaction
and on (b) the concentration of the probe used for the hybridisation. Both were optimised empirically on test blots
prior to analysis of patient samples.
The probes and hybridisation conditions used for test blot IV shown below were used to
perform the hybridisation shown in figure 16, page 62.
Four probes (A1, B1, A2, B2) were labelled by PCR according to the protocol described in the text. A1 and A2 were
probes of exon 2, B1 and B2 were probes of exon 3. For A1 and B1, 5µl of a PCR reaction was used as a template for
labelling. To generate probes A2 and B2, 5µl of a 1:10 dilution of the same PCR templates were used.
Probe A1 A2 B1 B2
Template for labelling PCR of exon 2 PCR of exon 2 PCR of exon 3 PCR of exon 3
Template PCR diluted 1: 10 prior to labelling? no yes no yes
The probes A1, A2, B1 and B2 were tested on a set of 12 control blots (I-XII). For this experiment, 8 different DNA
control samples (named "control DNA 1" to "control DNA 8") were digested with EcoRI or HindIII. 12 hybridisation
conditions, differing in (a) probe labelling conditions and (b) hybridisation concentration of the probe were tested on
12 blots. Probes were purified as described in the text and TE buffer was added to a final volume of 1500 µl. The
experiments I-XII were hybridised in parallel and washed with the same protocol (see text for details).
Blot I II III IV V VI VII VIII IX X XI XII
Volumes of labelled
probes used for 10
ml hybridisation
solution
50µl 
A1
50 µl
B1
= (1)
100µl
A1
100 µl
B1
= (2)
500µl
A1
500 µl
B1
= (3)
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A2
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B2
= (4)
100µl
A2
100 µl
B2
= (5)
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A2
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B2
= (6)
1: 10
dilution
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dilution
of (2)
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
,

 : Assignment of EcoRI and HindII fragments according to the physical map by Rommens et al. (1989).
The size was estimated relative to the band pattern of a BstEII-Digest of lambda DNA (data not shown).
Two bands are expected within each lane, one corresponding to exon 2 (  ) and one corresponding to
exon 3 (  ).

 : non-specific band
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2.2    Analysis of phenotype
For both studies described in this thesis, a characterisation of the clinical phenotype according to the
guidelines established at the Biomed genotype-phenotype workshop in 1994 (Association Francaise
de la Lutte contre la Mucoviscidose 1994: Genotype-Phenotype correlation in CF. AFLM, Paris.
pp 4-6) was attempted. This included assessment of pancreatic status by elastase from stool samples,
measured in the Department of Gastroenterology, MHH according to standard laboratory
procedures. To explore a bacterial colonisation of the patient's lung, sputum or throat swabs were
obtained. Pathogens were analysed by the Department of Microbiology, MHH. Interventions and
activities permitted only to medical professionals, such as the anamnesis and clinical investigation of
the patients, were performed by the participating physicians of the study.
Parameters used to quantify the disease severity were derived from weight and height of the
patient – used to characterise the nutritional status – and forced expiratory volume in 1is – used to
characterise the pulmonary status – by employing age corrected percentiles (chapter  2.2.1).
The basic defect, as defined by a defect in Cl
¯
conductance in CFTR expressing epithelia, was
investigated by a sweat test (carried out according to the procedure used at the hospital where the
research was performed), by nasal potential difference measurement (chapter 2.2.2.1) and by
intestinal current measurement (chapter 2.2.2.2).
2.2.1    Evaluation of disease severity and selection of pairs with
extreme phenotypes
For CF twin and sibling pairs, information on age, sex, weight, height, the lung function parameters
forced expiratory volume in 1is [FEV1] and vital capacity, pancreatic status and colonisation with
Pseudomonas aeruginosa was required. Out of a total of 540ipairs recruited from more than
200idifferent European CF centers, complete information could be obtained for 324ipairs.
2.2.1.1    Selection of twin and sib pairs
The quantification of disease severity and overall clinical status was assessed using an unbiased
mathematical approach. The aim of this procedure was to select pairs with an extreme phenotype. If
this selection is not made by an objective approach but by manual evaluation, the pairs selected will
express extreme phenotypes, but the selection will not be complete – simply because it is most likely
that a pair displaying features similar to a manually selected pair will escape notice when reviewing
clinical data of more than 300 patient couples. Consequently, evaluation done on manually selected
pairs will result in describing merely a subgroup of all pairs with likewise features.
On the other hand, the computed approach demands the use of simplified data. As will be
illustrated in chapter 2.2.1.2, the disease severity was quantified by equally weighing nutritional
status and pulmonary status, achieved by a diagram with a parameter representing each status on one
axis. The overall disease severity was then defined as distance from origin within that diagram,
ignoring the information of direction that is contained within a vector. This was compensated for as
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described in chapter 2.2.1.3. The result of the ranking procedure applied was the description of a
pair's phenotype with five rank numbers, each taking into account disease severity and intrapair
discordance. Selection of twin and sib pairs – for investigation of the basic defect and for candidate
gene testing – was carried out based on these computed rank numbers and revealed pairs possessing
non-average properties for their nutritional status, their lung function or the intrapair variation of one
or both of these characters.
For evaluation of candidate genes, the selected pairs were categorised to define the most
extreme ∆F508 homozygous pairs in the sequences with respect to the trait "discordant" or the
combined traits "concordant/mild disease" and "concordant/severe disease". Pairs ranked
simultaneously in two conflicting categories were categorised separately as "discordant and
concordant mild disease" (DC) and "non-discordant" (ND) as described in chapter 2.2.1.4.
2.2.1.2    Definition of age independent parameters used to describe disease
severity
Patients and pairs, who were heterogeneous in both age and age difference, were compared using
centiles. This allowed an age-independent description of disease severity and consequently enabled
comparison of disease severity between patients of different ages, within as well as between pairs.
The nutritional status was represented by weight expressed as a percentage of expected weight at the
patient's height percentile (wfh%). wfh% was calculated on the basis of age and sex dependent
centiles for weight and height published by Prader et al. (1989). Data for the complete patient cohort
are shown in figure 10b. Lung function was evaluated from predicted values for FEV1 as described
by Knudson et al. (1983) and converted to CF population centiles (FEVPerc). FEVPerc was
computed from FEV1%pred on the data basis of the European CF registry report of 1995 which
compiles lung function data from more than 20.000 CF patients. Figure 10a displays all data of the
CF patients lung function parameter FEV1%pred whereby the measured FEV1 value is normalised
for height, sex and age in a healthy non-CF population. Figure 10b shows the distribution of
parameter FEVPerc that corrects for the CF specific decline in FEV1%pred with age. Regression
formulas used for the calculation of wfh% and FEVPerc are listed in the appendix 8.3.3.
2.2.1.3    Ranking of pairs according to disease severity and discordance 
The selection of twin and sib pairs with extreme phenotypes was based on the combination of
nutritional and pulmonary status, represented by wfh% and FEVPerc, as defined in chapter 2.2.1.2.
Disease severity was defined as "overall clinical shape" with equal weight on nutritional and
pulmonary status. Nutritional status and pulmonary function were described non-parametrically by
assigning ranking numbers for wfh% and FEVPerc within a group of 324 patient pairs. Both
parameters were used to display a diagram with rank numbers of wfh% on the x-axis and rank
numbers of FEVPerc on the y-axis (figure 10c). Each patient, represented as a point in that diagram,
was then characterised in terms of disease severity by the distance from origin (DfO) in the plot. Low
DfO corresponded to severe disease and high DfO corresponded to mild disease. Likewise, intrapair
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distance was quantified by calculating the distance of the two data points representing two members
of a pair within the same diagram. This parameter was named DELTA, with low values for DELTA
corresponding to concordant pairs and high values of DELTA corresponding to discordant pairs
(figure 10c).
10
FIGURE 10: RANKING OF PATIENT PAIRS (I)
DEFINITION OF COMPOSITE PARAMETERS
The disease severity was quantified by equally weighing nutritional status and pulmonary status:
(a) raw data obtained from participating CF centers
(b) parameters with age independent centiles representing nutritional status and lung function
(c) definition of composite parameters DELTA (

 intrapair discordance) and DfO (

 disease severity)
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Alternatively, the intrapair discordance was judged by the difference in DfO for both members of a
pair. Two definitions for the intrapair discordance were employed because some pairs, being
concordant and in good clinical status in their weight for height but discordant in their lung function,
were scored as discordant when using DELTA. Discordance within a pair implies one sib being
mildly diseased while the other is severely affected. In contrast, these pairs with high values for
DELTA showed equally high DfO for sib A and sib B, demonstrating that both sibs are in good
health. These pairs were scored as concordant when the difference between the distances from origin
was chosen to define the intrapair discordance2.
When plotting the parameter DfO on the y-axis against the parameter DELTA on the x-axis for
all patients (figure 11a), pairs could be ranked according to their degree of discordance and their
degree of disease severity by successively tracing pairs from the lower left edge (concordant severe
pairs) or the upper left edge (concordant mild pairs) or the right rim (discordant pairs) of the
diagram towards the middle of the plot where both, disease severity and degree of discordance, were
average. However, this manual assignment was only reliable when ranking pairs according to their
discordance. For the concordant – mild or severe – pairs, the emphasis can be put either on
"disease.severity" or on "discordance". Hence, both attributes of a pair were combined in a diagram
with a parameter describing the discordance on the x-axis and a parameter describing disease severity
on the y-axis. The rank of concordant pairs was derived from their distance from origin in
that plot. With this definition, the impact of concordance and the disease severity were
identical for the definition of the combined properties "concordant./.mild.disease" and
"concordant./.severe.disease".
To sort all pairs according to the traits "discordant", "concordant./.mild.disease" and
"concordant./.severe.disease", a total of five rank numbers were assigned to each pair (figure 11b-f).
The rank defining the position of a pair according to its discordance (DISC) was the reverse rank
number of the parameter DELTA, with DISC.=.1 being assigned to the most discordant pair (figure
11b). The rank number defining the position of a pair according to its concordance and its disease
mildness (CON+∆) was calculated as rank number for the distance from origin in the plot of the rank
number for DELTA on the x-axis and the inverse rank number for the sum of the DfO for both sibs
on the y-axis. CON+∆.=.1 is referring to the most concordant and most mild pair (figure 11c).
Likewise, the rank defining the position of a pair according to its concordance and its disease
severity (CON-∆) was calculated as rank number for the distance from origin in the plot of the rank
number for DELTA on the x-axis and the rank number for the sum of the DfO on the y-axis. CON-
∆.=.1 is referring to the most concordant and most severe pair (figure 11d). While CON+∆ and
CON-∆ both employ the parameter DELTA for quantifying the discordance, in an alternative
2 An example for such a pair is given by the following data set for an adult sib pair: sib A had a wfh of 120 %,
corresponding to a rank of 578 for the nutritional status (maximal rank 648 within the evaluated 324 pair cohort).
The lung function of Sib A revealed an FEV1%pred of 17% resulting in a rank number of 12 for the pulmonary
status. The overall disease severity based on DfO was ranked as 502. Sib B showed a wfh of 120 %, ranking 582 in
the nutritional status. The lung function of Sib B was 91%pred in FEV1, resulting in a rank of 526 for the
pulmonary status. The overall disease severity evaluated via DfO was ranked 558.
This pair was categorised as "DC", as described in figure 12.
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approach the difference in DfO for both members of a pair was used to define discordance in
otherwise similar plots as described for CON+∆ and CON-∆. Rank numbers derived from differences
in DfO were called CON+diff and CON-diff with CON+diff.=.1 corresponding to the most
concordant and most mildly diseased pair (figure 11e) and CON-diff.=.1 corresponding to the most
concordant and most severely diseased pair (figure 11f).
11
FIGURE 11: RANKING OF PATIENT PAIRS (II)
DEFINITION OF RANK NUMBERS
(a) plot of disease severity vs discordance for all ∆F508 homozygous pairs 
left: 
	
 Sibling A of pair;


 Sibling B of pair
right: areas representing discordant pairs (

), concordant/mild disease pairs (

) concordant severe disease pairs (

)
(b)-(f): diagrams used to define rank numbers by ranking a pair's distance from origin in these plots
(b) discordance DISC (discordance defined by DELTA)
(c) concordance/mild disease CON+∆ (discordance quantified by DELTA)
(d) concordance/severe disease CON-∆ (discordance quantified by DELTA)
(e) concordance/mild disease CON+diff (discordance quantified by difference between DfO[SibA]and DfO[SibB]
(f) concordance/severe disease CON-diff (discordance quantified by difference between DfO[SibA]and DfO[SibB]
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2.2.1.4    Categorising of pairs selected for candidate gene typing
Based on the ranking described in chapter 2.2.1.3, all ∆F508 homozygous pairs with rank numbers
lower than 20 in any of the sequences CON+∆, CON-∆, CON+diff or CON-diff or lower than 25 in
the sequence DISC were selected for PCR typing if DNA samples were available by December 1997.
A total of 38.∆F508 homozygous pairs could be selected. The rank numbers for the selected ∆F508
homozygous pairs are shown in table 1.
For ranking pairs, disease severity was defined by DfO with nutritional and pulmonary status
balanced. As a combined parameter, DfO does not contain the information whether it was based on a
more than average wfh%, a more than average FEVPerc, or both. Likewise, the parameter DELTA,
defining the discordance of a pair, can be large even if both members of a patient pair have a equally
high DfO as for pairs concordant in one parameter – e.g. wfh% – but highly discordant for the other
parameter – e.g. FEVPerc. Furthermore, in defining rank numbers for concordant pairs, disease
severity and discordance was given equal importance. Consequently, pairs being extremely
concordant received comparably low rank numbers in CON+∆ and CON-∆.
To assure that all pairs grouped within the same category are comparable with respect to both
the intrapair difference of the wfh% and FEVPerc, the five rank numbers were combined to identify a
category as displayed in figure 37:
— All pairs categorised as discordant pairs (DIS, 12 couples) had a low rank number for DISC,
but not for CON+∆, CON-∆, CON+diff and CON-diff.
— 4 pairs selected based on the rank number for CON+diff also displayed a low rank number for
DISC and were categorised as discordant and concordant/mild disease (DC, 4 couples).
— All pairs categorised as concordant.mild (CON+, 8 couples) had low rank numbers for
CON+∆ and CON+diff but not for CON-∆, CON-diff and DISC.
— All pairs categorised as concordant.severe (CON-, 8 couples) had low rank numbers for
CON-∆ and CON-diff, but high rank numbers for CON+, CON+diff and DISC.
— 6 pairs had low rank numbers for CON+∆, CON-∆, CON+diff and CON-diff but a high rank
number for DISC and were categorised as non-discordant (ND, 6 couples)3.
The similarity of intrapair difference for wfh% and FEVPerc within each of the resulting categories is
demonstrated in figure 28. Diagrams displaying DELTA, DfO, wfh% and FEVPerc for all pairs
within the categories DIS, CON+ and CON- are shown in figure 29 (Chapter 3.2.3.2, page 99 and
page 100).
3 To discriminate pairs "CON+" and "CON-"from pairs "ND", the following borders were employed:  
CON+ vs ND: {Rank CON+∆ — Rank CON-∆} < 30 OR {Rank Con+diff — Rank Con-diff} < 30 ⇒ pair classified as
"CON+"
CON- vs ND: {Rank CON+∆ — Rank CON-∆}< 20 OR {Rank Con+diff — Rank Con-diff} < 20 ⇒ pair classified as "CON-"
whereby
{CON+∆ — Rank CON-∆} was used if the pair was selected based on Rank CON+ ∆ or Rank CON-∆
and
{Rank Con+diff — Rank Con-diff} was used if the pair was selected based on rank CON +diff or CON-diff.
The borders employed to distinguish concordant mild or severe pairs from non-discordant pairs by the rank number
differences, {Rank CON+∆ — Rank CON-∆} and {Rank Con+diff — Rank Con-diff}, were set to 10, 20, 30 and 40.
Other borders than those used in the definition above resulted either in omission of most pairs (e.g. border 40) or no
pair (e.g. border 10).
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1
TABLE 1: PAIRS SELECTED FOR GENETIC ANALYSIS (I)
RANK NUMBERS AND CATEGORIES
38 ∆F508 homozygous pairs were selected for genetic analysis (DNA available by December 1997) based on a rank
number of 20 or lower (CON+∆, CON+diff, CON-∆, CON-diff) or 25 or lower (DISC). Rank numbers leading to the
selection of a pair are printed in colour.
Categories DIS, CON+, CON-, DC and ND were defined as shown in figure  12.
For discriminating pairs "CON+" and "CON-" from pairs "ND" see text.
DISC CON+
∆
CON+
diff
CON-
∆
CON-
diff
DISC CON+
∆
CON+
diff
CON-
∆
CON-
diff
LOW HIGH HIGH HIGH HIGH HIGH LOW LOW HIGH HIGH
DIS3 3 114 114 99 85 CON+2 106 2 7 78 81
DIS5 5 110 106 103 100 CON+5 99 5 8 65 68
DIS6 6 106 105 104 104 CON+6 105 6 13 38 44
DIS8 8 102 88 105 87 CON+7 78 7 24 82 93
DIS9 9 113 112 91 82 CON+10 84 10 25 57 69
DIS14 14 112 113 79 75 CON+15 74 15 33 77 96
DIS15 15 78 80 97 103 CON+16 68 16 19 90 89
DIS16 16 85 91 96 97 CON+19 79 19 17 51 62
DIS18 18 80 44 95 50
DIS19 19 81 83 92 94 HIGH HIGH HIGH LOW LOW
DIS21 21 98 98 75 77 CON-2 113 68 73 2 4
DIS24 24 103 109 62 67 CON-5 103 65 66 5 2
CON-7 104 59 68 7 11
CON-8 97 79 89 8 15
CON-10 107 37 40 10 6
CON-12 86 50 53 12 10
CON-14 77 67 75 14 27
CON-25 76 45 35 25 8
LOW HIGH LOW HIGH LOW HIGH LOW LOW LOW LOW
DC(1) 7 70 10 114 99 ND(1) 95 17 21 35 41
DC(2) 17 51 2 111 70 ND(2) 85 39 47 19 19
DC(3) 38 33 1 110 83 ND(3) 110 13 14 28 28
DC(4) 31 46 15 102 59 ND(4) 102 20 26 26 34
ND(5) 96 27 49 17 38
ND(6) 93 11 12 40 40
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12
FIGURE 12: RANKING OF PATIENT PAIRS (III)
CATEGORISING OF SELECTED PAIRS
(a) rank number patterns defining the categories DIS (discordant), DC (discordant and concordant/mild disease),
CON+ (concordant mild disease), CON- (concordant/severe disease), ND (non-discordant)
(b)-(f): examples of pairs within each category represented by plots of ranknumber of wfh% vs ranknumber of
FEVPerc. This diagram was used to define the parameters DfO and DELTA representing the disease severity and the
intrapair-discordance (figure 10c).
(a) RANK NUMBERS AS DEFINED IN FIGURE  11
DISC CON+∆ CON+diff CON-∆ CON-diff
DIS LOW HIGH HIGH HIGH HIGH
DC LOW HIGH LOW HIGH HIGH
CON+ HIGH LOW LOW HIGH HIGH
CON- HIGH HIGH HIGH LOW LOW
ND HIGH LOW LOW LOW LOW
2.2.2    Assessment of the basic defect
The impaired Cl¯ permeability, regarded as the basic defect in CF, was assessed in three different
tissues: in the sweat gland (by measuring Cl¯ concentrations of the sweat in a pilocarpine
iontophoresis sweat test according to Gibson and Cooke 1959), in the respiratory tract (by
measuring the permeability of the epithelium of the lower nasal turbinate, chapter 2.2.2.1) and in the
intestinal tract (by measuring the permeability of rectal suction biopsies, chapter 2.2.2.2). Gibson-
Cooke-sweat test were performed by the technician of the pediatric clinic of the MHH according to
approved guidelines (National committee for clinical laboratory standards [1994] Sweat testing:
sample collection and quantitative analysis - approved guideline. Document C34-A. Wayne,
Pennsylvania.). The expertise and the equipment to measure NPD and ICM was provided by the
Rotterdam group. All NPD measurements were performed by I. Bronsveld, Rotterdam. The results
discussed within this thesis refer to the study "rare genotypes". ICM measurements were done by H.
Veeze, Rotterdam for all cases in the study "rare genotypes" and several cases of the "European CF
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twin and sibling study". ICM results from both studies are presented and discussed within this thesis.
Quantitative evaluation of ICM tracings was accomplished computer assisted, employing INTEG,
programmed by J. Greipel, Hannover.
2.2.2.1    Nasal potential difference (NPD) measurement
Nasal potential difference measurements were performed with a protocol adapted from Knowles et
al. (1981). The reference electrode was connected to a saline-filled needle which was placed
submucosally in the forearm. The epithelium of the lower nasal turbinate was accessed by a catheter
used to superfuse the nasal epithelium with different solutions. Both electrodes were connected to
the voltage measuring device via a salt bridge and Ag/AgCl electrodes. The nasal epithelium was
superfused subsequently with the solutions displayed in table 2.
2
TABLE 2: NPD PROTOCOL
(1) Basal
1.2 × 10-1 M NaCl
2.5 × 10-2 M NaGluconate
4 × 10-4 M NaH2PO4
2.4 × 10-3 M Na2HPO4
pH
7.4
basal value
(2) Amiloride (1) with 10-4 M amiloride blocking of Na+ channels
(3) Chloride free
1.45 × 10-1 M NaGluconate
4 × 10-4 M NaH2PO4
2.4 × 10-3
 
M Na2HPO4
10-4 M amiloride
pH
7.4
block of anion permeability by gluconate
(4) Isoproterenol 10-4 M isoprenaline in (3) stimulation of CFTR Cl
¯
 channels
NPD is employed as a sensitive method for diagnosing CF. The condition CF, characterised by a
reduced Cl
¯
permeability of the nasal epithelium, was identified by a high4 basal value compared to
non-CF controls (CF: PD = -39mV ± 14mV, non-CF: PD = -20mV ± 9mV). In borderline cases of
basal PD values between -25 mV and –35 mV, the spontaneous Cl
¯
conductance assessed by
superfusion of the nasal epithelium with chloride free solution after blocking of Na+ channels with
amiloride was employed to discriminate between CF and non-CF condition: a large hyperpolarization
(∆PD ≥ 16 mV) was considered confirmatory for the non-CF status; CF patients exhibiting low basal
values showed a smaller response (∆PD ≤ 7 mV; Bronsveld et al. 1996). The protocol allows the
assessment of residual chloride secretion in CF patients by measuring the responses to chloride-free
solution and isoproterenol. Within chapter 3.1.2, the conditions "normal", "CF" and "CF-res" are
distinguished accordingly.
4 A "high" basal refers to a negative potential difference with high absolute value by convention. -50mV is termed a
high basal PD compared to –20 mV.
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2.2.2.2    Intestinal current measurement (ICM)
Short circuit currents were measured in a micro Ussing chamber as described by Veeze et al. (1991).
Two samples were analysed in parallel. Freshly obtained rectal biopsies were mounted within 5
minutes in the Ussing chamber. Tissue was incubated in Meyler solution at 37°C and gassed with
carbogen (95% O2, 5% CO2). After stabilisation of the basal current, the protocol shown in table 3
was implemented.
3
TABLE 3: ICM PROTOCOL
Secretagogues (2)-(6) were added to the mucosal (M) or serosal (S) side.
(1) glucose 10-2 M M+S 10'-20' stabilisation of basal current 
(2) amiloride 10-4 M M 5' blocking of Na+ channels
(3) indomethacin 10-5 M M+S 5' blocking of prostaglandin synthesis
(4) carbachol 10-4 M S 5'-30'
raising intracellular Ca2+ concentration: †
transient activation of conductance, e.g., through
basolateral K+-channels and apical Cl
¯
 - channels
(5) cAMP/forskolin 10-3 M/10-5 M M+S 5'-30' raising intracellular cAMP 
(6) DIDS 2 × 10-4 M M 10' e.g. blocking of Ca2+ activated Cl
¯
 channels ‡
(7) histamine 5 × 10-4 M S 5'-30'
raising intracellular Ca2+ concentration: †
transient activation of conductance, e.g., through
basolateral K+-channels and apical Cl
¯
 channels
Alternatively, DIDS was added prior to carbachol when two working biopsies were obtained as
judged by the amiloride response.
‡ DIDS acts on multiple components of the ion transport system (Gögelein 1988)
†
 carbachol and histamine act through different, though both Ca2+ dependent, pathways
The employment of ICM as a diagnostic tool in CF was based on the response to carbachol (Veeze
et al. 1991). In non-CF tissue, the CFTR mediated Cl
¯
secretory current provoked a transient
increase in short circuit current while in most CF tissues a transient decrease in short circuit current
was observed due to the efflux of K+ ions through K+ channels. In some CF patients a response in
the non-CF Cl
¯
secretory direction was seen but the size of the responses differentiates between non-
CF (mean peak response 26 µA/cm2) and CF (mean peak response 3 µA/cm2) conditions. Residual
Cl
¯
secretion was also observed by CF patients exhibiting both the K+ mediated reversed and the Cl
¯
mediated residual response.
The protocol permits a dissection of residual Cl
¯
secretion in proportions mediated by CFTR
and mediated by alternative, Ca2+ activated Cl
¯
channels by the employment of DIDS which is
known to inhibit the Ca2+ activated secretory currents (reviewed by Gögelein 1988). In order to
assess the presence of alternative secretion, the residual component of responses obtained with
carbachol (in the absence of DIDS) and histamine (after 10' incubation with DIDS) were compared.
Finally, CFTR mediated chloride conductance was considered to be activated by addition of cAMP
and forskolin.
Representative tracings for the CF and the non-CF condition are displayed in figure 13.
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13
FIGURE 13: ICM RESULTS TYPICAL FOR NON-CF AND CF PATIENTS
(a) Idealised ICM results for non-CF controls and CF patients with protocol shown in table 3.
(b) Example for a non-CF ICM. The result was obtained on patient O (non-CF, described in chapter  3.1.2.5). 
(c) Example for a CF ICM. The result was obtained on patient D (CF, described in chapter  3.1.2.1).
(b) and (c): scales for Isc and t are adjusted for better viewing.
Carbachol-evoked responses with substantial proportions of a residual Cl¯ secretory component have
been shown to correlate with a mild CF phenotype in a group of unrelated CF patients with several
CFTR mutation genotypes (Veeze et al. 1994). Within this thesis, two approaches towards the
evaluation of ICM results were pursued: in chapter 2.2.2.2.1 the responses obtained by carbachol-
stimulation were analysed qualitatively based on the shape of the response in order to evaluate the
results of the study "rare genotypes and atypical cystic fibrosis" (chapter 3.1.2). A quantification of
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the residual component was attempted as described in chapter 2.2.2.2.2. The results gained on
patients participating in the "European CF twin and sibling study" were evaluated quantitatively as
shown in chapter 3.2.2.
2.2.2.2.1    Shapes of carbachol-induced short circuit currents in rectal biopsies
Ideally, the baseline is supposed to be constant during a response. However, when studying rectal
biopsies by ICM, most responses displayed either a change of the baseline level during the response
(defined as offset) or a change in the baseline slope during the response (defined as drift). The nine
shapes of carbachol- and histamine responses observed on analysing 66 tracings are displayed in
table 4. A clear distinction between presence and absence of residual chloride secretion is feasible for
five out of nine shape types observed (type I, II: without residual component; type VII, VIII, IX:
with residual component). These unequivocally interpretable shapes were assigned to 22 out of 43
carbachol-induced peaks and for 26 out of 39 histamine-induced peaks. In some cases, results for
two biopsies were obtained and different shape types were displayed by both biopsies. Especially
type III, characterised by its broadness , was found in combination with other shapes displaying a
residual component (type VII and VIII, respectively). Type III was observed only for carbachol- but
not for histamine-induced responses.
Figure 14 displays some uncommon response shapes. Each of the four patterns was seen in
only one patient, but was reproduced in both biopsies investigated.
14
FIGURE 14: UNUSUAL, BUT REPRODUCIBLE RESPONSE SHAPES IN ICM
Selected examples for unusually shaped ICM responses. Each of the four pairs of responses was obtained by
measuring two biopsies from the same patients. All results were obtained by stimulation with carbachol.
2.2.2.2.2    Quantitative evaluation of ICM signals
In order to evaluate all carbachol– and histamine-induced responses regardless of their shape, a
computer-assisted approach was taken: for each peak, a linear baseline was assigned prior to the
response and – independently of the former – following the response. The course of the baseline
during the response was calculated as a spline function, defined by a third degree polynomial
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equation starting with slope and baseline of the linear function defining the baseline prior to the
response and ending with slope and baseline of the linear function defining the baseline after the
response. After the spline function has been assigned as baseline to the response, height and area
above and below the baseline were calculated and considered representative for the reversed and the
residual proportions of the signal (data shown in figure 15, page 59).
4
TABLE 4: COMMON SHAPES OF CARBACHOL AND HISTAMINE INDUCED PEAKS
Definition of shape types I to IX by offset and drift conditions.  Offset: change of baseline level during response, either
towards the reversed direction (to rev) or towards the residual direction (to res). Drift: change of baseline slope
during response. Shape III is discriminated against shape II on the basis of the peak broadness.
reversed yes yes yes yes yes yes yes yes no
residual no no unknown unknown unknown unknown yes yes yes
offset to rev no no no to res to res to res no no
drift no no no yes no yes no no no
SHAPE
I II III IV V VI VII VIII IX
CARBACHOL-INDUCED SIGNALS
Shapes of carbachol-induced signals observed in ICM tracings of 66 patients. In 7 cases, no conclusive signal was
seen. 10 results were excluded from shape type analysis because of a high drift or too small response. Of the
remaining 49 patients, 43 results were obtained from either one biopsy only or both measurements showed the same
carbachol-induced shape. The number of observed shapes I-IX are displayed in the table below. In 6 cases, different
shapes were observed in both biopsies. Of these 6 cases, three displayed a combination of shape III in one
measurement and shape VIII in the other measurement. The following combinations of shapes were observed only
once: shape III and shape VII, shape VI and shape VIII, shape V and shape VIII.
SHAPE I II III IV V VI VII VIII IX
no. of
tracings
(n=43)
2 4 6 6 4 5 5 6 5
HISTAMINE-INDUCED SIGNALS
Shapes of histamine-induced signals observed in ICM tracings of 66 patients. In 19 cases, no conclusive signal was
seen. 3 results were excluded from shape type analysis because of a high drift or too small response. Of the remaining
44 patients, 39 results were obtained from either one biopsy only or both measurements showed the same histamine-
induced shape. The number of observed shapes I-IX are displayed in the table below. In 5 cases, different shapes were
observed in both biopsies. Of these 5 cases, three displayed a combination of shape II in one measurement and shape
VII in the other measurement. The following combinations of shapes were observed only once: shape V and shape VI,
shape II and shape VI.
SHAPE I II III IV V VI VII VIII IX
no of
tracings
(n=39)
1 3
—
2 7 3 9 9 4
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FIGURE 15: RELATION OF PEAK AREA AND PEAK HEIGHT
OF CARBACHOL –-    AND HISTAMINE –- INDUCED SIGNALS IN ICM
All data displayed were obtained using baselines calculated by INTEG as described in chapter 2.2.2.2.2. For each
response, four values were calculated: peak height below the baseline (parameter a), peak area below the baseline
(parameter A), peak height above the baseline (parameter b) and peak area above the baseline (parameter B); see
grey box for definition. Units are given as divisions on scale for short circuit current (Isc) and time (t).
(a), (b) Values below zero refer to the reversed proportion of a response (height a, area A) and values above zero
refer to the residual proportion of a response (height  b, area B).
-: carbachol-induced responses - : histamine-induced responses
——— : average height to area ratio for carbachol-induced peaks (2 nd degree polynomial fit)
——— : average height to area ratio for histamine-induced peaks (2 nd degree polynomial fit)
(c) Proportion of the reversed component of area (PDA%) and height (PDH%). Peaks displaying exclusively the
reversed component have values of 100% PDH and 100% PDA.
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3    RESULTS AND DISCUSSION
3.1    The study "Rare genotypes and atypical Cystic Fibrosis"
The study ″Rare genotypes and atypical CF″ aims at correlating CFTR genotype and CF phenotype
by investigating the effect of uncommon molecular lesions in the CFTR gene on the basic defect and
the clinical phenotype. The patients selected for this study can be divided into three groups:  
(a) compound heterozygous patients carrying a rare CFTR allele
nonsense mutations: G542X/Y1092X; R553X/L1059X ∆F508s
splice mutations: ∆F508/3272-26 A  G; ∆F508/3850-3 T  G; 4000-2 A  G/IVS8-6(5T)
complex allele: ∆F508-R553Q/R553X; ∆F508-V1212I/∆F508
(b) patients with homozygous CFTR genotypes other than ∆F508
R553X, CFTRdelEx2(a); CFTRdelEx2,3(b); E92K; 1898+3 A

G; 3849+10kb C

T∆ F508
(c) patients with atypical CF suspected to carry at least one functional CFTR allele ∆F5
patient P, Q, R, S (table 5)
All genotypes but those indexed by footnote and described in chapter 3.1.1 were resolved previously.
The states of CFTR mutation screening of the participants of unknown mutation genotype at the day
of entry are listed in table 5.
5
TABLE 5: SSCP SCREENING CARRIED OUT UNTIL 1994 ON PATIENTS PARTICIPATING IN
THE STUDY "RARE GENOTYPES AND ATYPICAL CF"
D, I, P, Q, R, S: patient identification S: exon was sequenced after SSCP analysis
1: SSCP analysis performed with one restriction digest;  2: SSCP analysis performed with two restriction digests
SSCP Screening of CFTR Exons
1 2 3 4 5 6a 6b 7 8 9 10 11 12 13 14
a
14
b
15 16 17
a
17
b
18 19 20 21 22 23 24
D 1 1 S S S 2 1 2 1 1 S 1 S 1
I 2 1 2 1 2 S S 2 1 2 1 2 S 1 S 1
P 2 1 S 2 1 2 2 2 1 2 S 2 2 2 2 2 1 2 1 1 1 1 2
Q 2 S 1 2 1 2 2 2 1 1 S 2 1 1 2 2 2 1 1 1 1 2 2 2 1
R 2 1 S 2 1 2 2 2 1 S 1 S 2 1 2 2 2 1 1 1 S S 2 2 2
S 2 S S 2 1 1 S 1 S S S 2 1 2 2 2 2 2 1 S S S 1 1
These patients suspected of carrying at least one functional CFTR allele were selected on the basis of
the work of T. Dörk who has analysed more than 350 CF patients without being able to identify both
disease-causing lesions in some cases. Within this thesis, SSCP screening of all CFTR exons and the
promoter region was completed for these 6 cases and another 14 patients who were diagnosed as
having CF but did not carry two mutations, as was known after mutation screening of most CFTR
coding sequences and flanking intron sites until 1994.
(a) This mutation was identified in patient I (table 5).
(b) This mutation was identified in patient D (table 5).
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3.1.1    Results of the genotype analysis 
3.1.1.1    CFTRDelEx2 and CFTRDel Ex2,3
Among the 770 CF mutations submitted to the Cystic Fibrosis Genetic analysis consortium,
(http://www.genet.sickkids.on.ca/cftr/), only seven large deletions have been reported. This is partly
based on the method employed for mutation analysis: the common screening methods rely on SSCP
or DGGE, which are both PCR based. Any deletion encompassing the analysed PCR fragment will
not be detected by PCR unless presented in the homozygous state.
In two patients, both children of a consanguineous marriage, deletions of complete exons
could be identified. The missing exons were first noticed during SSCP analysis where no product for
exoni2 (patient I) or exoni2 and exoni3 (patient D) was amplified.
Amplification of exoni3 from patient D under optimised conditions did not show a product of
the expected size, but showed several bands, the most prominent among them having a size of
450ibp, as judged on a 2% agarose gel. However, analysis of the excised band on a 12%
polyacrylamide gel revealed a composition of more than one band. Direct sequencing of the 450ibp
band excised from the agarose gel was carried out and the band pattern could be interpreted at
several stretches of 10-20 bp length, none of them composed of exoni3 sequences (data not shown).
Consequently, the PCR results were interpreted by assuming a deletion of exoni3 in patient D
leading to a non-specific amplification of other genomic sequences unrelated to exoni3.
Amplification of exoni2 with optimised PCR conditions in patients I and D failed to amplify
any product. The amplicon was further analysed by PCR employing protocols of increasing
stringency by subsequently rising the annealing temperature (figure 16a-c). At 45°C, 50°C and 55°C,
PCR product was amplified from DNA of a control, both parents of patient I and the father of
patient D. The same samples failed to amplify exoni2 product at annealing temperatures of 60°C and
65°C. From the DNA of patients I and D, no exoni2 band could be amplified under any condition.
However, an identical by-product pattern was generated when amplifying the DNA of either patient I
or D at low annealing temperatures or the DNA of the control, of both parents of patient I or the
father of patient D at higher annealing temperatures. The results were explained by assuming a
deletion of exoni2 in patients I and D, resulting in binding of PCR primers to sites within sufficient
homology to the target sequences to allow product formation. The same secondary binding sites are
present in patients and controls, resulting in an identical band pattern when the target sequence is not
available – either by deletion of the target sequence in the patient or by increasing the annealing
temperature above optimum conditions in control samples.
Both deletions were confirmed by Southern blotting as described in chapter 2.1.3 (figure 16d).
Since the PCR probe used for hybridisation was generated with exon-flanking intron primers
(Zielenski et al 1991), it is evident that complete exons are missing in the deletions and that the
respective deletion breakpoints are located within the introns upstream and downstream of the
oligonucleotide primer sequences. The sequence of the exon/intron boundaries from exon 1, 2, 3,
and 4 as published by Zielenski et al. (1991) predicts that the deletion of exoni2 is an in frame
deletion while the deletion of exoni2 and exoni3 will produce a frameshift (figure 16e).
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FIGURE 16: ANALYSIS OF THE DELETIONS CFTRDelEx2 AND CFTRDelEx2,3
(a) Analysis of exon2 deletion with PCR, Assignment of exon 2 product was done by size comparison with a 100 bp
ladder (lane S) and a lambda DNA BstEII digest (lane  λ)
(b) Detail showing similarity of by-product patterns between (left )sample without exon 2 target sequence and
(right) sample with exon 2 target sequence.
(c) Temperature profile of 35 extension cycles used to amplify products shown in figure (a).
(d) Detection of CFTRDelEx2 (patient I) and CFTRDelEx2,3 (patient D) by Southern blotting as described in
chapter 2.1.3. The PCR generated genomic probe encompasses the full exon and flanking intron sequences
(Zielenski et al. 1991). Fragments were assigned according to the physical map of Rommens et al. (1989):
the expected fragments are 7.3 kb (corresponding to exon2 — HindIII fragment) and 3.1 kb (corresponding
to exon3 — HindIII fragment).
(e) Predicted mRNA sequences for expression of CFTR-DelEx2 (in frame deletion) and CFTR-DelEx2,3 (out of
frame deletion) based on the published exon/intron structures of the CFTR gene (Zielenski et al. 1991).
3.1.1.2    Polymorphisms in intron 14a and intron 14b
A novel intronic sequence variant was detected in intron 14b in patient P. The mutation was detected
by SSCP in two different digest. Upon sequencing, two sequence alterations encompassing exon 14b
were detected: 2752-22A

G in intron 14a5 and 2789+32T

C in intron 14b (this work). Both
nucleotide exchanges were located on the maternal chromosome. SSCP and sequencing analysis is
shown in figure 17.
5 described by Marrigo et al. (personal communication)
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FIGURE 17: EXON14b SSCP AND SEQUENCING
(a) SSCP analysis of exon14b and flanking intron sites.
The arrows denote band shifts observed comparing control ( C) and patient P ( P) samples.
(b) Sequencing of 2789+32T  C and control sample. The arrow indicates the nucleotide exchange in the patient (  )
(c) Location of two sequence alterations of maternal chromosome in patient P.
3.1.2    Results of the phenotype analysis
The CFTR mutation genotypes have been categorised in five classes according to the anticipated
effect of the molecular lesion (reviewed by Zielenski and Tsui 1995). Mutations which are expected
to avert protein synthesis, such as nonsense and frameshift mutations, are combined in classiI. The
phenotype of four patients homozygous for class I mutations is described in chapter 3.1.2.1. ClassiII
mutations are presumed to fail in producing functional CFTR based on a processing defect, with the
most prominent classiII mutation being ∆F508. Three patients carrying a second sequence variant on
a ∆F508 chromosome were examined and the results are shown in chapter 3.1.2.2. Results on two
patients homozygous for mutations which might give rise to proteins defective in processing
(classiII), regulation (classiIII) or to CFTR with an altered conductance (classiIV) are reported in
chapter 3.1.2.3. Class V mutations are defined as molecular lesions leading to missplicing of RNA
implying reduced amounts of wild type CFTR. In chapter 3.1.2.4, data on patients carrying one or
two splice mutations is reported. The last paragraph of this section deals with CFTR genotypes that
fit into none of the above categories: for 5 patients participating in this study, only one or even no
disease-causing lesion could be identified in the CFTR gene (chapter 3.1.2.5).
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3.1.2.1    Nonsense mutation and out of frame deletion
The four adult patients carrying two nonsense mutations (A, B, C) or a frameshift mutation caused
by a deletion (D, see figure 16 for details6) are all pancreatic insufficient and all showed highly
elevated sweat Cl
¯
values. While their nutritional status, shown by wfh%, was average for all
patients, the lung function parameters of patient A to D ranged from normal (A) to severe
impairment (D). Patients B, C and D were colonised with  P. aeruginosa. Patient A had S. aureus.
6
TABLE 6: NONSENSE MUTATION AND OUT OF FRAME DELETION
PI: pancreatic insufficient
ICM intestinal current measurement Classification of ICM results as described in chapter  2.2.2.2.1, page 57:
CF: carbachol response displays only reversed component. n.c.: non-conclusive.
NPD nasal potential difference measurement Classification of NPD results as described in chapter2.2.2.1, page 54:
CF: no residual secretion. CF-res: residual secretion.
AGE CFTR GENOTYPE WFH%
FEV1
%pred
FVC
%pred
Sweat
Cl
¯
[mval/l]
ICM NPD
A 24 y m PI G542X Y1092X 94 111 98 115 n.c. CF-res
B 23 y f PI R553X L1059X 116 68 87 106 CF CF
C 25 y f PI R553X R553X 103 44 71 96 CF CF-res
D 18 y f PI CFTR DelEx2,3 CFTR DelEx2,3 92 46 64 103 CF CF-res
References: Kerem 1990 et al. (G542X), Shoshani et al. p. c. (Y1092X), Bozon et al. p. c. (Y1092X), Cutting et al. 1990 (R553X), Dörk et
al.
 1994b (L1059X),        this work (CFTR DelEx2,3)
The investigation of the basic defect in rectal tissue showed no evidence for residual secretion in any
of the four patients: the responses of the rectal tissue to carbachol and histamine showed only the
reversed response typical for CF. With NPD, residual secretion was detected in patients A and D
upon superfusion of the nasal epithelium with chloride free solution in the presence of amiloride
(∆PD of 3 mV in patient A and 4 mV in patient D, respectively). In patients A and C, chloride
secretion was stimulated by isoproterenol in chloride-free solution in the presence of amiloride (∆PD
of 2 mV in patient A and 6 mV in patient C, respectively). Patient B did not show any residual
secretion in nasal tissue.
3.1.2.2    Complex alleles
Two adult siblings carrying the complex allele ∆F508-V1212I (E, F) and one patient bearing ∆F508-
R553Q (G) have been investigated. On the day of clinical investigation, all patients had highly
elevated sweat Cl
¯
, were pancreatic insufficient and had a normal wfh%. Patient G had sweat
chloride values of 50-70 mval/l in childhood. The siblings E and F were discordant with respect to
lung function parameters FEV1%pred and FVC%pred. Patients E, F and G showed no (E),
moderate (F) or severe (G) impairment of pulmonary function. Siblings E and F were colonised with
P. aeruginosa. The sib pair was discordant in pulmonary status and sweat Cl
¯
 concentration.
6 Shown in chapter 3.1.1.1 on page 62
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TABLE 7: COMPLEX ALLELES
Patients E and F are siblings.
PI: pancreatic insufficient
ICM intestinal current measurement Classification of ICM results as described in chapter  2.2.2.2.1, page 57:
CF-res: carbachol response shows residual component
NPD nasal potential difference measurement Classification of NPD results as described in chapter2.2.2.1, page 54:
CF: no residual secretion.
AGE CFTR
 GENOTYPE WFH%
FEV1
%pred
FVC
%pred
Sweat
Cl
¯
[mval/l]
ICM NPD
E 22 y f PI ∆F508 ∆F508-V1212I 115 92 114 87 CF-res CF
F 24 y m PI ∆F508 ∆F508-V1212I 104 52 77 104 CF-res CF
G 17 y f PI R553X ∆F508-R553Q 101 49 66 117 CF-res CF
References:
 Rommens et al. 1989 (∆F508),    Macek Jr p.c. (∆F508-V1212I),    Cutting et al. 1990 (R553X),     Dörk et al. 1991 (∆F508-R553Q)
Patient E and F both showed residual secretion measured by ICM. The carbachol responses were
composed of equal proportions of reversed and residual secretion in patient E. Patient F displayed
only the residual component. In both siblings, no cAMP response was seen and the residual chloride
conductance was inhibited by DIDS. In rectal tissue, patient G showed upon stimulation with
carbachol and histamine a reversed response with a pronounced offset towards the residual direction
indicating underlying residual secretion. No effect of cAMP or DIDS was observed. The
investigation of nasal tissue by NPD did not give evidence for residual secretion in patient G. The
ICM tracings of patients E, F and G are shown in figure 18, page 68.
3.1.2.3    Missense mutation and in frame deletion
Two patients homozygous for mutations that might give rise to non-wild-type CFTR protein were
characterised. The patient carrying the missense mutation E92K (H) was pancreatic sufficient.
Patient I carried the in-frame deletion of exon 2 (see figure 16 for details7) and was pancreatic
insufficient. Both patients had highly elevated sweat Cl¯ , a more than average wfh% and a normal
lung function. On the day of clinical investigation, P. aeruginosa was detected for the first time in
patient H. Patient I had S. aureus.
In patient H, residual secretion was detected in ICM and NPD. The rectal tissue showed
residual secretion upon stimulation with carbachol and cAMP. The residual component was
insensitive to DIDS. By NPD, a hyperpolarization of 11 mV was detected after superfusion with
chloride-free solution in the presence of amiloride. In patient I, evidence for residual chloride
secretion was seen by ICM, but not by NPD. In rectal tissue, a cAMP stimulated residual secretion
was seen in the absence, but not in the presence, of DIDS. The ICM tracings of patients H and I are
shown in figure 18, page 68.
7 Shown in chapter 3.1.1.1 on page 62
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TABLE 8: MISSENSE MUTATION AND IN FRAME DELETION
PS: pancreatic sufficient, PI: pancreatic insufficient
ICM intestinal current measurement Classification of ICM results as described in chapter  2.2.2.2.1, page 57:
CF-res:carbachol response shows residual component (H) or cAMP response present (I). 
NPD nasal potential difference measurement Classification of NPD results as described in chapter2.2.2.1, page 54:
CF: no residual secretion. CF-res: spontaneous residual secretion.
AGE CFTR GENOTYPE WFH%
FEV1
%pred
FVC
%pred
Sweat
Cl
¯
[mval/l]
ICM NPD
H 12 y m PS E92K E92K 141 101 99 118 CF-res CF-res
I 16 y m PI CFTR DelEx2 CFTR DelEx2 121 133 130 102 CF-res CF
References:
 Nunes et al. 1993 (E92K), this work (CFTR DelEx2)
3.1.2.4    Splice mutations
Four adults and an infant, being homozygous for a splice site sequence alteration (J, K, N) or
heterozygous for splice mutation and ∆F508 (L, M) were investigated. Except for patient J, all had
elevated sweat Cl¯ values. All patients had a normal wfh%. Only patient M was pancreatic
insufficient. All adult patients showed moderately (patient K) to severely impaired (patient L)
pulmonary function. No lung function data was available for patient N. All adult patients J, K, L, M
were P. aeruginosa colonised. Sweat test values for siblings J and K were discordant on the day of
clinical investigation, but for patient K, lower values have been reported: sweat chloride values were
non-pathological until the age of 21. When diagnosed as CF, patient K had a sweat test of 68 mval/l.
By the age of 28 years, four sweat tests were within the borderline range (46, 51, 53 and 46 mval/l
respectively. Patient K received a lung transplant.
9
TABLE 9: SPLICE MUTATIONS
Patients J and K are siblings.
PS: pancreatic sufficient, PI: pancreatic insufficient
ICM intestinal current measurement Classification of ICM results as described in chapter  2.2.2.2.1, page 57:
CF-res: carbachol response shows residual component (J, K) or cAMP-response (L,M) CF: carbachol response
displays reversed direction. n.c..: non-conclusive
NPD nasal potential difference measurement Classification of NPD results as described in chapter2.2.2.1, page 54:
CF: no residual secretion. CF-res: spontaneous residual secretion.
AGE CFTR GENOTYPE WFH% FEV1
%pred
FVC
%pred
Sweat
Cl¯
[mval/l]
ICM NPD
J 20 y m PS 3849+10kb C  T 3849+10kb C  T 98 44 59 20 CF-res CF
K 31 y m PS 3849+10kb C  T 3849+10kb C  T 97 82‡ 68‡ 93 CF-res CF-res
L 58 y f PS ∆F508 3272-26 A  G 99 29 55 81 CF-res CF-res
M 36 y m PI ∆F508 3850-3 T  G 103 32 39 116 CF-res CF
N 3 y f PS 1898+3 A  G 1898+3 A  G 112 — — 74 n.c. CF-res
‡Patient K received a lung transplant.
References: Highsmith et al. 1994 (3849+10kbC  T), Rommens et al. 1989 (∆F508), Fanen et al. 1992 (3272-26A  G),
Dörk et al. 1993 (3850-3T  G),                             Ferrari et al. p.c. (1898+-3A G)
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In patients J, K and L, ICM measurement showed DIDS-insensitive residual secretion upon
stimulation with carbachol and histamine. The residual secretion was stimulated by cAMP for patient
L and M. The cAMP response of patient M was seen in the absence , but not in the presence, of
DIDS. With NPD, spontaneous chloride secretion was detected in patients K, L and N upon
superfusion of the nasal epithelium with chloride-free solution in the presence of amiloride (∆PD of
12 mV in patient K, 2 mV in patient L and 3 mV in patient N, respectively).
3.1.2.5    Unresolved CFTR genotypes
Mutation analysis is carried out to confirm the suspected diagnosis of CF. For the recessive inherited
disease, the identification of two mutant CFTR alleles is considered to be diagnostic. However, for
most populations a detection rate of 100% is not achieved due to the allelic heterogeneity of CF
disease-causing lesions. For the German population, extensive screening has enabled identification of
54 mutations on 94% of 700 CF chromosomes (Dörk et al. 1994b). In the Spanish CF population,
75 mutations were identified on 90% of the CF chromosomes from 640 families (Casals et al. 1997).
47 mutations were reported to account for 86% of CF chromosomes from 600 CF patients within
the French non-celtic population (Chevalier-Porst et al. 1994).
The failure to identify disease-causing lesions in all CFTR alleles of CF patients may be due to
technical reasons, as most screening protocols analyse the coding region and the flanking intron sites,
but not the entire CFTR gene encompassing 240 kb. Hence, sequence variants at regulatory elements
within the non-coding sequences might remain unnoticed. Further, deletions of entire exons cannot
be detected by PCR based methods in the heterozygous state because the non-deleted copy on the
other chromosome will always be amplified. Consequently, if a patient is diagnosed as having CF but
at least one CFTR allele appears to be normal after thorough mutation screening, it cannot be
distinguished whether a sequence variant within the CFTR gene has been missed due to technical
reasons or whether the disease is caused by another entity.
Within this chapter, the clinical phenotype and the basic defect is described for four patients
who do not carry two disease-causing CFTR mutations as judged by SSCP screening of all CFTR
exons and flanking intron sites (patients P, Q, R, S; table 10). A case of atypical CF carrying a splice
site alteration and the IVS8-6(5T) allele (patient O) is discussed in comparison to patient P. Patients
O – S were  pancreatic sufficient. The diagnosis of CF was unclear for patients O, P and Q.
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TABLE 10: UNRESOLVED GENOTYPES
S: Exon was sequenced after SSCP analysis
1: SSCP analysis performed with one restriction digest 2: SSCP analysis performed with two restriction digests
SSCP SREENING OF CFTR EXON
1 2 3 4 5 6a 6b 7 8 9 10 11 12 13 14
a
14
b
15 16 17
a
17
b
18 19 20 21 22 23 24 GENOTYPE
P 2 1 S 2 1 2 2 2 1 2 S 2 2 2 2 2 2 2 1 2 2 1 1 1 1 2 2 IVS8-6(5T); [1]
Q 2 S 1 2 1 2 2 2 1 1 S 2 2 1 2 2 2 2 1 1 2 1 2 2 2 1 2 1898+3 A  G
R 2 1 S 2 1 2 2 2 2 S 1 S 2 1 2 2 2 2 1 1 1 S S 2 2 2 2 —
S 2 S S 2 1 1 S 1 2 S S S 2 1 2 2 2 2 2 2 1 S S S 1 1 2 —
[1] : 2752-22A  G – 2789+32A  G
References: Chu et al. 1991 (IVS8-6(5T)),     Ferrari et al. p.c. (1898+3A G),      Marigo et al. p.c. (2752-22A  G),      this work (2789+32A  G)
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FIGURE 18: ICM RESULTS FOR SELECTED PATIENTS
WITH RARE GENOTYPES OR ATYPICAL CF
Examples for residual secretion in 6 CF patients. cAMP-sensitivity is assumed if a residual current is stimulated by
addition of cAMP and forskolin. The DIDS-sensitivity is assessed by comparison of the carbachol- and the histamine-
induced response when DIDS was added 10' prior to stimulation with histamine.
TYPE OF RESIDUAL SECRETION TYPE OF RESIDUAL SECRETION
cAMP-sensitive DIDS-inhibitable cAMP-sensitive DIDS-inhibitable
PATIENT E NO YES PATIENT F NO YES
PATIENT G NO NO PATIENT H YES NO
PATIENT I YES NO PATIENT R NO NO
Scales for Isc and t are identical for all tracings displayed in this figure.
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TABLE 11: PHENOTYPE OF UNRESOLVED GENOTYPES
PS: pancreatic sufficient
ICM intestinal current measurement Classification of ICM results as described in chapter  2.2.2.2.1, page 57:
normal: all values within range of non-CF controls. CF-res: carbachol response shows residual component.
NPD nasal potential difference measurement Classification of NPD results as described in chapter2.2.2.1, page 54:
normal: all values within range of non-CF controls. CF: no residual secretion. CF-res: spontaneous residual
secretion
AGE CFTR
 GENOTYPE WFH%
FEV1
%pred
FVC
%pred
Sweat
Cl
¯
[mval/l]
ICM NPD
O 8 y f PS IVS8-6(5T) 4000-2 G  A 88 82 83 20 normal normal
P 28 y m PS IVS8-6(5T) [1] 103 101 102 55 normal normal
Q 32 y f PS 1898+3 A

G — 84 18 40 7 normal CF res
R 37 y m PS — — 131 69 104 59 CF-res CF
S 24 y m PS — — 127 83 87 97 normal normal
[1] : 2752-22A  G – 2789+32A  G
Patients O and P
CLINICAL HISTORY OF PATIENT O Patient O presented a history of allergy, wheezing and
bronchiolar obstruction. She was referred to the CF clinic Hannover for differential diagnosis of
asthma/neurodermitis vs CF with pulmonary manifestations. CFTR mutation analysis had revealed
the splice mutation 4000-2 G

A and the variant IVS8-6(5T) on the two chromosomes, respectively.
CLINICAL HISTORY OF PATIENT P Patient P was born as a child of unrelated parents of
German descent. Respiratory symptoms were known for paternal members of a three generation
pedigree: the grandfather of patient P suffered from chronic bronchitis. The brother of the patient's
grandfather died of tuberculosis before the age of 10 years. The father of patient P suffered from a
chronic cough with sputum production. On the occasion of his son's diagnosis, a sweat test of 80
mval/l Cl¯ was reported. The patient's father was underweight and small in childhood, but gained
normal weight in adolescence. Patient P was diagnosed at the age of 14 years by sweat electrolytes8
of 74 mval/l Na+ and 76 mval/l Cl¯ . The clinical course during infancy and childhood was
characterised by growth retardation with poor nutritional status: by the age of 7 years, patient P had
the height and weight of a 5-year old child. Recurrent pulmonary infections were treated by three to
four courses of antibiotics per year. By the age of 24 years, he presented normal weight, height and
lung function parameters and a spermiogram was within the normal range.
GENETIC ANALYSIS OF PATIENT P The CFTR gene was screened for mutations in all exons
and flanking intron sites. No disease-causing lesion was identified. The patient carried intronic
sequence variants surrounding exon 14b on the maternal chromosome (figure 17, page 63). His
paternal CFTR gene carries the IVS8-6(5T) variant. He is heterozygous at M470V and T854T.
8 The value reported in table 11 was obtained on the day of investigation at the age of 28 years. Sweat tests of patient
P have been reported Na+ 74 mval/l and Cl- 76 mval/l; Na+ 62 mval/l and Cl- 65 mval/l; Cl- 55mval/l
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BASIC DEFECT OF PATIENTS O AND P The investigation of the basic defect did not provide
evidence for CFTR dysfunction in patients O and P: with ICM, normal ion secretion was seen upon
addition of carbachol and histamine. Results of NPD were consistent with non-CF based on the
basal PD (-34 mV and – 14 mV for patients O and P, respectively) and hyperpolarization (∆PD
19 and 15 mV for patients O and P, respectively) upon superfusion with chloride-free solution in the
presence of amiloride. An additional chloride secretory response was stimulated with isoproterenol
(∆PD 8 and 3 mV for patients O and P, respectively).
Patient Q [case report published in Thorax 54: 278-281(1999)]
CLINICAL HISTORY OF PATIENT Q Patient Q was the third child born to healthy German
parents who are first generation cousins. Both elder siblings of patient Q are deceased: one sibling
was born preterm with meconium ileus and died at the age of 10 days. The other sibling died before
the age of 6 months. CF was suspected from the autopsy. Patient Q had a history of pulmonary
complications with recurrent lower airway infections, chronic cough and sputum production.
Chronic nasal polyposis was surgically treated by 13 polypectomies between 5 and 23 years of age.
She underwent a lung biopsy at the age of 21 which revealed bronchiectasis, localised purulent
bronchitis and surrounding fibrosis. The diagnosis of CF was discarded due to repetitive sweat
electrolyte values within the normal range (7-32 mval/l). Nine out of ten throat swabs were positive
for S. aureus. Antibody titer against P. aeruginosa oprF were elevated though no P. aeruginosa
were cultured. Bronchodilators and antibiotics were prescribed, but the patient generally
discontinued medication after a few days. At the age of 32, the patient presented severe clubbing and
required continuous oxygen. The patient has been underweight since adolescence, but pancreatic
sufficient as determined by normal chymotrypsin, stool elastase and ultrasound of the pancreas. She
did not receive enzyme or vitamin supplements and had normal vitamin A and E levels in serum. The
differential diagnosis of allergy was excluded by normal specific IgE levels in serum and skin test.
The microscopic appearance of a nasal biopsy allowed exclusion of immotile cilia syndrome.
GENETIC ANALYSIS OF PATIENT Q Mutation analysis of the CFTR gene revealed
heterozygosity for the splice site consensus transition 1898+3 A

G. Mutation analysis of the CFTR
gene did not reveal other disease-causing lesions within the exons or the non coding region up to
4ikb 5' in front of the gene. No evidence for a large genomic deletion was found by Southern blot
analysis of an ApaI digest hybridised with a CFTR cDNA probe encompassing exons 7 to 24. The
patient is homozygous for the (TG)mTn-M470V-T854T haplotype (TG)11T7-2-1.
BASIC DEFECT OF PATIENT Q The analysis of the basic defect in rectal tissue showed no
evidence for defective CFTR as demonstrated by normal ion currents after stimulation with
carbachol and histamine in ICM. However, in nasal tissue CF conditions were detected by NPD:
patient Q had a basal of –52 mV. Evidence for residual chloride secretion was provided by a
hyperpolarization of 3 mV upon superfusion with chloride-free solution in the presence of amiloride.
An additional chloride secretory response of 4 mV was stimulated with isoproterenol.
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Patient R 
CLINICAL HISTORY OF PATIENT R Patient R was diagnosed as having CF during adulthood
at the age of 28 based on pulmonary symptoms. He suffered from pneumonia in childhood and
always had nasal polyps. Sweat tests have been reported to be borderline or within the lower
pathological range. On the day of clinical investigation at 37 years of age, he had an impaired lung
function and clubbing was noticed. Pseudomonas aeruginosa was detected in sputum culture and the
antibody titer against P. aeruginosa oprF was elevated. He was treated with inhalation of β2
adrenergic agonists, oral n-acetylcystein and antibiotics. Patient R was pancreatic sufficient. He
received vitamin supplements. Serum vitamin A and E levels have been within the normal range. He
did not show any signs of liver disease. Patient R is the father of two healthy children.
GENETIC ANALYSIS OF PATIENT R Mutation analysis of the CFTR gene did not provide
evidence for disease-causing lesions within the exons or the non coding region up to 4kb 5' in front
of the gene. The CFTR gene was investigated for deletions by pulsed field gel electrophoresis.
Detection of restriction fragments after an ApaI digest (fragment size 30 kb and 65 kb), FspI digest
and SalI digest (fragment size ≈ 500 kb) did not show any deviation compared to control samples
when hybridized to a CFTR cDNA probe containing exons 7 to 24. Patient R is homozygous for the
M470V-T854T haplotype 2-1.
BASIC DEFECT OF PATIENT R The investigation of the basic defect confirmed the diagnosis of
CF in patient R. In rectal tissue, carbachol and histamine stimulated a residual current without the
reversed component typical for CF. However, the magnitude of the responses was only a fifth of the
size encountered in non-CF controls (figure 18, page 68). DIDS did not have an effect on the
residual currents provoked by carbachol or histamine. In nasal tissue, a basal PD of –39 mV was
seen. In the presence of amiloride, neither the superfusion with a chloride-free solution nor the
stimulation with isoproterenol provoked a hyperpolarization.
Patient S [case report published in Hum Genet 102: 582-586 (1998)]
CLINICAL HISTORY OF PATIENT S Patient S had a history of respiratory symptoms: from the
age of 6 years, he has suffered from recurrent bronchitis and chronic cough with excessive sputum
production. At the age of 17 years he was diagnosed as having CF on the occasion of a severe
pneumonia by highly elevated sweat Cl
¯
of 102 mval/l. Since then he has been treated by daily
inhalation of salbutamol and oral n-acetylcystein and antibiotics. The patient had three to four
two-week courses of antibiotic therapy per year. S. aureus was detected occasionally in throat swabs
or sputum cultures. He is pancreatic sufficient and received no vitamin supplements. Reduced
fertility was diagnosed by spermiogram. The differential diagnoses of pseudohypoaldosteronism and
Liddle's disease were excluded by normal blood pressure and serum electrolytes as well as plasma
renin and aldosterone levels prior to and after administration of furosemide.
GENETIC ANALYSIS OF PATIENT S AND HIS SISTER Mutation analysis of the CFTR gene
did not reveal any disease-causing lesions. Furthermore, the CFTR genes of the patient and his
healthy sister are identical by descent as demonstrated by haplotype analysis of polymorphisms
within the CFTR gene including the fully informative microsatellite marker IVS17bTA. No
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recombination event was detected within a 40 cM region encompassing the CFTR gene, ranging
from the markers PON2 to D7S495 (figure 19). The patient is carrying the (TG)mTn-M470V-T854T
alleles (TG)11T7-2-1 and (TG)10T7-2-1.
BASIC DEFECT OF PATIENT S AND HIS SISTER The investigation of the basic defect did not
provide evidence for CFTR dysfunction in patient S or the patient's sister in intestinal or nasal tissue:
with ICM, normal ion secretion was seen upon addition of carbachol and histamine. Results of NPD
were consistent with non-CF based on a low basal PD (-21 mV and –12 mV for patient S and the
patient's sister, respectively) and hyperpolarization (∆PD 28 and 21 mV for patient S and the
patient's sister, respectively) upon superfusion with chloride-free solution in the presence of
amiloride.
19
FIGURE 19: HAPLOTYPES OF PATIENT S AND HIS SISTER
(a) Map showing 40 cM region encompassing the CFTR gene investigated in family of patient S.
(b) 16 marker haplotype for patient S (indicated by arrow) and his sister.
  : non-conclusive (PCR-failure)
Informative phase: alleles identical by descent are marked in red. 
Non-informative phase: alleles identical by state are printed in black.
Alleles at dimorphic marker loci (PON2, MetH, XV-2c, KM.19, J44, GATT, M470V, T854T, TUB20, J3.11) are
named according to standard nomenclature (see figure 5 on page 39).
Alleles at polymorphic loci are named according to their size in repeat units (GATT, IVS8CA, IVS17bCA,
IVS17bTA) or in arbitrary repeat units as defined in chapter  2.1.2.2.4 (D7S525, D7S514, D7S495).
The alleles of patient S and his sister at J3.11 are identical by descent unless a double recombination event flanking
J3.11, with breakpoints between TUB20 and D7S514, is assumed.
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FIGURE 20: RESIDUAL CHLORIDE SECRETION IN CF AND ATYPICAL CF
Residual chloride secretion in patients A-S as assessed by nasal potential difference (PD) measurement, sweat test
and intestinal current measurement (ICM).
NPD: response to superfusion with chloride-free solution in the presence of amiloride given as  ∆PD[mV]

 

 : CF- typical basal potential difference |PD| ≤  40mV 

 

 : non-CF or borderline basal PD |PD| ≥  40mV
Patient B probably had a cold on the day of investigation and hence a low basal PD.
Sweat chloride: 

 : sweat chloride concentration  given as  [10 × mval/l]
(< 40 mval/l: non-CF range, 40-60 mval/l: borderline range , > 60 mval/l: CF range)
ICM:   : tracing non conclusive
          classification of carbachol-response:

, 

 

, 

 

, 

 

 : % reversed component of carbachol induced signal
maximum 100% (only reversed response), patient B, C, D, I, L, M
minimum 0% (only residual response), patient F, K, O, P, Q, R, S
          amplitude of chloride secretory component of the carbachol-response (Veeze et al. 1991, 1994):

 

 : carbachol-response within non-CF range 

, 

 

, 

 

 : carbachol-response within CF range 
          type of residual chloride secretion:

 : no classification of residual component or no residual component observed

 

 : DIDS-sensitive residual chloride secretion

 

 : cAMP-sensitive chloride secretion
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3.1.3    Discussion of genotype-phenotype relations
The basic defect in cystic fibrosis is defined by an absence of CFTR mediated chloride conductance
in CFTR expressing epithelia. Within the study "rare genotypes and atypical cystic fibrosis", patients
have been investigated with respect to their basic defect expressed in the epithelium of the lower
nasal turbinate (considered representative for the respiratory epithelium), of the sweat gland and of
rectal tissue (considered representative for the intestinal epithelium). The results obtained are studied
in two approaches: chapter 3.1.3.1. aims at correlating the basic defect in the three tissues examined,
regardless of the underlying CFTR genotype. In chapter 3.1.3.2, the patient's CFTR genotype is
taken into account: the basic defect phenotype is evaluated on the basis of the CFTR genotype and
the clinical phenotype is evaluated on the basis of the basic defect results.
3.1.3.1    Correlation of the basic defect in three different tissues
Given the hypothesis that the basic defect in cystic fibrosis relies solely on the inability of mutant
CFTR to conduct chloride, CFTR expressing epithelia from different tissues but from the same
patient should express a comparable picture as the underlying CFTR mutation is identical for all
tissues of one CF patient. Alternatively, the defect in ion conductance observed in one tissue would
not be predictive for the expression of the basic defect in other CFTR expressing tissues from the
same patient due to tissue specific, but CFTR gene independent factors. This chapter confronts this
hypothesis in three sections: first, cases of typical CF are discussed. Then, patients with atypical CF
are evaluated. Finally, a brief survey of published data on CFTR associated ion secretion in epithelial
cells is presented as a lack of correlation between the impairment of ion conductance of the sweat
gland, the intestinal and the respiratory tissue cannot be based on the  CFTR mutation genotype.
3.1.3.1.1    Cystic fibrosis patients A-N
Given the hypothesis that the defective ion conductance is mainly determined by the CFTR genotype,
the expression of the basic defect is supposed to be concordant in the three examined tissues taken
from the same patient. Figure 20 clearly demonstrates that this is not the case: residual chloride
secretion detected in the rectal tissue (patient E, F, G, H, I, J, K, L, M) was not always indicative of
residual secretion in the nasal tissue (no residual seen in NPD in patients E, F, G). Neither was the
evidence for residual secretion in nasal tissue (patients A, D, H., K, L, N) indicative in all cases of
residual secretion in the rectal tissue (no residual seen in ICM in patient D). Sweat chloride
concentrations in the borderline range on the day of clinical investigation (patient J) were not
matched by a higher content of residual chloride secretion in nasal tissue compared to patients with
higher sweat chloride concentrations (no residual secretion seen in NPD of patient J, the low basal
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PD displayed by patient J was likewise observed in patients K, L and N9 which all showed sweat
chloride concentrations in the pathological range). Two patients (patients G and K) were reported
to have increasing sweat chloride concentrations with increasing age. This indication of residual
chloride secretion is concordant with the residual secretion detected by NPD and ICM in one of the
two patients only (patient K, no evidence for chloride secretion was seen by NPD of patient G). In
conclusion, when reduced to the presence or absence of residual chloride secretion, the basic defect
in the three tissues examined seems to be independently expressed. Hence, other chloride
conductances than those mediated by CFTR itself must contribute to the effects observed in a tissue
specific manner. Evidence for different sources of residual chloride secretion have been provided by
ICM (figure 1810): three chloride secretory currents, differing with respect to their sensitivity to
DIDS and cAMP, could be discriminated in CF patients.
3.1.3.1.2    Atypical cystic fibrosis patients Q-S
Among the five patients with unresolved CFTR genetics (patients O-S) investigated in the study
"rare genotypes and atypical CF", the diagnosis of cystic fibrosis was rejected for two patients
based on normal ICM and NPD values (see chapter 2.2.2.1 and 2.2.2.2 for details) and sweat
chloride concentration in the normal (patient O) or lower pathological range (patient P).
Complete discordance of the basic defect between the two organs affected mainly in CF was
observed in patient Q: no evidence for CFTR dysfunction was seen in rectal tissue, but the nasal
tissue displayed the CF-typical condition. Residual secretion was detected by NPD. The sweat test of
patient Q was non-pathological. In patient R, the basic defect was expressed in all three tissues
investigated, but while no evidence for residual chloride secretion was seen in nasal tissue, the rectal
tissue showed the chloride secretory component. Patient R had a sweat test compatible with the
diagnosis of CF. Patient S had sweat chloride concentrations in the pathological range, but neither
NPD nor ICM indicated dysfunctional CFTR in nasal or rectal tissue.
In summary, the tissue-specific expression of the basic defect that was observed for patients
with a clear diagnosis of CF (patients A-N) was seen more distinctly for patients with atypical CF.
This is consistent with the definition of atypical CF as based on the condition CBAVD, wherein the
manifestation of the disease is associated with molecular lesions in the CFTR gene (Dumur et al.
1990, Chillon et al. 1995) and leads to symptoms within one organ only.
9 Patient B also had a low basal, presumably due to a cold.
10 Figure 18 is shown in chapter 3.1.2.5 on page 68.
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3.1.3.1.3    Ion transport in epithelial cells
The ion transport in CFTR expressing epithelial cells (reviewed by Anderson 1992) is complex on
the level of the regulation pathways and with respect to the variety of the molecular entities involved:
different chloride secretory responses have been attributed to Ca2+ mediated and cAMP mediated
pathways in HT29 cells (Bajnath et al. 1992), T84 cells (Vajanaphanich et al. 1994) and cultured
colonic epithelia (MacVinish et al. 1993). Both intracellular mediators are considered to be linked
(Vajanaphanich et al. 1995). Molecular entities, contributing to the chloride transport of epithelial
cells, have been described as outwardly rectifying chloride channel ORCC (Egan et al. 1992, Gabriel
et al. 1993) and, distinguishable from the ORCC (Fischer et al. 1992), the outwardly-rectifying
depolarisation induced channel ORDIC (reviewed by Thinnes and Reymann 1997). The transport of
counterions, as mediated by the amiloride-sensitive Na+ channel and the basolateral K+ channel, has
been demonstrated to be controlled by CFTR (Ismailov et al. 1996, Stutts et al. 1997, Loussouarn et
al. 1996, McNicholas et al. 1997). The activation of CFTR by extracellular ATP in airway cells
(Stutts et al. 1995) is considered to be mediated by P2Y2 receptors and CFTR-associated ATP
channels (Sugita et al. 1998, Watt et al. 1998). The cytoskeleton is considered to regulate the
interaction of CFTR and the ENaC (Ismailov et al. 1997) and the regulation of CFTR mediated
chloride transport itself (Naren et al. 1998). Recently, the PDZ protein motif, known to bind factors
interacting with for example the β2- adrenergic receptor, the purinergic receptor, components of the
cytoskeleton (Short et al. 1998) or proteins directly involved in ion transport such as the Na+/H+
exchanger, has been identified in CFTR (Hall et al. 1998) and thus provides evidence for the link of
CFTR to other regulatory pathways.
Regarding the complexity of this network, the lack of correlation between the basic defect in
the tissues examined seems obligatory: nasal tissue, intestinal tissue and the sweat gland represent
different organs and consequently, the regulation of ion transport can be expected to reflect the
individual characteristics of the differentiated tissues. Furthermore, while CFTR is expressed in all
three tissues examined, this is most likely not the case for other ion pathways. In conclusion, while
non-functional CFTR may be regarded as the basis of the basic defect of defective ion conductance
in sweat gland, nasal and rectal tissue, various tissue-specific elements can be expected to modulate
the ion conductance properties of CFTR expressing epithelia.
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3.1.3.2    Correlation of CFTR genotype, basic defect and disease severity
Since the molecular analysis of the CFTR gene has allowed the identification of more than 700
sequence variations with presumed functional consequences for the CFTR protein, correlation of
CFTR mutation genotype and disease severity has been attempted (reviewed by Zielenski and Tsui
1995). Figure 21 illustrates the concept employed: the prediction of the molecular phenotype for a
given CFTR allele is used to assess whether functional CFTR protein can be expressed. A severe
disease phenotype is then assumed to result from non-functional CFTR mutants while CFTR alleles
allowing the generation of wild type protein are generally expected to result in milder phenotypes. In
chapter 3.1.3.2.1, data from the literature on the mutations displayed by patients A to P is
summarised. The patient's genotypes are grouped according to whether their CFTR genotype is
expected to result in no CFTR protein, some mutant CFTR protein or reduced amounts of wild-type
CFTR protein. The genotype-phenotype correlation for the patients investigated in the study "rare
genotypes and atypical cystic fibrosis" is discussed in two steps: the relation between the CFTR
mutation genotype and the basic defect is discussed in chapter 3.1.3.2.2 and the correlation of basic
defect and disease phenotype is investigated in chapter  3.1.3.2.3.
21
FIGURE 21: CFTR GENOTYPE — CF PHENOTYPE CORRELATION: A CONCEPT
CF disease severity viewed as a consequence of the CFTR genotype. Severe CF disease is considered to be the result
of absent CFTR function, while mild CF disease is surmised to result from residual  CFTR activity.
                                                        CHAPTER                                          CHAPTER
                                                          3.1.3.2.2                                                 3.1.3.2.3 
3.1.3.2.1    The molecular phenotype of mutant CFTR alleles
Generally, no functional CFTR protein is expected to arise from frameshift mutations, as for
CFTRdelEx2,3 investigated in patient D. Most nonsense mutations – such as G542X, R553X,
Y1092X, studied in patients A, B and C – have been associated with mRNA reduction and/or exon
skipping (Hamosh et al. 1991, Hamosh et al. 1992b, Hull et al. 1994b, Will et al. 1995). However,
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not all nonsense mutations can be considered to result in null phenotypes: wild type mRNA levels,
possibly translated into a truncated CFTR protein, have been detected for R1162X (Rolfini et al.
1993, Will et al. 1995).
Like most CFTR alleles, ∆F508-CFTR has been characterised as a protein with defective
maturation (Cheng et al. 1990). Secondary missense mutation R553Q or R553M or R555K have
been shown to revert this maturation defect (Teem et al. 1993, Teem et al. 1996). The Patients E, F
and G carried one ∆F508 allele with a second missense mutation.
Rare CFTR missense mutations have been investigated in heterologous expression systems
with respect to the processing of the protein and its electrophysiological properties. Most
investigated missense mutations have been shown to result in a maturation defect or altered chloride
conductance properties (Smit et al. 1995, Seibert et al. 1996a, Seibert et al. 1996b, Seibert et al.
1997, Vankeerberghen et al. 1998a, Vankeerberghen et al. 1998b). Milder CF phenotypes,
characterised for example by pancreatic sufficiency, were assumed to correlate with residual activity
(Champigny et al. 1995, Sheppard et al. 1995), correct processing (Seibert et al. 1996a) or
unimpaired interaction with the CFTR regulated ORCC (Fulmer et al. 1995). However, not all
mutations classified as correlating with pancreatic sufficiency show cAMP stimulated chloride
conductance (Fanen et al. 1997). The relation between defective maturation and chloride
conductance phenotype is unresolved, as most mutant CFTR proteins are processed inefficiently and
most CFTR mutants exhibit chloride conductance to some degree when localised correctly. Different
functional properties for CFTR proteins underlying the same degree of maturation impairment have
been shown for CFTR-R1066H, CFTR-R1066C and CFTR-R1066L (Cotton et al. 1996). Mutations
expected to belong in the category of mutant CFTR proteins with altered conductance or processing
were investigated in patient H and I in the homozygous condition.
CFTR mutations which generate or delete mRNA splicing consensus sequences have been
shown to give rise to incorrectly spliced mRNA (Hull et al. 1993, Zielenski et al. 1993). However,
reduced levels of correctly spliced mRNA have been shown for some nucleotide substitutions
affecting less conserved positions distinct to the splice site consensus sequence (Highsmith et al.
1994, Highsmith et al. 1997). Consequently, wild type CFTR protein might be formed in those cases,
associated with a milder CF phenotype. Patients J, K, L, M and N are carrying mutations which are
known (J, K, L) or expected (M, N) to yield reduced amounts of wild type mRNA.
Defective splicing, leading to the insertion or omission of single or multiple exons for a part of
the CFTR mRNA, has also been observed in non-CF tissues (Chu et al. 1991, Slomski et al. 1992,
Melo et al. 1993, Yoshimura et al. 1993, Hull et al. 1994a). The most prominent alternatively
spliced transcript results from exclusion of exon 9 (Chu et al. 1991), which gives rise to non-
functional CFTR protein (Strong et al. 1993). The amount of misspliced mRNA was shown to
correlate with the length of a preceding (TG)mTn-repeat (Chu et al. 1993, Cuppens et al. 1998). The
condition (TG)mT5, termed IVS8-6(5T) (Chillon et al. 1995), was shown to be overrepresented in
several disease conditions exhibiting symptoms of CF or atypical CF (Chillon et al. 1995, Pignatti et
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al. 1996, Friedman et al. 1997, Sharer et al. 1998) and hence, the allele IVS8-6(5T) is considered as
a risk allele. Two patients (O, P) bearing the IVS8-6(5T) allele on one chromosome, were
investigated.
3.1.3.2.2    Correlation of CFTR mutation genotype and basic defect phenotype
The relation of CFTR mutation and basic defect phenotype is discussed in four subsections in which
patients are grouped according to whether their CFTR genotype is expected to result in no CFTR
protein, some mutant CFTR protein or reduced amounts of wild-type CFTR protein. Thereafter, the
few cases where at least one CFTR allele appeared to be functional according to the CFTR mutation
analysis on the genomic level, are evaluated on a case-to-case basis.
3.1.3.2.2.1    No CFTR protein expected: patients A, B, C, D
Consistent with the hypothesis of nonsense-mutations resulting in functional knock-outs, all patients
homozygous for stop-mutations had highly elevated sweat chloride concentrations and none showed
residual chloride secretion in the intestinal tissue. However, in three out of the four cases evidence
for residual secretion was seen by NPD in respiratory tissue. This points to the existence of non-
CFTR chloride channels in airway tissue in these patients. Residual chloride conductances mediated
by non-CFTR channels in patients homozygous for a nonsense mutation have been described before:
two patients homozygous for G542X have been reported as showing residual secretion in rectal
tissue (Veeze et al. 1994).
3.1.3.2.2.2    Expression of mutant CFTR protein possible: patients E, F, G, H, I
Three patients, bearing a second missense mutation on the ∆F508 allele, all showed sweat chloride
concentrations within the pathological range. No evidence for residual chloride secretion was
detected in nasal tissue, but clear evidence for residual secretion was detected by ICM (figure 18).
However, the chloride secretory component was sensitive to DIDS, indicating that this current is not
CFTR mediated but due to alternative, Ca2+ activated channels. DIDS has been shown to inhibit
CFTR only when having access to the intracellular, cytosolic domains of the protein (Linsdell et al.
1996). For patients H and I, who are homozygous for a missense mutation or an in-frame deletion,
CFTR activity cannot be excluded on the basis of the CFTR genotype. However, both patients had
highly elevated sweat chloride concentrations indicative of a lack of CFTR mediated chloride
transport in the sweat duct. Residual chloride secretion activity was seen in both patients, either by
NPD and ICM (patient H) or only in rectal tissue (patient I) upon stimulation with cAMP. This
discrepancy might reflect the opposing roles of CFTR in the sweat gland (reabsorption of chloride)
compared with nasal and rectal tissue (chloride secretion), indicating that alterations like E92K in
patient H impair the role of CFTR in reabsorption, but not in secretion of chloride. Alternatively, the
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residual secretion observed by ICM or NPD might be mediated by an alternative channel not
expressed in the sweat gland. For patient I, a cAMP activated chloride conductance was seen in the
absence, but not in the presence, of DIDS indicating its origin by alternative, non-CFTR chloride
channels.
3.1.3.2.2.3    Low amounts of wild type CFTR expected: patients J, K, L, M and N
All patients with splice mutations showed residual chloride secretion in nasal or rectal tissue: in
NPD, four out of the five patients showed a basal PD in the borderline or non-CF range, indicating
residual chloride secretion. Furthermore, a response to superfusion with chloride-free solution was
seen in three of the four patients. Apart from the elevated sweat chloride concentrations in patients
K, L and N, the data obtained by NPD and ICM for the patients J, K, L and N are consistent with
the hypothesis of CFTR-mediated residual chloride conductance. For patient M, a non-CFTR
mediated chloride conductance can be surmised: the highly elevated sweat chloride concentration,
the CF-typical basal PD and the lack of residual secretion in nasal tissue points to defective CFTR in
this patient, being compound heterozygous for 3850-3 T ﬀ G. Even though this mutation is affecting
the not obligatory conserved –3 position and thus has been presumed to yield more wild type CFTR
transcript than alleles bearing mutations at the highly conserved positions –2 and –1 (Dörk et al.
1993), no evidence for CFTR mediated chloride conductance was found in patient M. The cAMP
stimulated chloride conductance in rectal tissue of patient M was seen in the absence, but not in the
presence, of DIDS and hence is most likely not CFTR-mediated. An inactivation of a –3 splice site
has also been shown for 297-3 C ﬀ T (Bienvenue et al. 1994).
3.1.3.2.2.4    Normal amounts of wild type CFTR expected: patients O, P, Q, R and S
Five patients suspected of carrying at least one wild type CFTR allele have been investigated in three
tissues with respect to the basic defect. In two out of the five cases, none of the tissues examined
showed a pattern typical for CF (patients O and P). A pathological condition restricted to one of the
three tissues investigated was observed in two patients (Q and S). Only for one out of the five cases
with unresolved CFTR genotypes were conditions consistent with the diagnosis CF seen in nasal
tissue, rectal tissue and the sweat gland (patient R).
Heterozygosity for IVS8-6(5T) and non-CF condition in three tissues (patients O and P)
Based on the basic defect measurements, the diagnosis of CF was rejected in patients O and P even
though patient O was compound heterozygous for a mutation affecting a splice site at the conserved
–2 position and the IVS8-6(5T) variant. Patient P, whose CFTR alleles were screened throughout
the complete coding sequence (table 1011), likewise carried the IVS8-6(5T) variant but except for
two nucleotide exchanges encompassing exon 14b (described in detail in chapter 3.1.1.2), patient P
11  Table 10 is shown in chapter 3.1.2.5 on page 67.
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did not carry any sequence variations. Presumably, the alterations of introns 14a and 14b were
without consequence for the transcription of the CFTR gene as they did not introduce a novel
splicing signal nor did they destroy the splice site consensus sequences of exon 14a. Hence, when
comparing the CFTR alleles of patients O and P under the assumption that all sequence variations
have been detected, patient P can be considered as heterozygous for a wild type allele and the IVS8-
6(5T) variant and patient O can be considered as heterozygous for a disease-causing lesion and the
IVS8-6(5T) variant. Though IVS8-6(5T) is established as a sequence alteration modulating the
penetrance of a mutant CFTR allele (Kiesewetter et al. 1993) and can be considered as a risk allele
for pulmonary disease (Pignatti et al. 1996, Friedman et al. 1997), CBAVD (Chillon et al. 1995) and
pancreatitis (Sharer et al. 1998), neither the isolated IVS8-6(5T) condition nor compound
heterozygosity with a CFTR disease-causing lesion was sufficient to transmit the basic defect typical
for CF to nasal or rectal tissue, as demonstrated by patients P and O, respectively.
Carriership for a disease-causing lesion and CF condition in nasal tissue (patient Q)
Patient Q showed a CF-typical NPD but no evidence for defective CFTR in rectal tissue or the sweat
gland. All CFTR exons and flanking intron sequences were screened by SSCP (table 10) and the
CFTR gene was investigated for large genomic alterations by PFGE, but only the splice site
consensus transition 1898+3 A ﬁ G was identified on one chromosome. This sequence variation can
be considered to be a disease-causing lesion since patient N, being homozygous for this allele,
exhibited clinical symptoms and showed an impaired chloride conductance in nasal tissue and the
sweat gland compatible with CF. The carrier status of patient Q was sustained by the family history:
a sibling died presumably of meconium ileus and CF and thus, the CFTR alleles within the family of
patient Q were most likely associated with pancreatic insufficiency. However, patient Q was
pancreatic sufficient and hence, carriership of patient Q seems more likely than the condition of her
carrying two CFTR mutant alleles causing a severe gastrointestinal phenotype.
The tissue-dependency of the CF typical chloride conductance defect seen in patient Q can be
explained assuming an impaired regulation of CFTR expression in the respiratory epithelium,
mediated by tissue specific regulatory elements. The manifestation of the basic defect is probably
eased by the consanguineous background yielding an excess of homozygous genotypes at many loci
throughout the genome, including sequence variants with an unfavourable effect.
No disease-causing lesion identified and CF condition in sweat gland (patient S)
Patient S showed highly elevated sweat electrolytes but no evidence for defective chloride
conductance was seen in ICM or NPD. Screening of all CFTR exons and flanking intron sites did not
reveal any disease-causing lesion (table 1012) and consequently, patient S was suspected of carrying
two wild type CFTR alleles. Furthermore, patient S shares the CFTR spanning haplotype with his
asymptomatic sister and hence, any disease-causing lesion missed by screening the CFTR gene of
patient S should be present in the patient's sister unless a de novo mutation has occurred.
12  Table 10 is shown in chapter 3.1.2.5 on page 67.
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As for patient Q, the chloride conductance defect observed in the the sweat gland in patient S, but
not by ICM or NPD, could be explained by tissue specific regulatory elements being defective in
patient S but unimpaired in his sister. Another hypothesis involves a defect in the transport of the
counterion Na+ via the amiloride-sensitive Na+ channel ENaC: as in CF, the condition
pseudohypoaldosteronism type I can lead to elevated sweat chloride and sodium values (Hanakoglu
et al. 1994, Marthinsen et al. 1998). The ENaC coding genes SCNN1A, SCNN1B and SCNN1G
have been shown to cause pseudohypoaldosteronism (Chang et al. 1996, Strautnieks et al. 1996a).
Within the family of patient S, the polymorphisms D12S889 — located near SCNN1A (Baens et al.
1995) — and β-ENaCGT — located in in SCNN1B (Shimkets et al. 1994) and near SCNN1G
(Voilley et al. 1995) — have been investigated. Patient S and his sister share at both loci only one
allele. Thus, it is possible that different alleles for the α, β and γ subunits of the ENaC were inherited
by the siblings, presumably related to different Na+ conductance properties of the resulting channel.
No disease causing lesion identified and CF condition in three tissues (patient R)
The investigation of patient R clearly demonstrated CF conditions in the rectal and nasal tissue and a
sweat test consistent with CF. Thus, an impairment of the CFTR protein has to be assumed and
accordingly, a defect of the CFTR gene, a regulatory element in cis or a regulating element acting in
trans has to be inferred. Both CFTR alleles of patient R have been screened extensively by PFGE for
large genomic alterations and by SSCP for small sequence variations in all CFTR exons and flanking
intron sites (table 10) including 4 kb of sequence preceding exon 1. The 4 kb sequence exceeds the
characterised promoter region (Chu et al. 1991, Koh et al. 1993). Though sequence alterations
within the CFTR promoter sequence have been described (Bienvenue et al. 1995), they seem to be
rare: extensive screening of interspecies conserved regions of the CFTR promoter in 205 patients
with CF, atypical CF or CF-like conditions conditions without an identified mutation on both CFTR
alleles failed to reveal disease-causing lesions (Verlingue et al. 1998). Hence, unless both CFTR
mutations were missed in patient R because the respective sequence was not screened for — as in
the case of a sequence alteration generating a cryptic splice site as described for 3849+10kbC
ﬂ
T
(Highsmith et al. 1994) or in case of a regulatory element located within an intron as described
for intron 1 (Smith et al. 1996) — the molecular lesions causing the lack of CFTR related
conductance measured in patient R have to be located in trans, presumably mediating the expression
of the CFTR gene through a regulatory element. A defective regulation of CFTR expression of at
least one allele can be considered equivalent to a splice site mutation that allows the generation of
minor proportions of wild type transcript and thus should lead to a basic defect pattern comparable
to that displayed by patients J, K, L, M and N. Indeed, patient R showed residual chloride secretion
in rectal tissue similar to patient K (homozygous for 3894+10kbC ﬂ T) and had a moderately elevated
sweat chloride concentration.
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3.1.3.2.3    Correlation of basic defect phenotype and severity of CF disease
Out of the 19 patients who participated in the study "rare genotypes and atypical cystic fibrosis", a
non-conclusive ICM result was obtained for patients A and N. Patients O, P and S are not discussed
within this chapter due to their non-CF condition displayed in nasal and rectal tissue. The remaining
14 patients were grouped with respect to their basic defect: no residual chloride secretion was seen
in both, ICM and NPD, for one patient. Discordance when comparing nasal and rectal tissue was
observed for 2 patients (residual in NPD only) and 8 patients (residual in ICM only). 3 patients
displayed residual chloride secretion in both tissues. Within this chapter, three attempts were made to
relate the clinical phenotype – as accessible by pancreatic status, wfh% and FEVPerc – of these 14
patients to the results of the basic defect measurements. Chapter 3.1.3.2.3.1 examines if discordant
basic defect phenotype is reflected by the clinical status. In chapter 3.1.3.2.3.2, pancreatic sufficient
and pancreatic insufficient patients are compared with respect to their ICM results. Chapter
3.1.3.2.3.3 discusses whether the patient's pulmonary status is reflected by the presence or absence
of residual chloride secretion as measured by ICM or NPD.
3.1.3.2.3.1    Disease severity and expression of the the basic defect in 14 CF patients
No residual chloride secretion in nasal and rectal tissue
Among the 14 patients investigated with a conclusive result for ICM and NPD, only one patient did
not show any evidence for residual chloride secretion in both tissues investigated with respect to the
basic defect. Patient B was pancreatic insufficient, had a normal wfh%, but an impaired lung
function.
Residual chloride secretion in nasal, but not in rectal tissue
In two patients, (C and D), residual chloride secretion was detected by NPD, but not by ICM. These
patients all had a normal wfh%, an impaired pulmonary status and were pancreatic insufficient.
Residual chloride secretion in rectal, but not in nasal tissue
In seven patients, (E, F, G, I, J, M, and R), residual chloride secretion was seen in rectal tissue, but
not in nasal tissue. Patient Q was likewise discordant comparing ICM and NPD: while the CF-
condition was detected in nasal tissue, the rectal tissue displayed a non-CF condition. Patients E, F,
G, I, J, M and R all had a normal wfh%. Patients E, F, G, I and M were pancreatic insufficient while
patients J and R were pancreatic sufficient. An impaired pulmonary status was seen in patients F, G,
J and M (severely affected) and patient R (moderately affected), but not in patients E and I. Patient
Q was pancreatic sufficient, had a reduced wfh% and the pulmonary status was severely impaired.
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Residual chloride secretion in nasal and rectal tissue
Three patients (H, K, L) showed residual chloride secretion by NPD and ICM. The patients were all
pancreatic sufficient and had a normal wfh%. An unimpaired pulmonary status was seen in patient H,
patient K received a lung transplant and patient L had a severely affected pulmonary status.
3.1.3.2.3.2    Pancreatic status and residual chloride secretion in rectal tissue
6 of the 14 patients discussed here were pancreatic sufficient (H, J, K, L, R and Q). In all cases,
chloride secretion was detected by ICM. Considering the rectal tissue as representative of the
gastrointestinal tract, the correlation between pancreatic status and residual chloride conductance is
evident as described by Veeze et al. (1994). However, of the remaining 8 pancreatic insufficient
patients (B, C, D, E, F, G, I and M), residual chloride secretion was detected by ICM in 5 patients.
Interestingly, in four of these five cases, evidence was seen for a non-CFTR origin of the detected
chloride conductance (patients E, F, I and M). In contrast, a chloride secretory pattern in ICM
consistent with the hypothesis of CFTR mediated conductance was seen in patients H, J, K, L, R and
Q. Hence, it is tempting to speculate that pancreatic sufficiency is not solely determined by any
residual chloride secretion, but based on residual CFTR activity. This finding suggests that
alternative chloride channels, detected by NPD and ICM, are not expressed in pancreatic tissue and
hence do not protect against pancreatic disease. Sustaining this hypothesis, it was recently
demonstrated that CLCA1, the Ca2+ activated chloride channel, is not expressed in pancreatic tissue
(Gruber 1998b).
3.1.3.2.3.3    Pulmonary status and residual chloride secretion in nasal tissue
Various degrees of impairment of pulmonary function were observed regardless of the presence or
absence of residual chloride conductance in nasal or rectal tissue (chapter 3.1.3.2.3.1). In six cases
among the 14 patients discussed here, residual secretion was detected by NPD (patients C, D, H, K,
L and Q). As shown in table 12, no correlation between FEV1%pred and presence of residual
chloride conductance was observed. Likewise, no correlation of residual chloride secretion measured
in rectal tissue and FEV1%pred was detected (table 13). This observation is consistent with the
concept of high variability of the pulmonary status, described for patient groups carrying the same
CFTR genotype (Kerem et al. 1990, Gasparini et al. 1992, Rozen et al. 1995, de Braekeleer et al.
1997).
The patients examined within the study "rare genotypes and atypical cystic fibrosis" represent
a small selected panel of elderly patients. Thus, even though no correlation between FEV1%pred and
the presence of residual chloride secretion in nasal or intestinal was noticed, the advanced age of
most patients investigated indicates an advantage of residual secretion for the survival. Sustaining
this hypothesis, the five patients (K, L, M, Q and R) who were older than 30 years on the day of
investigation all showed residual chloride secretion detectable by ICM.
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The complexity of CF lung disease is the subject of other chapters within this thesis wherein the
results of the "European CF Twin and Sibling study" are presented: the influence of genetic vs
epigenetic factors on CF lung disease is discussed in chapter 3.2.1. Modulation of CF lung disease by
the candidate gene locus D12S889, close to the SCNN1A gene encoding the α subunit of the ENaC,
is discussed chapter 3.2.3.8.1. The modulation of disease severity due to modulating factors within
the CFTR linkage group is discussed in chapter 3.2.3.8.2.
12
TABLE 12: RESIDUAL SECRETION IN NASAL TISSUE AND PULMONARY STATUS
Pulmonary status, judged by FEV1%pred and the patient's age, and residual chloride secretion in nasal tissue.
no residual chloride secretion in NPD PATIENT (age in years)
residual chloride secretion in NPD PATIENT (age in
years)
FEV1%pred ———————————————PATIENT (age in years)———————————————
> 100% H (12 y) I (16 y)
80%-100% E (22 y) K (‡)
60%-80% B (23 y) R (37 y)
40%-60% C (25 y) D (18 y) F (24 y) G (17 y) J (20 y)
< 40% L (58 y) M (36 y) Q (32 y)
‡ patient K received a lung transplant
13
Table 13: RESIDUAL SECRETION IN ICM AND PULMONARY STATUS
Pulmonary status, judged by FEV1%pred and the patient's age, and residual chloride secretion in
rectal tissue.
no residual chloride secretion in ICM PATIENT (age in years)
residual chloride secretion in ICM PATIENT (age in
years)
FEV1%pred ———————————————PATIENT (age in years)———————————————
> 100% H (12 y) I (16 y)
80%-100% E (22 y) K (‡)
60%-80% B (23 y) R (37 y)
40%-60% C (25 y) D (18 y) F (24 y) G (17 y) J (20 y)
< 40% L (58 y) M (36 y) Q (32 y)†
‡ patient K received a lung transplant
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3.2    The European CF Twin and Sibling study
Within this chapter, the analysis of the clinical data (chapter 3.2.1), of the basic defect as accessible
by intestinal current measurement (chapter 3.2.2) and of the genotype at selected candidate gene loci
are presented (chapter 3.2.3).
3.2.1    Analysis of clinical phenotype
The data collected on twins and sibs were used to analyse the effect of sex, age difference, CFTR
genotype, pancreatic status, monozygosity and colonisation with Pseudomonas aeruginosa on the
severity of the disease (chapter 3.2.1.1). The parameters employed were weight for height (wfh%),
percentiles for FEV1%pred (FEVPerc) and, derived thereof by combination, the quantity DfO13.
22
FIGURE 22: SCHEMES FOR STATISTICAL TESTS
Patients are symbolised as grey figure or black figure to denote the attribute analysed, e.g. gender (comparison of
males and females) or pancreatic status (comparison of pancreatic sufficient and pancreatic insufficient patients).
PATIENTS INCLUDED: pairs used for evaluation in scheme I, II and III
GROUPS COMPARED: patients compared using scheme I, II and III
SCHEME I: comparison of individual patients with different attributes regardless of kinship
SCHEME II: comparison of individual patients with different attributes within one pair
SCHEME III: comparison of pairs with different attributes
Three different approaches were used to calculate the influence of an attribute (e.g. monozygosity
status or pancreatic status) on the parameters (e.g. wfh% or FEVPerc): ignoring the relationship of
the patients within their pairs, patients were sorted into two groups with different attributes (figure
22, scheme I). To evaluate the effect of the attribute on the parameter, a Mann-Whitney rank test
was applied. Alternatively, only pairs composed of two sibs differing in the attribute studied were
considered (figure 22, scheme II). A Wilcoxon rank test was used to evaluate the effect of the
13 Defined in figure 10 on page 48 as distance from origin of a data point representing a patient in the diagram of
rank number of FEVPerc plotted against rank number of wfh%.
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attribute on the parameter in this intrapair comparison. When grouping pairs composed of two
patients with identical attribute (figure 22, scheme III), a parameter reflecting the intrapair variance
was studied (e.g. the intrapair difference of wfh%). A Mann-Whitney rank test was employed for
statistical analysis of the effect of a pair's characteristic on the intrapair difference in a parameter. In
chapter 3.2.1.2, an approach is shown to estimate the number of modulating factors involved in
shaping the disease phenotype. Non-parametric analysis was carried out according to:
E. Weber "Grundriss der biologischen Statistik" 8th ed. Fischer Verlag, Stuttgart; 1980
3.2.1.1    Non parametric analysis of disease severity and discordance
GENDER
Comparing all males and females from sib pairs regardless of their kinship (figure 22, scheme I),
males and females did not differ in their wfh% (273 males, 270 females; p = 0.46) or FEVPerc (284
males, 278 females; p = 0.34). Within the group of monozygous twins (figure 22, scheme I), males
had a better wfh (18 males, 18 females; p = 0.05) and a slightly better FEVPerc (18 males, 18 females;
p = 0.16). The combined parameter DfO reached significance (18 males, 18 females; p = 0.04). An
intrapair comparison of the disease severity for males and females was made (figure 22, scheme II)
for all dizygous patient pairs composed of a male and a female sibling. Males and females were
significantly different in wfh% and FEVPerc, but not in the combined parameter DfO. While females
were significantly better in wfh% (203 pairs, p = 0.05), males were significantly better in FEVPerc
(143 pairs, p = 0.05). Upon combining the parameters to DfO this crosswise relationship resulted in
nonsignificance (137 pairs, p = 0.8). Table 14 summarises the findings on the influence of the gender
in CF twins and sibs.
14
TABLE 14: INTERPAIR- AND INTRAPAIR INFLUENCE OF GENDER
p-values classified as: p > 0.05 ﬃ  non-significant (n.s.); p < 0.05 ﬃ  significant (sig)
SCHEME (figure 22) GROUP COMPARISON
OF PATIENTS
p PARAMETER
BETTER
PHENOTYPE
I ALL SIB PAIRS INTERPAIR n.s. FEVPerc, wfh% —
I MONOZYGOUS TWINS INTERPAIR sig DfO, wfh% males
—    — INTERPAIR n.s. FEVPerc males
II SIB PAIRS INTRAPAIR sig wfh% females
—    — INTRAPAIR sig FEVPerc males
—    — INTRAPAIR n.s. DfO —
The influence of the patient's gender on the nutritional status, as represented by wfh%, seems
inconsistent comparing the results of the intrapair- and interpair analysis: while males and females did
not differ in wfh% when all twins and sibs were compared, irrespective of their kinship (interpair
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comparison; figure 22, scheme I), females were significantly better in wfh% than males when only
sibpairs of brother and sister were compared (intrapair comparison; figure 22, scheme II). In order to
assess the influence of age, four classes of patients and patient pairs were defined (age below 7 years,
age 7 to 12 years, age 12 to 16 years, age 16 to 21 years) and the statistical tests were repeated for
each age class to allow a cross-sectional analysis.
23
FIGURE 23: CROSS SECTIONAL ANALYSIS OF GENDER INFLUENCE
The influence of gender on nutritional status (wfh%, top row) and pulmonary status (FEVPerc, bottom row) is
quantified by the parameter u obtained from the non-parametric test statistics. u depends on the sample size analysed
and the number of patients or patient pairs used for the test are given in the tables on the right. Significance (p<0.05)
is reached for |u| < 1.65 (one-tailed test).
Interpair-comparisons (employing scheme I, figure 22): ——————
Intrapair-comparisons (employing scheme III, figure 22): ——————
     wfh%
age no ofpatients
no of
pairs
<7 y
m 112
f 96
58
7-12 y
m 111
f 103
45
12-16 y
m 80
f 65
30
16-21 y
m 82
f 76
36
   FEVPerc
age no ofpatients
no of
pairs
7-12 y
m 67
f 74
39
12-16 y
m 67
f 57
26
16-21 y
m 80
f 72
34
The x-axis represents the age
analysed. The following age-
classes were defined: 
<7y (wfh% only)
7-12 y
12-16 y
16-21 y
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Results are displayed in figure 23: while males had a better wfh% than females within the age group
of 7 to 12 years, the situation was reversed among patients with an age of 16 to 21 years. This
observation is consistent with the data published by Morison et al. (1997), reporting an increased
mortality among females in the age of 5 to 15 years, but a n increased stability of the weight of
grown-up females compared to grown-up males. As displayed in table 14, both effects compensated
each other when the complete group of patients (all ages) was analysed.
As observed for wfh%, the influence of gender on FEVPerc changed with the patient's age. A
discrepancy between intrapair and interpair comparison of females in the age of 7 to 12 years was
calculated. As the measurement of pulmonary function requires compliance and practice of the
patient, the deviation might be due to the fact that siblings are trained for lung function at the same
CF center and hence, brother and sister are performing equally while the results of unrelated males
and females are subject to different errors.
It is a generally accepted fact that females with cystic fibrosis have a worse prognosis than
males (Corey et al. 1996) characterised by poorer survival and poorer nutritional status (Corey et al.
1988). This effect could not be attributed to a different calorie uptake or energy management
comparing CF males and females, but it was hypothesised that the onset of menarche and the change
in the hormonal balance interferes with "immunological defence mechanisms in the lung of CF
females facilitating progressive pulmonary involvement and subsequent mortality" (Corey et al.
1988). Even though the data presented here was not sampled to allow a longitudinal study, the cross
sectional analysis of wfh% and FEVPerc in age groups provides evidence for this hypothesis: the
influence of the gender on the nutritional status changes dramatically during puberty and correlates
with a slightly delayed change in gender influence on FEVPerc, leading to an overall worse
pulmonary status for female CF patients. This hypothesis is sustained by the impairment of CFTR
function by progesterone and estradiol (Sweezy et al. 1996).
CFTR GENOTYPE
The influence of the CFTR genotype on the disease severity was evaluated by comparing ∆F508
homozygotes to carriers of other genotypes (table 15). When comparing all patients (figure 22,
scheme I), ∆F508 homozygous patients were significantly worse in wfh% (933 patients, 332 thereof
∆F508 homozygous; p = 0.01) and FEVPerc (745 patients, 264 thereof ∆F508 homozygous; p < 0.0001).
When testing the same hypothesis for monozygous twins, no difference between ∆F508
homozygotes and patients with other genotypes was observed (36 patients, 20 thereof ∆F508
homozygous; wfh: p = 0.18; FEVPerc: p = 0.13). The intrapair difference of wfh% and FEVPerc did not
differ between ∆F508 homozygous pairs and pairs with other genotypes (figure 22, scheme III;
wfh%: 404 pairs, 166 thereof ∆F508 homozygous; p = 0.11; FEVPerc: 356 patient pairs, 114 thereof ∆F508
homozygous; p = 0.22).
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15
TABLE 15: INFLUENCE OF ∆F508 HOMOZYGOSITY
p-values classified as: p > 0.05 
!
 non-significant (n.s.); p < 0.05 !  significant (sig)
SCHEME (figure 22) GROUP COMPARISON p PARAMETER
I SIB PAIRS PATIENTS sig FEVPerc, wfh%
I MONOZYGOUS TWINS PATIENTS n.s. FEVPerc, wfh%
IIIa ALL PAIRS PAIRS n.s.
INTRAPAIR DIFFERENCE IN 
FEVPerc, wfh%
AGE DIFFERENCE IN SIB PAIRS
All sib pairs were tested for differences of disease severity caused by the age difference of the two
sibs (figure 22, scheme II). The older and the younger sib were not significantly different in wfh%
(396 pairs, p = 0.13)
 or FEVPerc (282 pairs, p = 0.80).
PANCREATIC STATUS
An effect of the pancreatic status on the disease severity but not on the intrapair variation thereof
was observed: pancreas insufficient patients were significantly worse in wfh% (figure 22, scheme I;
933 patients, 787 thereof pancreas insufficient; p < 0.0001) and FEVPerc (656 patients, 538 thereof
pancreas insufficient; p < 0.0001). The intrapair differences of wfh% and FEVPerc did not differ
statistically between pairs with two pancreas sufficient sibs and pairs with two pancreas insufficient
sibs (figure 22, scheme III; wfh%: 426 pairs, 63 pairs thereof composed of two pancreas sufficient sibs; p
= 0.33; FEVPerc: 307 pairs, 52 pairs thereof composed of two pancreas sufficient sibs; p = 0.23).
MONOZYGOSITY
The disease severity did not differ comparing patients derived from monozygous twin pairs and
patients derived from dizygous patient pairs (figure 22, scheme I; wfh%: 933 patients, 83 thereof from
monozygous twin pairs, p = 0.27; FEVPerc: 657 patients, 62 thereof from monozygous twin pairs, p = 0.27).
When comparing monozygous and dizygous patient pairs, the intrapair difference was significantly
lower for wfh% and almost significantly lower for FEVPerc (figure 22, scheme III; wfh%: 464 pairs,
27 thereof monozygous twins, p < 0.0001; FEVPerc: 328 pairs, 18 thereof monozygous twins, p = 0.06).
COLONISATION WITH Pseudomonas aeruginosa
Patients colonised with Pseudomonas aeruginosa had a significantly lower wfh% and FEVPerc than
those without P.a. (figure 22, scheme I; wfh%: 933 patients, thereof 504 P.a. colonised, p < 0.0001;
FEVPerc: 657 patients, 403 thereof P.a. colonised, p < 0.0001). This was not observed within the
subgroup of monozygous twins where wfh% and FEVPerc were not significantly different between
colonised and non-colonised patients (figure 22, scheme I; 36 patients, thereof 25 P.a. colonised; wfh%:
p =0.20, FEVPerc p =0.25).
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3.2.1.2    Estimation of the number of disease modulating factors
Within chapter 3.2.1.1, the following results can be interpreted as evidence for the influence of the
genetic background on the CF disease phenotype:
(I) Monozygous twins are significantly more concordant than dizygous patient pairs. This is
especially of interest because only half of the monozygous twin pairs are ∆F508 homozygous
whereas the other half of the pairs displays other CFTR genotypes. Hence, a group of patient pairs,
non-homogeneous with respect to the major disease-causing gene, displayed the highest degree of
concordance among all groups of pairs analysed.
(II) Comparing groups of pairs sorted according to their CFTR genotype, no higher degree of
concordance was observed when a group of ∆F508 homozygous patient pairs (being homogeneous
with respect to their CFTR genotype) was compared to all other patient pairs (being non-
homogeneous with respect to their CFTR genotype). Likewise, no higher degree of concordance was
observed comparing pairs composed of two pancreatic insufficient patients (displaying
predominantly severe CFTR mutation genotypes) to pairs composed of two pancreatic sufficient
patients (displaying mostly mild CFTR mutation genotypes).
(III) Within most sib pairs, the time point of diagnosis is the same for both siblings and
consequently, the older sibling is diagnosed at a later age. However, no significant difference
between the disease severity of the older and the younger sib was observed.
In order to assess the influence of modulating effects on the concordance of CF twins and sibs, a
quantitative description of the intrapair-concordance was defined: the difference of rank numbers
between sibling A and sibling B of a patient pair was calculated for wfh% and FEVPerc. The
resulting distributions of these intrapair-rank number differences (IRND), obtained for all patient
pairs (non-homogeneous CFTR mutation genotype) or the subgroup of ∆F508 homozygous patient
pairs (homogeneous CFTR mutation genotype) was than compared to the distribution of IRND
expected for a group of unrelated couples.
The IRND distribution expected for a group of unrelated couples was deviated based on the
following considerations: the probability of obtaining a specific rank number difference depends on
the magnitude of the rank number difference "m" and the total number of pairs "n/2". n/2 pairs result
in the rank numbers 1, 2, 3, 4, ·····, n-1, n. The rank number difference m=1 can be obtained by
occupying rank numbers 1 and 2 or similarly rank numbers 2 and 3 or similarly rank numbers n-1 and
n. This results in 2×(n-1) probable constellations to obtain the rank number n=1. In contrast, there is
only one constellation to obtain the maximal rank number difference n-1, by occupying rank numbers
1 and n, respectively. The mean expected frequency f for any rank number difference m is therefore
given by the normalised expression f = (n-m)/(n-1).
For comparison of expected and observed IRND distribution, classes of equally sized IRND
were estimated based on the expected IRND distribution (minimal size of the IRND classes:
expectancy value E = 10 couples per IRND class). The occupation of these IRND classes was than
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calculated for the observed IRND distribution (CF twin and sibling pairs). Random fluctuations of
the IRND class occupation were minimised by raising the size of the IRND classes (E = 20, 30, 40
couples expected per IRND class). Statistical comparison was done with a  χ2 test.
24
FIGURE 24: INTRAPAIR-RANK NUMBER DIFFERENCES FOR CF TWINS AND SIBS
The distribution of intrapair - rank number differences for CF twins and sibs was compared to a distribution of
intrapair - rank number differences for a group of unrelated couples. See chapter  3.2.1.2 for details.
Parameter: i = number of intrapair - rank number difference classes used for calculation
E
 = number of pairs expected within each of the n classes
Deviation from expectancy value : difference between the number of pairs expected within a class and the number of
pairs observed within each class expressed as % of  E
intrapair rank number difference  was expressed as % of maximal rank number difference
(a) Distribution of intrapair - rank number differences in wfh% for all CF twins and sibs
  : i = 47, E = 10    : i = 9, E = 50
(b) Distribution of intrapair - rank number differences in FEVPerc for all CF twins and sibs
 : i = 32, E = 10    : i = 7, E = 50
(c) Distribution of intrapair - rank number differences in wfh% for all ∆F508 homozygous twins and sibs
 : i = 11, E = 10    : i = 4, E = 30
(d) Distribution of intrapair - rank number differences in FEVPerc for all  ∆F508 homozygous twins and sibs
 : i = 11, E = 10    : i = 4, E = 30
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Figure 24 displays the results in normalised form: the x-axis represents the IRND, expressed as % of
the maximal IRND n-1. The y axis represents the occupation of the IRND class, expressed as % of
the expected occupation E. The IRND distribution for wfh% and FEVPerc rank numbers differs
significantly when comparing all CF twins and sibs to a group of unrelated couples (wfh%: 9 IRND
classes, p << 0.001, figure 24a; FEVPerc: 7 IRND classes, p << 0.001, figure 24b). Analysing the
subgroup of ∆F508 homozygous patient pairs only, a significant difference between observed IRND
distribution compared to a group of unrelated couples was obtained for wfh% (4 IRND classes, p =
0.025, figure 24c), but not for FEVPerc (4 IRND classes, p = 0.9, figure 24d).
CF twins and sibs carry identical mutations within the CFTR gene, live in a similar environment
and share sequences from the genetic background. Hence, it can be expected that the patient pairs do
not resemble a set of unrelated couples. When analysing pairs representing all CFTR genotypes, the
difference between wfh% and FEVPerc IRND distributions of CF twins and siblings compared to a
group of unrelated couples demonstrates the influence of the major affected gene on the intrapair
concordance. In contrast, the CFTR gene cannot be held responsible for the deviation of IRND
distributions when ∆F508 homozygous patient pairs are analysed. Any deviation of observed from
expected IRND distribution is caused by shared – i.e. inherited – factors besides the CFTR gene
itself. 
Considering the results obtained on ∆F508 homozygous twins and siblings, the number of
modulating factors detectable by this approach must be taken into account: when a class shows an
excess of pairs compared to the expected number of couples, another class must in a likewise manner
display less pairs than expected as both, the group of unrelated couples and the analysed group of
patient pairs are equally sized by definition. Thus, the maximal number of independent modulating
factors detectable due to an occupation of an IRND class deviating from the expectancy value is
given by half of the number of IRND classes analysed. Hence, the nutritional status, represented by
wfh%, is most likely to be regulated by a small number of modulating factors besides the CFTR gene
– otherwise, no difference between the IRND distribution of ∆F508 homozygous twins and siblings
compared to a group of unrelated pairs would have been observed. For the pulmonary status, a large
number of modulating factors besides the CFTR gene can be estimated, as the IRND distribution of
∆F508 homozygous twins and siblings resembles the group of unrelated couples. While the
concordance of monozygous twins in FEVPerc points to the existence of inherited factors,
modulation of lung disease by epigenetic factors cannot be excluded. It seems most likely that
inherited factors which determine the ability of an individual to deal with the environment are the
basis of the variation observed.
In conclusion, the analysis of the intrapair variance of wfh% and FEVPerc has demonstrated an
influence of shared factors on the nutritional status in CF while the modulation of the pulmonary
status appears to be dominated by individual factors.
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3.2.2    Intestinal current measurement
The basic defect in CF, i.e. the impaired chloride conductance of affected tissues, is accessible by
short circuit current measurement of rectal suction biopsies (Veeze et al. 1991). In addition, residual
chloride secretion has been observed among CF patients, predominantly when genotypes associated
with a milder course of the disease have been analysed (Veeze et al. 1994). Within the "European
CF twin and sibling study", patients homozygous for ∆F508 have been selected for investigation if
they express an extreme phenotype with respect to their nutritional status, their pulmonary status or
the intrapair concordance of one or both parameters (see chapter 2.2.1 for details on the selection of
patient pairs).
Carbachol has been demonstrated to stimulate the basolateral and apical K+ channels through
an increase of the intracellular Ca2+ concentration (Schultheiss and Diener 1997). Cl
¯
secretion is
then supported by the hyperpolarization of the cell membrane. In CF patients, the lack of CFTR
mediated chloride secretion was shown to result in a net K+ efflux ("reversed response"), which can
be followed by a small current compatible with Cl
¯
secretion ("residual response", Veeze et al.
1994). Figure 25 displays the intrapair variation of carbachol-induced signals for the investigated
patient pairs. Signals are given as PDH% (defined in figure 15, page 59) representing the reversed
proportion of the response with PDH% = 100 corresponding to a signal composed of only the K+
secretory response. In the plot each data point represents one patient pair, by assigning the PDH%
value obtained for one sib on the x axis and by assigning the PDH% value obtained for the other sib
on the other axis.
Pairs who are concordant with respect to their secretory response are to be found near the 45°
diagonal axis in figure 25. Monozygous twins, being genetically identical, are expected to be
concordant unless environmental factors or the experimental variance obscure the result. Estimating
an error of ± 20% PDH, monozygous twins are found in 6 out of 8 pairs in a concordant status. For
the remaining two cases, the influence of epigenetic factors may have to be taken into account.
Indeed, one of the two monozygous twins discordant with respect to ICM is likewise discordant in
clinical state and general appearance as these twins do not look monozygous, but resemble rather a
sib pair.
Non-monozygous patient pairs demonstrated various combinations of a residual component
and the intrapair variation thereof. Interestingly, for 1/3 of the ∆F508 homozygous patients, residual
secretion could be observed. This is consistent with the analysis of the shape types (table 414),
likewise indicating the presence of residual chloride secretion in 1/3 of the patients.
14  Table 4 is shown in chapter 2.2.2.2.2 on page 58.
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25
FIGURE 25: INTRAPAIR VARIATION OF CARBACHOL-INDUCED SIGNALS
PDH% as defined in figure 15, page 59 for Sib A and Sib B of a pair ( " ). "  : monozygous twin pair.
In cases of discordant residual secretion within a twin or sib pair, factors other than the CFTR gene –
shared by both sibs – have to attribute for the modulation of the basic defect. Nevertheless,
discordance might be assigned to the CFTR protein, as a modulation of CFTR expression mediated
by a factor acting in trans could lead to a discordant CFTR expression when comparing two sibs.
As described in chapter 2.2.2.2, the protocol employed makes an attempt to discriminate between
residual currents with respect to their DIDS-sensitivity. CFTR is considered DIDS-insensitive unless
DIDS is added to the intracellular side (Lindsdell and Hanrahan 1996). In contrast, the Ca2+
regulated chloride channel CLCA1 was shown to be sensitive to DIDS (Gruber et al. 1998b). To
allow comparison of secretory currents in the presence and the absence of DIDS within one tissue
sample, the signals obtained upon stimulation of the biopsy by carbachol (without DIDS) and
histamine (after an incubation with DIDS) are compared. However, carbachol and histamine are
considered to act through non-identical pathways: both carbachol and histamine have been
demonstrated to raise the intracellular Ca2+ levels. But, in contrast to histamine, the stimulation with
carbachol could not be repeated immediately due to elevated levels of an inositol tetrakis phosphate
species with an inhibitory effect (Vajanaphanich et al. 1994).
In figure 26, the effect of DIDS on the residual current is shown. Within the plot, each data
point represents a patient. No effect of DIDS on the residual component was seen for all cases
plotted near the 45° diagonal axis. However, several points within the upper left corner
demonstrated a Cl¯ conductance sensitive to DIDS indicating the presence of a non-CFTR mediated
conductance in these patients.
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FIGURE 26: DIDS SENSITIVITY OF RESIDUAL CURRENTS 
Comparison of reversed proportion of carbachol- and histamine stimulated signals after 10' incubation with DIDS.
PDH% as defined in figure 15, page 59. The pictograms show idealised tracings representing the data points
indicated by the arrows. C: carbachol, D: DIDS; H: histamine
In summary, residual Cl
¯
secretion was detected among ∆F508 homozygous patients. This
conductance was sensitive to DIDS in a subset of these patients indicating the presence of a non-
CFTR mediated conductance, possibly based on the Ca2+ regulated chloride channel CLCA1.
3.2.3    Analysis of selected candidate genes
3.2.3.1    Selection of patient pairs for genotyping
The phenotype of ∆F508 homozygous patient pairs was analysed in order to identify pairs with an
extreme course of the disease. Patients were ranked according to their nutritional status –
represented by wfh% – and their pulmonary status – represented by percentiles for FEV1%pred –
and pairs were selected based on non-average properties for the nutritional status, the pulmonary
status or the intrapair discordance of one or both parameters (chapter  2.2.1).
The quantitative description of both the intrapair discordance and the disease severity enabled
the ranking of pairs in sequences expressing the trait "discordance" (DIS) or the combined traits
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"concordant/severe disease" (CON-) and "concordant/mild disease" (CON+). 114 ∆F508
homozygous patient pairs were ordered in each sequence and all pairs with rank numbers lower than
20 (concordant pairs) or lower than 25 (discordant pairs) were selected for genetic analysis15. Pairs
ranked simultaneously in two conflicting categories were categorised separately as "discordant and
concordant mild disease" (DC) and "non-discordant" (ND) as described in chapter 2.2.1.4. In total,
38 non-monozygous ∆F508 homozygous patient pairs, 19 thereof with both parents sampled, were
selected. In addition, 5 monozygous ∆F508 homozygous twin pairs and 9 dizygous non-∆F508
homozygous twin pairs, 3 thereof with both parents sampled, were typed (figure 27).
27
FIGURE 27: SELECTION OF PAIRS FOR GENOTYPING
3.2.3.2    Selection of markers near candidate gene loci
With an increasing number of genes mapped during the process of the human genome project, a
candidate gene approach becomes feasible in accessing a gene's role in shaping the course of a
disease. For CF, several groups of genes with examples listed in table 16 can be considered:
(a) ion channels having the capability of altering the CF basic defect
(b) gene products which might be involved in processing of CFTR protein as most CFTR
mutants have been described to be defective in maturation in in vitro systems
(c) gene products involved in determining the major clinical manifestations
(d) gene products which maintain the integrity of polarised, CFTR expressing epithelial cells
(e) gene products which mediate the response to therapeutic drugs.
Within this thesis, results on the candidate gene ENaC are presented (chapter 3.2.3.4). The role of
the obesity-related gene LEP on chromosome 7 is addressed by investigating a 40 cM region
encompassing CFTR (chapter 3.2.3.5).
15 based on DNA availability by December 1997
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TABLE 16: EXAMPLES FOR CANDIDATE GENES
#
# #
# gene products with the capability of altering the basic defect
$ alternative Cl¯  channels
$ outwardly rectifying chloride channel ORCC
$ outwardly rectifying depolarisation induced chloride channel (ORDIC)
$ Ca2+ activated chloride channel (CLCA1)
$ channels interacting with CFTR 
$
 amiloride-sensitive Na+ channel ENaC
#
# #
# gene products involved in processing maturing CFTR proteins
$ chaperones: HSP70, HSP90, calnexin
#
# #
# gene products involved in determining the major clinical manifestations
$ modulation of nutritional status / obesity related genes, e.g. LEP
$ modulation of pulmonary status
$ gene products involved in host defence
$ against chemicals / xenobiotics
$ glutathione S transferases (GST-Genes)
$ cytochrome P450 Enzymes (CYP-Genes)
$ against bacterial pathogens: HLA
$ antiproteases
#
# #
# gene products maintaining integrity of the epithelium
$ cell differentiation, e.g. hepatocyte growth factor HGF
#
# #
# gene products mediating response to therapeutic drugs
$ e.g. response to bronchodilators: β2 adrenergic receptor
17
TABLE 17: LOCI NEAR CANDIDATE GENES ANALYSED WITHIN THIS THESIS
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TEST OF POLYMORPHIC
LOCUS FOR
ALLELIC ASSOCIATION
CORRELATION OF
GENOTYPE TO
 CLINICAL PHENOTYPE
Marker Candidate Gene
CHAPTER 3.2.3.4 D12S889βENaCGT ENaC
CHAPTER 3.2.3.5
PON2
D7S525
MetH
J3.11
D7S514
D7S495
Linkage group/obesity
CHAPTER 3.2.3.6 D2S1788 POMC/obesity
CHAPTER 3.2.3.7.1 D12S889
CHAPTER 3.2.3.7.2 D7S525, MetH, J3.11, D7S514, D7S495
CHAPTER 3.2.3.7.3 D2S1788
THE EUROPEAN CF TWIN AND SIBLING STUDY
28
FIGURE 28: PAIRS SELECTED FOR GENETIC ANALYSIS: INTRAPAIR DIFFERENCES
Within this figure, each patient pair is represented by a plot of the ranknumber for wfh% on one axis and ranknumber
for FEVPerc on the other axis. This diagram was used to calculate the parameters DfO and DELTA quantifying the
disease severity and the intrapair-discordance, respectively (see figure 10c, page 48). The categories DIS, CON+,
CON-, ND and DC were defined based on the rank numbers for the respective pairs which were displayed in table 1,
page 52 (see also in figure 12 on page 53 or refer to chapter 2.2.1.4 for details on the ranking procedure). The
following pictograms are representative for the five categories:
PATIENT PAIRS SELECTED FOR GENOTYPING
Colour coding is used to emphasise the pairs which were ranked discordant (DIS), concordant/mild disease (CON+)
and concordant/severe disease (CON-) as introduced in figure 2 on page 26.
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FIGURE 29: PAIRS SELECTED FOR GENETIC ANALYSIS: CLINICAL DATA
Figures (a) - (d) display DELTA (the composite parameter quantifying discordance, see figure 10c, page 48), DfO
(the composite parameter quantifying disease severity, see figure 10c, page 48), wfh% (representing the nutritional
status) and FEVPerc (representing the pulmonary status) for the patient pairs ranked DIS, CON+ and CON-. Within
each diagram, rank number decreases from left to right, hence the pairs fulfilling the criteria best are found closest
to the y-axis. Clinical data for the pairs with the following rank numbers are displayed:
DIS: 3, 5, 6, 8, 9, 14, 15,p16, 18, 19, 21, 24
CON+: 2, 5, 6, 7, 10, 15, 16, 19 
CON-: 2, 5, 7, 8, 10, 12, 14, 25
(a), (b) composite parameters as defined in chapter 2.2.1.3
(a) DELTA describing the discordance (b) distance from origin (DfO) describing the severity of disease
(c) weight for height (wfh%) (d) percentiles for FEV1%pred (FEVPerc)
(b), (c), (d): 
%
 Sibling A of pair;
&
 Sibling B of pair
    g  apgapgapg  3, 5, 6, 8, 9, 14, 15, 16, 18, 19, 21, 24ga     2, 5, 6, 7, 10, 15, 16, 19 pgapga   2, 5, 7, 8, 10, 12, 14, 25
— 88 —
0
200
400
600
0
200
400
600
0
25
50
75
100
0
25
50
75
100
0
25
50
75
100
60
80
100
120
60
80
100
120
0
250
500
750
1000
0
200
400
600
0
250
500
750
1000
0
250
500
750
1000
60
80
100
120
(a) DELTA
(b) DfO
(c) WFH%
(d) FEVPERC
(a) - (d) RANK DIS RANK CON+ RANK CON-
THE EUROPEAN CF TWIN AND SIBLING STUDY
3.2.3.3    Evaluation of genotype data of pairs in ranked in cohorts
Rank numbers for all selected non-monozygous ∆F508 homozygous patient pairs were shown in
table 116. The diagrams in figure 28 represent each pair used in candidate gene analysis by displaying
the clinical parameters wfh% and FEVperc as defined for evaluation of the composite parameters
DELTA (describing the intrapair discordance by the distance of both patients to each other within that
diagram, figure 10c17) and DfO (describing the disease severity as the distance from origin in that
diagram; figure 10c). Within each of the categories DIS, CON+ and CON-, pairs are arranged by
decreasing rank number corresponding to a decline in the representation of intrapair discordance
(sequence DIS), disease mildness and intrapair concordance (sequence CON+) and disease severity
and intrapair concordance (sequence CON-). The decrease in DELTA within the sequences of pairs
ranked DIS and the increase in DELTA within the sequences of pairs ranked CON+ and CON- is
shown in figure 29a. As expected, siblings from discordant pairs (DIS) differ markedly in wfh%,
FEVPerc and DfO while siblings from concordant pairs (CON+ and CON-) are comparable in all three
parameters (figure 29b, c, d). The groups of pairs scored "concordant" (CON+ and CON-) and
"discordant" (DIS) pairs differ completely with respect to the parameter DELTA : none of the selected
pairs ranked CON+ or CON- have values of DELTA larger than 300 while all selected pairs ranked
discordant have values of DELTA larger than 300. Likewise, the groups of pairs with mild disease
(CON+) and severe disease (CON-) differ completely with respect to DfO: none of the siblings from
pairs ranked CON- have values of DfO larger 500 than while all of the siblings from pairs ranked
CON+ have values of DfO larger than 500. Hence, the selected patient pairs compose three groups
with extreme and non-overlapping phenotypes.
Data on DNA polymorphisms was analysed by an association study: alleles were counted for the
extreme ranking pairs within each group and the allele frequencies were compared. For 114 ∆F508
homozygous pairs, the 10% most extreme pairs correspond to 11 couples, defined by a rank number
border of 11. However, DNA for less than 6 pairs was available if that cut-off border was used
resulting in numbers too small to be evaluated statistically. Hence, for an initial comparison of
genotype data the rank number 15 – enabling typing of 6 or more pairs for all markers studied – was
employed. Upon detection of an allelic imbalance for any of the three groups, the complete cohort
typed was evaluated involving the following sequences (pairs defined as extremes are  underlined)18:
14 discordant pairs
— rank number DIS 3, 5, 6, 8, 9, 14, 15, 16, 18, 19, 21, 24 
— 2 pairs from combined categories DC(1), DC(2)
16 Shown in chapter 2.2.1.4 on page 52.
17 Shown in chapter 2.2.1.3 on page 48.
18 dizygosity status of DC(4) and ND(2) not confirmed by July 1998, these pairs were excluded from evaluation
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13 concordant/mild disease pairs
— rank numbers CON+ 2, 5, 6, 7, 10, 15, 16, 19
— 5 pairs from combined categories ND(1), ND(3), ND(4), ND(6), DC(3)
9 concordant/severe disease pairs 
— rank numbers CON- 2, 5, 7, 8, 10, 12, 14, 25 
— 1 pair from combined category ND(5)
Analysis of the data for complete cohorts was carried out as follows: starting with the 6 most
extreme ranking pairs, allele frequencies were determined. Subsequent inclusion of the next ranking
pair with genotype data lead to groups of cumulatively pooled couples with a size of 7, 8, 9 pairs
etc. up to 14 pairs (all discordant pairs if all patients successfully typed), up to 13 pairs (all
concordant / mild disease pairs if all patients successfully typed) or up to 9 pairs (all concordant /
severe disease pairs if all patients successfully typed).
When data on expectancy values for alleles were available, the observed allele frequencies were
compared to the values expected for the cohort of the respective size [frequencies for ∆F508
chromosomes were published for MetH and J3.11 (Tümmler et al. 1990), XV-2c, KM19 and TUB20
(Dörk et al. 1992)]. For chromosome 7 markers PON2 (Adkins et al. 1993), D7S525, D7S514 and
D7S495 (Dib et al. 1996), no allele frequencies were available for ∆F508 chromosomes. For these
markers all equally sized cohorts were compared to detect an allelic imbalance between pairs ranked
DIS, CON+ or CON-. A similar approach was necessary for the markers D12S889 (Baens et al.
1995) and βENaCGT (Shimkets et al. 1994): these markers were selected due to their position
relative to the candidate genes but are not integrated into common marker sets and, consequently, no
expected allele frequencies are known.
Results on polymorphic markers are reported in the following format:
locus name - size in arbitrary repeat units, e.g. D7S514 - 13
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3.2.3.4    Results on ion channel ENaC 
The amiloride sensitive sodium channel ENaC is related to CF disease in two ways: the channel was
reported to be regulated by CFTR (Ismailov et al. 1996, Stutts et al. 1997) and mutations within the
genes encoding for ENaC subunits have been demonstrated to cause pseudohypoaldosteronism
(Chang et al. 1996, Strautnieks et al. 1996a), a disorder described as mimicking the clinical
appearance of mild CF lung disease (Hanakoglu et al. 1994, Marthinsen et al. 1998). The ENaC is
composed of three subunits. SCNN1A, coding for the α subunit, was mapped to chromosome
12p13. A complex repeat polymorphism, D12S889, has been mapped within a 40kb distance to
SCNN1A on a cosmid clone (Baens et al. 1995). The satellite is composed of a (CA)n(GT)m core
repeat. Five alleles were identified among 10 unrelated Caucasians (Baens et al. 1995). The genes
SCNN1B and SCNN1G, encoding the β and γ subunits of the ENaC, are both located within a
400kb fragment on chromosome 16p12-p13 (Voilley et al. 1995). Within SCNN1B, the dinucleotide
repeat polymorphism β-ENaCGT was described (Shimkets et al. 1994). Five different alleles have
been typed at β-ENaCGT in 50 unrelated Caucasians.
30
FIGURE 30: ALLELES NEAR SCNN1A, SCNN1B AND SCNN1G
D12S889 - near SCNN1A
Left: allele distributions for 33 typed pairs (132 chromosomes)
Right: alleles displayed by the 6 most extreme pairs ranked
 DIS       CON+       CON- 
ARU 8 9 10 12 13 14 15
DIS
(13) — — 19 2 23 8 —
CON+
(11) 2 — 27 — 10 5 —
CON-
(9) 2 1 10 3 14 4 2
Σ 4 1 56 5 47 17 2
βENaCGT - near SCNN1B and SCNN1G
Left: allele distributions for 35 typed pairs (140 chromosomes)
Right: alleles displayed by the 6 most extreme pairs ranked
 DIS       CON+       CON- 
ARU 6 7 9 10 11
DIS
(13) 2 13 4 33 —
CON+
(13) 2 17 3 29 1
CON-
(9) 3 5 — 28 —
Σ 7 35 7 90 1
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3.2.3.4.1    Allelic association at D12S889 and βENaCGT
For all CF pairs typed, 7 different alleles were detected at D12S889 and 5 different alleles were
detected at β-ENaCGT. The most frequent alleles were D12S889-10, on 38% of chromosomes typed,
and β-ENaCGT-10, on 63% of chromosomes typed. At D12S889, for 24 out of 44 pairs a different
genotype was observed between sib A and sib B. For β-ENaCGT, only 16 out of 46 pairs displayed
non-identical genotypes for both sibs. For both, D12S889 and β-ENaCGT, no noticeable differences
were observed comparing the number of pairs sharing one or more alleles identical by state within
the groups of extreme pairs DIS, CON+ and CON-.
At D12S889, an association of the allele D12S889-10 with the phenotype "concordant / mild
disease" was observed (figure 30). On all ∆F508 chromosomes, the two alleles D12S889-10 and
D12S889-13 were presented on equal proportions of chromosomes (40% D12S889-10 and 38%
D12S889-13, respectively). Within the extreme DIS and CON- pairs, both alleles were distributed as
described for the complete cohort, but CON+ pairs ranking 15 or lower displayed D12S889-10 on 16
out of 24 chromosomes and D12S889-13 on 3 out of 24 chromosomes. The allele distribution at
D12S889 for the 6 pairs with lowest rank numbers differed most noticeable between groups DIS and
CON+.
The marker β-ENaCGT showed no evidence of an allelic imbalance as judged by comparing the
groups CON+, CON- or DIS (figure 30): within each group of extreme pairs ranking 15 or lower,
the allele β-ENaCGT-10 was found on equivalent proportions of typed chromosomes (15 out of 24
extreme DIS, 12 out of 24 extreme CON+ and 21 out of 28 extreme CON- pairs, respectively).
3.2.3.5    Results on the linkage group on chromosome 7
The high frequency of carriers for CF causing alleles – 1 in 22 healthy persons, as deduced from an
incidence of 1 affected person in 2000 newborns (Romeo 1989) – has been the subject of speculation
as to the underlying mechanisms leading to the prevalence of the CF causing alleles. The
maintenance of a high frequency of mutant CFTR alleles was attributed to genetic drift or a
reproductive advantage of the heterozygous state, the latter being either transmitted through the
CFTR gene itself or by genes within linkage disequilibrium to CFTR. Evidence for so-called "hitch-
hiking genes", detectable through markers localised in the CFTR gene region, has been reported by
three authors: Santis et al. (1990b) has reported an association of J3.11-2 alleles with milder
pulmonary disease among ∆F508 homozygotes. Tümmler et al. (1990) has described an association
of MetH and J3.11 alleles with growth parameters in CF patients. Macek et al. (1997) has reported an
increased proportion of CS.7/HhaI-2 alleles in elderly female individuals within the Czech population.
Within this chapter, allele frequencies at loci PON219, MetH/MspI, XV-2c/TaqI, KM.19/PstI, TUB20/PvuII,
J3.11/MspI, D7S514 and D7S495 – localised in a 40 cM interval surrounding the CFTR gene as showed
in figure 31 – are reported for CF twin and sib pairs with selected phenotypes.
19 Sequence variant Arg191Gln in PON2 as shown in figure 5 in chapter 2.1.2.2.4 on page39.
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FIGURE 31: INTEGRATED MAP OF 40 cM REGION AROUND CFTR
The relative positions of the map elements are consistent with mapping data generated by Tsui et al. 1985, Rommens
et al. 1989, Green et al. 1995, Höglund et al. 1995, Bouffard et al. 1997, Fisher et al. 1998, Li et al. 1998. Positions
in cM are given as published by Bouffard et al. 1997. Colours refer to positions on the genetic map or the physical
map
18
TABLE 18: ALLELE FREQUENCIES FOR D7S525, D7S514 AND D7S495
Expected frequencies are derived from the GDB for 56 Caucasian chromosomes (CEPH).
D7S525 (34 ∆F508 homozygous pairs and 8 non-∆F508 homozygous dizygous twin pairs typed)
Size [bp] 219 221 223 227 229 231 233 235
Frequency [%]
 non-CF chromosomes (CEPH) 2 2 7 10 30 43 4 2
Size [ARU] 4 5 6 8 9 10 11 12
Frequency [%]
 
∆F508 homozygous pairs — 1 7 4 26 57 4 —
Number of alleles
(8 Non-∆F508 homozygous pairs) — — 3 — 20 9 — —
D7S514
 (34 ∆F508 homozygous pairs and 6 non-∆F508 homozygous dizygous twin pairs typed)
Size [bp] 147 149 151 153 155 157 159
Frequency [%] non-CF chromosomes (CEPH) 3 3 17 41 28 5 —
Size [ARU] 8 9 10 11 12 13 14
Frequency [%]
 
∆F508 homozygous pairs — 15 6 42 35 1 1
Number of alleles
(6 Non-∆F508 homozygous pairs) — 3 4 13 4 — —
D7S495 (36 ∆F508 homozygous pairs and 8 non-∆F508 homozygous dizygous twin pairs typed)
Size [bp] 150 152 154 158 160 162 164 166 168
Frequency [%] non-CF chromosomes (CEPH) 7 — 14 18 — 20 27 5 5
Size [ARU] 8 9 10 12 13 14 15 16 17
Frequency [%]
 
∆F508 homozygous pairs 5 1 19 23 1 25 21 4 1
Number of alleles
(8 Non-∆F508 homozygous pairs) 1 2 5 10 — 10 1 — 3
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3       RESULTS AND DISCUSSION
3.2.3.5.1    Allele distributions at D7S525, D7S514 and D7S495
Allele frequencies for D7S525, D7S514 and D7S495 were published for non-CF families (references
see chapter ). The allele distributions for ∆F508 chromosomes and non-CF chromosomes matched
with regard to the most frequent alleles. Additionally, similar "gaps" in the sequence of D7S495
alleles arranged by size – alleles D7S495-9, D7S495-11 and D7S495-13, respectively – were discernible
for both the CEPH panel and the typed ∆F508 chromosomes. However, the most frequent and the
second most frequent alleles were observed in different proportions for all polymorphic markers,
most pronounced at D7S525 and least pronounced at D7S495. Furthermore, the allele spectrum at
D7S525 and D7S514 appeared to be smaller for typed CF chromosomes than for typed non-CF
chromosomes: the shortest and the largest D7S525 allele observed on non-CF chromosomes was not
observed among ∆F508 homozygous patients and the shortest D7S514 allele on non-CF
chromosomes did not occur on typed CF chromosomes. A small set of non-∆F508 CF chromosomes
was analysed for dizygous twin pairs. The differences of the allele distributions between ∆F508
homozygous and non-∆F508 homozygous pairs were again most striking at D7S525 and nearly
unnoticeable at D7S495.
3.2.3.5.2    Allelic association at loci between PON2 and D7S495
3.2.3.5.2.1    MetH and J3.11:  ± 1 Mb near CFTR
No difference between the allele distributions among CON+, CON- or DIS pairs have been observed
at the loci XV-2c, KM.19 and TUB20. Allele frequencies for the markers XV-2c, KM.19 and TUB20
observed in the groups of CF twins and sibs did not differ from the expected frequencies (Tümmler
et al. 1990, Dörk et al. 1992) for ∆F508 chromosomes. Genotypes at XV-2c and TUB20 were
identical for both sibs within a pair for all patient couples investigated. Non identical genotypes
within a pair were observed for one pair at KM.19.
32
FIGURE 32: ALLELE DISTRIBUTIONS AT MetH AND J3.11
Left: allele distributions for 32 typed pairs (64 alleles) at MetH and 34 typed pairs (68 alleles) at J3.11
Right:: alleles displayed by the 6 most extreme ranking  pairs  DIS   CON+   CON- 
               MetH J3.11
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At MetH, an association of MetH-1 with the phenotype "concordant / mild disease" was detected
(table 19 and figure 32). The deviation of observed allele frequency to the frequency expected for
∆F508 chromosomes was significant for the extreme CON+ pairs ranked 15 or lower (χ2i=i3,81 with
pi=i0.05 at χ2i=i3.84). The allele frequencies for CON- pairs and DIS pairs were as expected for
∆F508 chromosomes. In one pair, sib A and sib B carried different genotypes at MetH.
At J3.11, an association of allele J3.11-1 with the phenotype "discordant" was noticed (table 20
and figure 32). Among DIS pairs the deviation from the allele frequency expected for ∆F508
chromosomes was significant for the 6 pairs ranked 14 and lower (χ2ii=i3.81 with pi=i0.05 at
χ2ii=i3.84). The allele frequencies for the CON+ pairs and the CON- pairs at J3.11 were as expected
for ∆F508 chromosomes. For all patient pairs studied, the same genotype was observed for sib A and
sib B at J3.11.
19
TABLE 19: GENOTYPES AT METH FOR CONCORDANT / MILD DISEASE PAIRS
pair ND(1) showed a recombination event: genotype sib A 1-2, sib B 2-2  
expected allele frequencies for ∆F508 chromosomes: MetH allele 1 0.7, allele 2 0.3
Pair: CON+2 CON+5 CON+6 CON+7 CON+10 CON+15 CON+16 CON+19 ND(1) ND(3) ND(6)
MetH 1—1 1—1 1—1 1—1 1—1 1—1 1—1 1—2 rec 1—1 1—1
OBSERVED IN CON+ 2-15 CON+ 2-16 CON+ 2-19 ALL CON+
ALLELE 1 12 14 15 19.5
ALLELE 2 0 0 1 2.5
EXPECTED FOR n=12 n=14 n=16  n=24
ALLELE 1 8.4 9.8 11.2 15.4
ALLELE 2 3.6 4.2 4.8 6.6
χ2 3.8 4.7 3.2 4.4
20
TABLE 20: GENOTYPES AT J3.11 FOR DISCORDANT PAIRS
expected allele frequencies  for ∆F508 chromosomes: J3.11 allele 1 0.6, allele 2 0.4
Pair: DIS3 DIS5 DIS6 DIS8 DIS9 DIS14 DIS16 DIS18 DIS19 DIS21 DIS24 DC(1) DC(2)
J3.11 1—1 1—1 1—1 1—1 1—1 1—2 1—2 1—2 1—2 1—2 2—2 1—2 1—2
OBSERVED IN DIS 3-14 DIS 3-16 DIS 3-18 ALL DIS
ALLELE 1 11 12 13 17
ALLELE 2 1 2 3 9
EXPECTED FOR  n=12  n=14  n=16  n=26
ALLELE 1 7.2 8.4 9.6 15.6
ALLELE 2 4.8 5.6 6.4 10.4
χ2 3.8 2.9 2.2 0.1
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FIGURE 33: ALLELE DISTRIBUTIONS AT D7S525 AND D7S514
D7S525
Left: allele distributions for 32 typed pairs (128 chromosomes)
Right: alleles displayed by the 6 most extreme pairs ranked
 DIS       CON+       CON- 
ARU 6 7 8 9 10 11
DIS
(12) — 6 2 6 30 4
CON+
(11) 2 2 2 18 19 1
CON-
(9) — 1 2 6 27 —
Σ 2 9 6 30 76 5
D7S514
Left: allele distributions for 32 typed pairs (128 chromosomes)
Right: alleles displayed by the 6 most extreme pairs ranked
 DIS       CON+       CON- 
ARU 9 10 11 12 13
DIS
(13) 8 3 18 23 —
CON+
(10) 4 — 22 14 —
CON-
(9) 9 3 14 8 2
Σ 21 6 54 45 2
3.2.3.5.2.2    D7S525 and D7S514: 10 cM and closer to CFTR
Localised further towards the centromer than MetH, D7S525 was studied. 6 alleles were identified on
all chromosomes typed, with allele D7S525-10 being most frequent on ∆F508 chromosomes (57% of
alleles were D7S525-10 and 26% were D7S525-9) while allele D7S525-9 was most frequent for non-
∆F508 homozygous dizygous twins tested (D7S525-9 was found on 20 out of 36 chromosomes, and
D7S525-10 was observed on 9 out of 36 chromosomes). For 9 out of 43 pairs, a non-identical
genotype was observed between both sibs. Association of a D7S525 allele with the phenotype
"concordant / mild disease" was noticed (figure 33): chromosomes from pairs ranking 15 or lower
were typed D7S525-10 on 19 out of 24 alleles for DIS pairs, on 20 out of 28 alleles for CON- pairs,
but only on 8 out of 24 alleles on CON+ pairs. The allele distribution at D7S525 was different
comparing six pairs with lowest rank numbers between CON+ and DIS or between CON+ and
CON-. Allele distributions between DIS and CON- pairs did not differ at  D7S525.
Located further towards the telomer than J3.11, D7S514 was investigated. On all chromosomes
typed, 6 alleles were identified. On ∆F508 chromosomes, alleles D7S514-11 and D7S514-12 were
most frequent (42% and 35%, respectively). The proportion of both alleles was different for non-
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∆F508 homozygous dizygous twins typed: D7S514-11 was found on 13 out of 36 chromosomes and
allele D7S514-12 was observed on 4 out of 36 chromosomes. In 3 out of 42 pairs, the genotype at
D7S514 was different for sib A and sib B. Allelic imbalances at D7S514 were found comparing all
three groups of pairs, DIS, CON+ and CON- (figure 33). The differences in allele distributions were
most pronounced between DIS and CON+ pairs: for the six pairs with lowest rank numbers, 6 alleles
showed D7S514-11 and 12 alleles showed D7S514-12 on DIS pairs, while on CON+ pairs 14 alleles
carried D7S514-11 and 6 alleles carried D7S514-12. Interestingly, an association between
heterozygosity at D7S514 and the phenotype "concordant/severe disease" was observed: for 5 out of
12 pairs ranked CON+ or DIS with rank number 15 or lower, both sibs were homozygous for a
D7S514 genotype. In contrast, 8 out of 9 pairs ranked CON- showed a heterozygous D7S514
genotype for both sibs (table 21).
21
TABLE 21: HETEROZYGOSITY AT D7S514
NUMBER OF SIBLINGS WITHIN A PAIR WITH HETEROZYGOUS GENOTYPES AT D7S514
Extreme DIS, CON+, CON- pairs 0 1 2 All DIS, CON+, CON- pairs 0 1 2
DIS (6 pairs) 2 — 4 DIS (13 pairs) 4 1 8
CON+ (6 pairs) 3 — 3 CON+ (10 pairs) 5 — 5
CON- (6 pairs) — — 6 CON- ( 9 pairs) 1 — 8
3.2.3.5.2.3    PON2 and D7S495: further away than 10 cM from CFTR
Localised further towards the centromer than D7S525, PON2 was analysed. No difference was
observed when comparing allele frequencies between pairs ranked DIS, CON+ or CON-.
Comparison of PON2 allele frequencies expected for non CF chromosomes to those observed for
CON+, CON- or DIS pairs showed a significant deviation in all three cases, indicating the expected
linkage disequilibrium for the CFTR region (Eiberg et al. 1985). In 4 out of 36 typed pairs, a different
genotype for sib A and sib B was observed at  PON2.
Located further towards the telomer than D7S514, D7S495 was analysed. 10 different alleles were
observed at D7S495. The allele spectrum differed between pairs ranked DIS, pairs ranked CON+ and
pairs ranked CON- (figure 34): for pairs ranking 15 or lower, the most frequent allele was D7S495-15 for
DIS pairs, D7S495-12 for CON+ pairs and D7S495-14 for CON- pairs (observed on 8 out of 24, 9 out
of 24 and 10 out of 28 chromosomes, respectively). The difference between allele frequencies was
pronounced when comparing DIS and CON+ pairs or CON+ and CON- pairs. Non-identical D7S495
genotypes for both sibs within a pair were observed for 15 out of 46 pairs. For 3 out of 11 pairs
ranked DIS, no identical D7S495 allele was found when comparing sib A and sib B. This condition
was not observed among 8 pairs ranked CON+ or 8 pairs ranked CON-. For 13 out of 22 pairs
ranked concordant (CON+ or CON- or ND), both alleles of both siblings at D7S495 were identical by
state (table 22). In three cases, a double recombination event resulted in a different  D7S495 allele on
both chromosomes for both sibs of a pair (0 identical alleles between sib A and sib B). These three
pairs were ranked discordant and this condition was not observed on any concordant pair.
— 97 —
3       RESULTS AND DISCUSSION
34
FIGURE 34: ALLELE DISTRIBUTIONS AT D7S495
D7S495
Left: allele distributions for 34 typed pairs (136 chromosomes)
Right: alleles displayed by the 6 most extreme pairs ranked
 DIS       CON+       CON- 
ARU 8 9 10 12 13 14 15 16 17
DIS
(13) 5 — 9 6 2 8 21 1 —
CON+
(12) 2 1 17 16 — 9 3 — —
CON-
(9) — — — 11 — 16 3 4 2
Σ 7 1 26 33 2 33 27 5 2
22
TABLE 22: ALLELES IDENTICAL BY STATE AT D7S495
NUMBER OF ALLELES IDENTICAL BY STATE WITHIN A PAIR
Extreme DIS, CON+, CON- pairs 0 1 2 All DIS, CON+, CON- pairs 0 1 2
DIS (6 pairs) 3 — 3 DIS (13 pairs) 3 4 6
CON+ (6 pairs) — 2 4 CON+ (12 pairs) — 4 8
CON- (6 pairs) — 4 2 CON- (9 pairs) — 5 4
3.2.3.5.2.4    Recombination events at loci between PON2 and D7S495
The probability of observing a recombination event increases with the physical distance between the
loci studied as well as with the number of alleles displayed by the locus investigated. Consequently,
more non-identical genotypes were observed at polymorphic markers D7S525, D7S514 and D7S495
compared to PON2. As shown in table 23, the most recombination events were observed at D7S495: a
third of all pairs did not display  two alleles identical by state.
When comparing the genetic map of the region encompassing the CFTR gene and the observed
frequency of recombination events, a crosswise relationship between the genetic distances of
polymorphic markers to CFTR and the number of recombination events among the typed pairs were
observed. Regarding the positions on the genetic map of D7S525 and D7S514, displaying a similar
allele spectrum, D7S514 is located at twice the distance to CFTR compared with D7S525. However, a
fifth of the pairs typed had non-identical genotypes at D7S525 but less than a tenth of the pairs typed
at D7S514 provided evidence for recombination events between the CFTR gene and D7S514 (table
23).
— 98 —
8 9 10 12 13 14 15 16 17
2 0 2
5
01
8
4
2
2 1
6
9
001
5
0
0 0 0
9
233
7
0
THE EUROPEAN CF TWIN AND SIBLING STUDY
23
TABLE 23: RECOMBINATION AT LOCI BETWEEN PON2 AND D7S495
(a) number of pairs displaying less than 2 alleles identical by state when genotypes of sib A and sib B were compared.
(b) Graphical representation of non-proportional relationship, observed at D7S525 and D7S514, between the
distance on genetic map and number of recombination events observed among selected twins and sibs with extreme
phenotypes.
PON2 is a diallelic marker, thus less recombination events are observable at PON2 compared to polymorphic marker
loci. In contrast, D7S525 and D7S514 are comparable with respect to the allele distribution (see figure 17 on page
63). However, only a minority of patient pairs showed recombination events at D7S514 while a fifth of the typed pairs
displayed less than two alleles identical by state at D7S525. This is unanticipated when taking the genetic map into
account: D7S525 is located closer to the CFTR gene than D7S514 (Bouffard et al 1997) indicating that on
chromosomes of the general population, a lower recombination frequency has been observed between CFTR and
D7S525 compared to CFTR and D7S514.
(a) PON2 D7S525 MET J3.11 D7S514 D7S495
PAIRS TYPED 36 43 38 31 42 46
NO OF PAIRS ≠ 2 IBS 4 9 1 0 3 15
 ≠ 2 IBS: less than two alleles identical by state comparing sib A to sib B within a pair
3.2.3.6    Results on D2S1788
D2S1788 was evaluated due to the results gained on markers J3.11 and D7S514: located further
towards the telomer than CFTR, obesity related traits have been mapped linking D7S514 to extremity
skinfolds and D7S495 to waist circumference (Duggirala et al. 1996). The human homologue of the
murine obesity gene, the leptin gene LEP, maps within 1 Mb of D7S514 (Green et al. 1995) and is a
candidate gene for the modulation of CF disease via the nutritional status. The results gained on
J3.11 and D7S514 show an allelic imbalance in pairs ranked discordant which points to a trans
conducted influence on a gene located further towards the telomer than CFTR: CF twins and sibs
have inherited the same CFTR gene region up to D7S514, demonstrated by the fact that two D7S514
alleles are identical by state for all but 3 out of 42 pairs. Hence, any influence at a locus close to
D7S514 evoking discordance within a CF sib pair cannot be caused by the gene transmitted with
D7S514 itself, but by a gene for which both discordant siblings carry different alleles. A candidate
region influencing serum leptin levels has been identified near D2S1788 (Comuzzie et al. 1997), close
to the POMC gene encoding for proopiomelanocorticoin, which gives rise to hormones inducing
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glucocorticoid secretion. Glucocorticoids have been shown to regulate the expression of leptin (De
Vos et al. 1995). An influence on the expression levels of a gene qualifies as a trans influence and
accordingly, D2S1788 was investigated in the panel of CF twins and sibs.
3.2.3.6.1    Allelic association at D2S1788
At D2S1788, a total of 13 alleles have been observed on 34 typed ∆F508 homozygous pairs. The
most frequent alleles were D2S1788-12, D2S1788-19, D2S1788-20 and D2S1788-22 on 11%, 13%, 14%
and 21% of chromosomes, respectively. Comparable proportions of these alleles were observed for
subgroups of CON+ and CON- pairs, but among DIS pairs, other alleles were dominant (figure 35):
D2S1788-18 was typed on 8 alleles out of 14 pairs ranked DIS while D2S1788-18 was found on no
chromosome from 12 CON+ or 8 CON- pairs. D2S1788-21 was identified on 13 chromosomes from
14 pairs ranked DIS but only 3 chromosomes from 12 pairs ranked CON+ and no chromosome from
8 pairs ranked CON- were typed D2S1788-21. For a total of 10 out of 14 pairs categorised as DIS, at
least one sib carried one of the alleles D2S1788-18 or D2S1788-21 on either one or both chromosomes.
Based on the observation of the association of D2S1788-18 and D2S1788-21 alleles with the
phenotypic trait "discordance", pairs sharing one or both of these alleles identical by state were
excluded from the analysis of allele sharing among concordant and discordant pairs20 (table 24, row
DIS*: all pairs with one or both alleles D2S1788-18 or D2S1788-21 identical by state excluded). 7 pairs
ranked discordant and 20 pairs ranked concordant remained. A fifth of the concordant pairs had no
identical allele comparing genotypes of sib A and sib B. This condition was observed in 4 out of 7
DIS* pairs. In a third of the pairs ranked concordant, both alleles were identical by state. This was
observed for one out of 7 DIS* pairs.
24
TABLE 24: ALLELES IDENTICAL BY STATE AT D2S1788
NUMBER OF ALLELES IDENTICAL BY STATE WITHIN A PAIR
Extreme DIS, CON+, CON- pairs 0 1 2 All DIS, CON+, CON- pairs 0 1 2
DIS – all genotypes (6 pairs) 3 1 2 DIS (14 pairs) 4 4 6
DIS* (4 pairs) 3 1 — DIS* (7 pairs) 4 2 1
CON+ (6 pairs) 2 2 2 CON+ (12 pairs) 3 6 3
CON- (6 pairs) 1 2 3 CON- (8 pairs) 1 4 3
CON+ and CON- (12 pairs) 3 4 5 CON+ and CON- (20 pairs) 4 10 6
*7 out of 14 pairs ranked DIS with one or two alleles D2S1788-18 or D2S1788-21 IBS excluded;
  this condition was not observed for pairs ranked CON+ or CON-
20 The hypotheses tested by (a) comparison of the number of alleles identical by state between pairs ranked
concordant and pairs ranked discordant or (b) analysing allelic association with the phenotypes concordant and
discordant are incompatible when an allelic association with the phenotype "discordance" is detected: when
analysing a gene modulating the phenotype, discordance is expected when both sibs of a pair carry non-identical
genotypes at the gene locus. If a marker locus analysed is linked to the gene, non-identical genotypes at the marker
locus indicate non-identical genotypes at the gene locus. Overrepresentation of one allele in the subgroup of
discordant pairs points to the hypothesis that an allele at the gene locus is itself causing the phenotype
"discordance", even if —or, caused by the fact that — both sibs are carrying that allele identical by descent.
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FIGURE 35: ALLELE DISTRIBUTIONS AT D2S1788
D2S1788
Left: allele distributions for 34 typed pairs (136 chromosomes)
Right: alleles displayed by the 6 most extreme pairs ranked
 DIS       CON+       CON- 
ARU 11 12 13 14 15 17 18 19 20 21 22 23 24
DIS
(14) 1 4 1 — — 1 8 9 4 13 12 2 1
CON+
(12) — 6 3 2 1 1 — 8 8 3 10 4 2
CON-
(8) — 4 3 5 — 1 — 2 7 — 9 1 —
Σ 1 14 7 7 1 3 8 19 19 16 31 7 3
3.2.3.7    Correlation of genotype and clinical phenotype
In chapters 3.2.3.4, 3.2.3.5 and 3.2.3.6, the overrepresentation of one allele was described at loci
D12S889, D7S525, MetH, D7S514, D7S495 for pairs ranked "concordant / mild disease" (CON+), at
locus D7S495 for pairs ranked "concordant / severe disease" (CON-) and at loci J3.11, D7S514,
D7S495 and D2S1788 for pairs ranked "discordant" (DIS). The effects are summarised in table 25.
This chapter aims at correlating a pair's genotype and the phenotypic trait suspected to be influenced
by the allele studied.
25
TABLE 25: SUMMARY OF OBSERVED ALLELIC ASSOCIATIONS
LOCUS ALLELE OVERREPRESENTED FOR PAIRS RANKED
D7S525 D7S525-9 CON+
MetH MetH-1 CON+
J3.11 J3.11-1 DIS
D7S514 D7S514-11 CON+
D7S514 D7S514-12 DIS
D7S495 D7S495-10 CON+
D7S495 D7S495-14 CON-
D7S495 D7S495-15 DIS
D12S889 D12S889-10 CON+
D2S1788 D2S1788-18 DIS
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For all alleles overrepresented in one of the three patient groups DIS, CON+ and CON-, a direct
relationship of intrapair-discordance (allelic imbalance observed for DIS pairs) or disease severity
(allelic imbalance observed for CON+ or CON- pairs) was conjectured. The maximal effect was
presumed for the condition when all four chromosomes of both patients of a pair were carrying the
allele that was suspected as modulating the phenotypic appearance. The similarity of a pair's
genotype to this genotype with inferred maximal influence was estimated by counting the number of
chromosomes of a pair carrying the allele that was overrepresented in one patient pair group DIS,
CON+ or CON-. In detail, the following genotypes of a pair are possible when assessing the
influence of an allele a at a locus displaying more than two alleles:
GENOTYPE Sib A GENOTYPE Sib B NUMBER OF ALLELES aOBSERVED IN PAIR
NUMBER OF ALLELES
IDENTICAL BY STATE
a
 — a a — a 4 2
a
 — a a — other 3 1
a
 — a other — other 2 0
a
 — other a — other 2 1 or 2
a
 — other other — other 1 0, 1 or 2
other
 — other other — other 0 0, 1, or 2
The condition "two alleles a observed within pair" does not discriminate between pairs where one sib
carries both alleles a and pairs where each sib carries one allele a.
The allelic imbalances were detected within groups of patient pairs which were categorised
employing parameters that combine nutritional and pulmonary status. In order to analyse the
influence of an allele on the nutritional and the pulmonary status, the genotypes were correlated to
parameters describing either disease severity or the discordance based on wfh%, FEVPerc and the
combined parameters DfO and DELTA21. To describe the disease severity, the sum of rank numbers
of both sibs within a pair (ΣRANK) was calculated for wfh%, FEVPerc and DfO respectively. The
intrapair discordance was assessed using the intrapair rank number difference (∆RANK) of wfh% and
FEVPerc as well as the rank number for DELTA. Statistical analysis was carried out with a Mann-
Whitney rank test.
3.2.3.7.1    Near SCNN1A: D12S889
Figure 36 displays the similarity of a pair's genotype to the condition of homozygosity for the allele
D12S889-10, found associated with the phenotype concordant / mild disease (chapter 3.2.3.4). An
increasing wfh%, FEVPerc and DfO was seen with an increasing number of D12S889-10 alleles. The
effect was significant comparing pairs where each sib carries at least one D12S889-10 allele to pairs
where one or no sib carries a D12S889-10 allele (p < 0.01 for FEVPerc and p < 0.05 for wfh%).
21 Defined in figure 10 on page 48.
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FIGURE 36: MODULATION OF DISEASE SEVERITY AT D12S889
ΣRANKwfh%, ΣRANKFEVPerc and ΣRANKDfO vs number of D12S889-10 alleles per pair
No of D12S889-10 alleles per pair 0 1 2 3 4
No of pairs ranked CON+ or CON- 4 4 6 3 3
3.2.3.7.2    40 cM region encompassing the CFTR gene
At two loci located further towards the centromer than CFTR and at three loci located further
towards the telomer than CFTR an allelic imbalance was observed for pairs ranked concordant.
Figure 37 and figure 38 display the relationship between alleles D7S525-9, MetH-1, D7S514-11,
D7S495-10 and D7S495-14 and the disease severity for all pairs ranked CON+ or CON-. The influence
of alleles J3.11-1, D7S514-12 and D7S495-15 on the intrapair discordance is shown in figure 39. The
effects are summarised in chapter 3.2.3.8.2.
3.2.3.7.2.1    Modulation of disease severity among concordant pairs
The association observed for MetH-1 and disease mildness was mediated by the nutritional status as
demonstrated by increasing ΣRANKwfh% comparing 1 or 2 alleles MetH-1 for a patients genotype
(p < 0.01). ΣRANKFEVPerc and MetH-1 showed no correlation. The combined parameter ΣRANKDfO
displayed a less pronounced relationship to the number of MetH-1 alleles than ΣRANKwfh%
(figure 37b). At D7S525, located further towards the centromer than MetH, a similar trend was
observed: with an increasing number of D7S525-9 alleles, ΣRANKwfh% but not ΣRANKFEVPerc was
higher. Pairs with no D7S525-9 alleles displayed the broadest spectrum of ΣRANKwfh%,
ΣRANKFEVPerc and ΣRANKDfO (figure 37a).
Further towards the telomer than CFTR, the relationship of the genotype to the clinical
severity was observed at D7S495: while pairs carrying D7S495-10 alleles had higher ΣRANKwfh% and
ΣRANKDfO than pairs carrying no D7S495-10 allele (p < 0.01), pairs with D7S495-14 alleles had a
lower ΣRANKwfh% and ΣRANKDfO than pairs carrying no D7S495-14 allele (p < 0.01). The number
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of D7S495-10 or D7S495-14 alleles did not correlate with ΣRANKFEVPerc. Again, the broadest
spectrum of ΣRANKwfh% and ΣRANKDfO was observed for pairs without the alleles detected in
allelic imbalance at locus D7S495 (figure 38b, c). At D7S514, the influence of D7S514-11 alleles on
disease severity was week: the 5 pairs displaying four D7S514-11 alleles had a higher ΣRANKwfh%
than most pairs with other genotypes. The mean ΣRANKFEVPerc and ΣRANKDfO increased with the
number of D7S514-11 alleles (figure 38a). At D7S514 and D7S495, both alleles found associated with
CON+ pairs occurred nearly exclusively on either 0 or 2 or 4, but not on 1 or 3 chromosomes of
pairs ranked concordant. In four cases, D7S495-14 – observed most frequently among CON- pairs –
was found on one out of four chromosomes within a pair. All cases with 2 alleles D7S514-11 or
D7S495-10
 or D7S495-14 were composed of genotypes wherein each sib carried one of the alleles.
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FIGURE 37:MODULATION OF DISEASE SEVERITY (I): CENTROMER
(a) ΣRANKwfh%, ΣRANKFEVPerc and ΣRANKDfO vs number of D7S525-9 alleles per pair
No of D7S525-9 alleles per pair 0 1 2 3 4
No of pairs ranked CON+ or CON- 11 2 2 3 2
(b) ΣRANKwfh%, ΣRANKFEVPerc and ΣRANKDfO vs number of MetH-1 alleles per sib
No of MetH-1 alleles per pair 0 1 2
No of pairs ranked CON+ or CON- 0 7 13
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FIGURE 38: MODULATION OF DISEASE SEVERITY (II): TELOMER
(a) ΣRANKwfh%, ΣRANKFEVPerc and ΣRANKDfO vs number of D7S514-11 alleles per pair
No of D7S514-11 alleles per pair 0 1 2 3 4
No of pairs ranked CON+ or CON- 6 — 8 — 5
(b) ΣRANKwfh%, ΣRANKFEVPerc and ΣRANKDfO vs number of D7S495-10 alleles per pair
No of D7S495-10 alleles per pair 0 1 2 3 4
No of pairs ranked CON+ or CON- 14 1 4 — 2
(c) ΣRANKwfh%, ΣRANKFEVPerc and ΣRANKDfO vs number of D7S495-14 alleles per pair
No of D7S495-14 alleles per pair 0 1 2 3 4
No of pairs ranked CON+ or CON- 8 4 7 1 1
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FIGURE 39: ALLELES OBSERVED PREDOMINANTLY FOR PAIRS RANKED DIS
(a) ∆RANKwfh%, ∆RANKFEVPerc and DELTA vs number of J3.11-1 alleles per sib
No of J3.11-1 alleles per sib 0 1 2
No of pairs ranked DIS 2 7 5
(b) DELTA vs number of D7S514-12 alleles per pair         (c) DELTA vs number of D7S495-15 alleles per pair
No of D7S514-12 alleles per pair 0 1 2 3 4 No of D7S495-15 alleles per pair 0 1 2 3 4
No of pairs ranked DIS 5 1 3 — 4 No of pairs ranked DIS 3 5 2 — 3
(d) Alleles IBS at D7S495 (pairs with 1 or 2 alleles D7S495-15 IBS are excluded as explained in footnote on page
119)
No of alleles IBS per pair 0 1 2
No of pairs CON+, CON- or DIS* 3 13 12
— 106 —
-1 0 1 2 3
-1 0 1 2 3
-1 0 1 2 3 -1 0 1 2 3
-1 0 1 2 3 4 5
-1 0 1 2 3 -1 0 1 2 3
225
325
R
A
N
K
 [P
A
IR
]
WFH% FEVPerc DELTA
(a)
 NO OF  J3.11-1 ALLELES PER SIB
-1 0 1 2 3 4 5
DELTA
225
325
R
A
N
K
 [P
A
IR
]
225
325
R
A
N
K
 [P
A
IR
]
DELTA
(b)
 NO OF  D7S514-12 ALLELES PER PAIR (c) NO OF  D7S495-15 ALLELES PER PAIR
WFH% FEVPerc DELTA
(d)
 NO OF  D7S495 ALLELES IBS PER PAIR
0
400
R
A
N
K
 [P
A
IR
]
0
600
∆ ∆∆∆R
A
N
K
 [S
ib
A
; S
ib
B
]
0
400
∆ ∆∆∆R
A
N
K
 [S
ib
A
; S
ib
B
]
0
400
∆ ∆∆∆R
A
N
K
 [S
ib
A
; S
ib
B
]
0
600
∆ ∆∆∆R
A
N
K
 [S
ib
A
; S
ib
B
]
THE EUROPEAN CF TWIN AND SIBLING STUDY
3.2.3.7.2.2    Modulation of intrapair discordance
The association found for J3.11-1 was seen to have a larger influence on the discordance of the
pulmonary status than on the discordance of the nutritional status. This was demonstrated by higher
∆RANKFEVPerc and DELTA for pairs homozygous for J3.11-1 compared to the heterozygous state
(p < 0.01). No association between J3.11-1 alleles and ∆RANKwfh% was observed (figure 39a). At
D7S514 and D7S495, the most frequent alleles for discordant pairs were D7S514-12 and D7S495-15.
However, no correlation between the number of D7S514-12 or D7S495-15 alleles within a pair and
∆RANKwfh%, ∆RANKFEVPerc or DELTA was detected (figure 39b,c) for all pairs ranked DIS.
When analysing the sharing of alleles at D7S495 after exclusion of pairs with one or two alleles
D7S495-15 identical by state22, intrapair discordance in wfh% and FEVPerc was found to decrease
with an increasing number of alleles shared by both siblings.
3.2.3.7.2.3    Reconstruction of haplotypes surmised to transmit extreme phenotypes
So far, the genotype-phenotype correlation was investigated for single loci within the CFTR linkage
group within this chapter. Next, the additive effect of all loci for which alleles have been observed in
association with an extreme phenotype is assessed. The resulting allele combination, i.e. the
haplotype for the chromosomal region, was considered to transmit the phenotype for which the
allelic association was noticed. As in the case of single loci, the maximum effect was presumed to
occur when all four chromosomes of both patients of a pair were carrying the haplotype considered
to transmit the extreme phenotype.
In order to compare a pair's genotype to these proposed haplotypes, the similarity of a pair's
genotype to homozygosity for a haplotype has to be described. In order to do so for a single marker
locus "m" exhibiting an association of the allele "a" with a phenotypic trait, the genotype of a pair
was construed to the number of alleles "a" encountered within the genotypes of both patients within
a pair. In order to quantify the similarity of a pair's genotype to homozygosity for a haplotype "a1-a2
-a3- ... -an" composed of multiple marker loci "m1-m2-m3- ... -mn", a similar approach was taken: at all
loci composing the haplotype the number of alleles "a1", "a2", "a3", ... ,"an" observed in the genotype
of both patients within a pair was counted.
This approach considers each locus composing the haplotype as equal. However, neighbour
loci are linked and consequently alleles at adjacent marker loci are not independent of each other.
The probability of encountering a definite allele at locus "m2" depends on the allele observed at locus
22 The hypotheses tested by (a) comparison of the number of alleles identical by state between pairs ranked
concordant and pairs ranked discordant or (b) analysing allelic association with the phenotypes concordant and
discordant are incompatible when an allelic association with the phenotype "discordance" is detected: when
analysing a gene modulating the phenotype, discordance is expected when both sibs of a pair carry non-identical
genotypes at the gene locus. If a marker locus analysed is linked to the gene, non-identical genotypes at the marker
locus indicate non-identical genotypes at the gene locus. Overrepresentation of one allele in the subgroup of
discordant pairs points to the hypothesis that an allele at the gene locus is itself causing the phenotype
"discordance", even if —or, caused by the fact that — both sibs are carrying that allele identical by descent.
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"m1" or "m3". The similarity of a pair's genotype to homozygosity for a given haplotype as defined
above ignores this fact: deviations from the definite haplotype are weighed equally, irrespective of
the marker position showing the deviation. Furthermore, all loci considered within this chapter are
near CFTR and consequently, both siblings within a patient pair have a higher probability of sharing
their alleles than of carrying non-identical genotypes. Linkage is only taken into account at loci
J3.11 and MetH: no recombination was observed at either loci located within a 1 Mb range to the
CFTR gene (see tables 26 and 27 for details). Finally, the probability of encountering a definite allele
at a marker locus depends on the frequency of that allele and on the number of alleles displayed at
that locus. Allelic distributions are not taken into account within this chapter.
26
TABLE 26: D7S525-MetH-D7S514-D7S495 HAPLOTYPE 9-1-11-10
The map displays all markers for which the alleles shown were detected in association with the phenotype
"concordant/mild disease" (see chapter 3.2.3.5). The table displays the maximum number of these alleles encountered
per genotype of a pair at each locus. For the markers D7S525, D7S514 and D7S495, a maximum of four alleles
D7S525-9, D7S514-11 and D7S495-10 can compose the genotype of the pair. At MetH, genotypes were, in all but
one case investigated, identical between sib A and sib B of a pair. This lack of recombination was compensated for by
arbitrarily counting only the alleles observed per single genotype, yielding a maximum of two alleles MetH-1 per
pair.
(1) Marker D7S525 MetH D7S514 D7S495
(2) Alleles at loci (1) associated with
phenotype "concordant / mild disease"
D7S525-9 MetH-
1
D7S514-11 D7S495-10
Maximal number of alleles (2) observed
per genotype of a pair:
4 2 4 4 Σ:
14
Observed number of alleles D7S525-9, MetH-1, D7S514-11 and D7S495-10 for pairs ranked DIS, CON+ and CON-
n:  number of alleles 9, 1, 11, 10 at loci D7S525, MetH, D7S514, D7S495 observed per pair
av. : average number of alleles D7S525-9, MetH-1, D7S514-11 and D7S495-10 observed per pair
av. ={Σ (n × number of pairs carrying n alleles)}/{sum of all pairs}
n
number of alleles 9, 1, 11, 10 at loci D7S525, MetH, D7S514, D7S495
observed per pair
1 2 3 4 5 6 7 8 9 10 11 12 av.
number of pairs ranked
CON+ with
   n  alleles
— 1 — 1 1 1 1 1 — 1 1 1 7
number of pairs ranked
CON- with
   n  alleles
— 1 4 3 — 1 — — — — — — 4
number of pairs ranked
DIS with
   n   alleles
2 2 2 2 1 1 — 1 1 — — — 4
— 108 —
MetH-1
10 cM
D7S525-9 D7S514-11 D7S495-10
CEN
THE EUROPEAN CF TWIN AND SIBLING STUDY
Based on the results summarised in table 28, haplotypes were reconstructed for the traits
"discordant" (involving loci J3.11, D7S514 and D7S495) and "concordant / mild disease" (involving
loci D7S525, MetH, D7S514 and D7S495): taking the observed associations of the alleles D7S525-9,
MetH-1, D7S514-11 and D7S495-10 with the phenotype "concordant / mild disease" into account, the
concluding D7S525-MetH-D7S514-D7S495 haplotype is 9-1-11-10. Likewise, the association of alleles
J311.-1, D7S514-12 and D7S495-15 with the phenotype "discordant" leads to the J3.11-D7S514-D7S495
haplotype 1-12-15.
The results are displayed in table 26 for the D7S525-MetH-D7S514-D7S495 haplotype 9-1-11-10
(surmised as transmitting the phenotype "concordant / mild disease"). Homozygosity for the
haplotype 9-1-11-10 corresponded to a total of 14 matching alleles encountered at these 4 loci. On the
average, a pair ranked CON+ displayed 7, but a pair ranked DIS or CON- only 4 matching alleles.
Genotypes with 10, 11 or 12 alleles encountered in the haplotype 9-1-11-10 were found only in pairs
ranked CON+. The correlation of the genotype – interpreted as similarity to homozygosity for the
D7S525-MetH-D7S514-D7S495 haplotype 9-1-11-10 – to the clinical phenotype is displayed in figure 40
for all pairs ranked CON+ or CON-. An increasing number of matching alleles was found to
correlate with a better wfh%, but not FEVPerc.
40
FIGURE 40: SIMILARITY TO "CON+ HAPLOTYPE" AND DISEASE SEVERITY
Similarity of a pairs genotype to homozygosity for the haplotype 9-1-11-10 (D7S525-MetH-D7S514-D7S495)
All pairs ranked CON+ or CON- with information on all four loci are shown (18 pairs).
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Table 27 displays the results for the J3.11-D7S514-D7S495 haplotype 1-12-15 (suspected as
transmitting the phenotype "discordance"). A total of 10 matching alleles corresponded to
homozygosity for the haplotype at these 3 loci. On the average, a pair ranked DIS displayed 5, but a
pair ranked CON+ or CON- only 3 matching alleles. For pairs ranked concordant, a maximum of 5
matching alleles was observed while pairs ranked DIS also displayed 6 or 7 alleles matching the
haplotype. The correlation of the genotype – converted into similarity to homozygosity for the J3.11-
D7S514-D7S495 haplotype 1-12-15 – to the intrapair discordance in the clinical parameters is displayed
in figure 41 for all pairs. No quantitative relationship was observed between the number of matching
alleles and the intrapair discordance in wfh%, FEVPerc or the combined parameter DELTA.
27
TABLE 27: J3.11-D7S514-D7S495 HAPLOTYPE 1-12-15
The map displays all markers for which the alleles shown were detected in association with the phenotype
"discordant" (see chapter 3.2.3.5). The table displays the maximal number of these alleles encountered per genotype
of a pair at each locus. For the markers D7S514 and D7S495, a maximum of four alleles D7S514-12 and D7S495-
15 can compose the genotype of the pair. At J3.11, genotypes were, in all but one case investigated, identical
between sib A and sib B of a pair. This lack of recombination was compensated for by arbitrarily counting only the
alleles observed per one genotype, yielding a maximum of two alleles J3.11-1 per pair.
(1) Marker J3.11 D7S514 D7S495
(2) Alleles at loci (1) associated with
phenotype "discordant"
J3.11-1 D7S514-12 D7S495-15
Maximal number of alleles (2) observed
per genotype of a pair: 2 4 4
Σ:
10
Observed number of alleles  J3.11-1, D7S514-12 and D7S495-15 for pairs ranked DIS, CON+ and CON-
n:  number of alleles 1, 12, 15 at loci J3.11, D7S514, D7S495 observed per pair
av. : average number of alleles J3.11-1, D7S514-12 and D7S495-15 observed per pair
av. ={Σ (n × number of pairs carrying n alleles)}/{sum of all pairs}
n
number of alleles J3.11-1, D7S514-12 and D7S495-15 
observed per pair
0 1 2 3 4 5 6 7 av.
number of pairs ranked
CON+ with
   n  alleles 1 2 1 2 3 1 — — 3
number of pairs ranked
CON- with
   n  alleles — 1 4 1 2 1 — — 3
number of pairs ranked
DIS with
   n   alleles — 1 1 2 1 3 4 1 5
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41
FIGURE 41: SIMILARITY TO "DIS HAPLOTYPE" AND DISCORDANCE
    Similarity of a pairs genotype to homozygosity for the haplotype  1-12-15 (J3.11-D7S514-D7S495)
' : pairs ranked DIS (13 pairs) ' :  pairs ranked CON+ or CON- (19 pairs)
3.2.3.7.3    Locus D2S1788
At D2S1788, an allelic imbalance was noticed: allele D2S1788-18 was noted only for pairs ranked DIS
and allele D2S1788-21 was detected predominantly for pairs ranked DIS. The analysis of genotype-
phenotype relations with respect to locus D2S1788 was performed by comparing the number of
alleles identical by state with the intrapair discordance in the clinical parameters wfh% and FEVPerc
and the combined parameter DELTA. As shown in figure 42, a decrease of the intrapair discordance
in wfh% with an increasing number of identical alleles between siblings was noted only when pairs
sharing the alleles found associated with the phenotype "discordance" were excluded (marked by red
data points in the top row in figure 42 and omitted in the bottom row; p < 0.01 comparing pairs with
0 alleles IBS to pairs with 1 or 2 alleles IBS in wfh%).
The hypotheses tested by (a) comparing the number of alleles identical by state between pairs
ranked concordant and pairs ranked discordant or (b) analysing allelic association with the
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3       RESULTS AND DISCUSSION
phenotypes concordant and discordant are incompatible when an allelic association with the
phenotype "discordance" is detected: when analysing a gene modulating the phenotype, discordance
is expected when both sibs of a pair carry non-identical genotypes at the gene locus. If a marker
locus analysed is linked to the gene, non-identical genotypes at the marker locus indicate non-
identical genotypes at the gene locus. Overrepresentation of one allele in the subgroup of discordant
pairs points to the hypothesis that an allele at the gene locus is itself causing the phenotype
"discordance", even if —or, caused by the fact that — both sibs are carrying that allele identical by
descent. Consequently, the correlation of intrapair discordance and allele sharing was carried out
after omitting pairs sharing alleles associated with the phenotype "discordance".
42
FIGURE 42: IBS AT D2S1788
(a), (b) ∆RANKwfh%, ∆RANKFEVPerc and DELTA vs number of D2S1788 alleles IBS per pair
Top row:  all pairs
No of D2S1788 alleles IBS 0 1 2
No of pairs 8 14 12
( : pairs sharing one or two alleles 18 or 21 IBS ( : other pairs
Bottom row:  pairs sharing one or two alleles D2S1788-18 or D2S1788-21 excluded
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3.2.3.8    Discussion: CF disease severity modulation by non-CFTR genetics
3.2.3.8.1    Hypothesis: CF disease severity is modulated by ENaC
As shown in chapter 3.2.3.7.1, a D12S889 allele was observed to be associated with a mild clinical
course in CF twins and siblings : ∆F508 homozygous patient pairs had a better wfh% and FEVPerc
when both siblings carried at least one allele D12S889-10.
D12S889  is located within a 40 kb distance to SCNN1A (Baens et al. 1995), encoding
for the α subunit of the amiloride sensitive sodium channel ENaC. Presumably, the observed effect
is transmitted by the ENaC itself: the amiloride-sensitive sodium channel was reported to be
regulated by CFTR (Ismailov et al. 1996, Stutts et al. 1997) and thus, sequence variations within the
α subunit that convey a different phenotype to the channel might compensate for the regulatory
defect in the CF condition. For the ENaC, allelic variants leading to a "gain of function " and allelic
variants leading to a "loss of function" have been described: mutations resulting in increased Na+
reabsorption have been discovered in SCNN1B and SCNN1G in patients with Liddle's disease
(Shimkets et al. 1994, Hansson et al. 1995, Schild et al. 1995, Jeunemaitre et al. 1997). Sequence
variations leading to decreased Na+ reabsorption have been identified in patients with
pseudohypoaldosteronism type 1 in SCNN1A, SCNN1B and SCNN1G (Chang et al. 1996,
Straunieks et al. 1996b).
Apart from a postulated benign effect transmitted by an allelic variant of the α subunit of the
ENaC (presumably linked to the allele D12S889-10), the amiloride-sensitive Na+ channel can also be
considered to be a risk factor as patients with pseudohypoaldosteronism type 1 have been described
as exhibiting symptoms of lung disease compatible with mild CF (Hanakoglu et al. 1994), including
colonisation with Pseudomonas aeruginosa (Marthinsen et al. 1998). Nevertheless, no D12S889
allele was identified in association with a severe phenotype in CF twins and sibs. Finally, an
association of a benign phenotype was observed with a D12S889 allele (located close to SCNN1A),
but not with a βENaCGT allele (located near SCNN1B and SCNN1G), inviting speculation on a
dominant role of the α subunit in modulating CF disease, distinct from the β and γ subunits of the
ENaC.
Generally, the detection of an association of an allelic variant at a polymorphic marker locus
with a phenotypic character is eased (a) if alleles at the candidate gene locus transmitting the same
phenotype are linked to the same allele at the marker locus investigated and (b) if two alleles at the
candidate gene locus conveying the opposite phenotypes are linked to different alleles at the marker
locus investigated. Hence, the lack of association between any D12S889 allele with severe CF disease
among the twins and sibs typed and the lack of association of any βENaCGT allele with an extreme
disease phenotype fail to exclude a risk allele at SCNN1A or the modulating role of SCNN1B and
SCNN1G for CF disease severity.
In conclusion, the observed effect of an association of mild CF disease with the allele  D12S889-
10 can be explained by assuming a benign SCNN1A allele. However, other allelic variants at
SCNN1A, conveying a risk for lung disease, might be existent. Likewise, a modulating effect of the
SCNN1B and SCNN1G loci cannot be excluded.
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3.2.3.8.2    CF disease severity modulated by CFTR linked loci 
As described in detail within chapter 3.2.3.7.2, three effects on the clinical phenotype could be
described as being associated with loci close to the CFTR gene (table 28): 
(I) Located further towards the centromer than CFTR, modulation of wfh% was observed at MetH
and D7S525. The effect was seen in an allelic association of allele MetH-1 and, less pronounced,
allele D7S525-9 with the phenotype "concordant / mild disease". Pairs of sibs whose genotype
was composed of the allele MetH-1 had a significantly better wfh% than sibpairs with other
genotypes (p < 0.01).
(II) Located further towards the telomer than CFTR, an influence on the pulmonary status was
noticed at J3.11. The effect was detected by an association of the allele J3.11-1 with the
phenotype "discordant". Pairs of sibs homozygous for J3.11-1 were significantly more
discordant in FEVPerc (p < 0.01), but not in wfh%, compared to other sibpairs.
(III) An influence on the nutritional status was detected at D7S495 by an association of allele D7S495-
10 with the phenotype "concordant / mild disease", of the allele D7S495-14 with the phenotype
"concordant / severe disease" and of the allele D7S495-15 with the phenotype "discordant". Pairs
where each sib carried at least one allele D7S495-10 had a significantly better wfh% (p < 0.01)
and pairs of sibs carrying at least one allele D7S495-14 had a significantly worse wfh% (p <
0.01) than pairs of sibs with other genotypes. When excluding pairs composed of sibs carrying
one or two alleles D7S495-15, those pairs whose sibs were sharing two D7S495 alleles were less
discordant than sibpairs carrying one or no allele IBS at D7S495.
All effects observed are not directly mediated by CFTR: both patients of a pair share the CFTR
alleles as CF is inherited in the recessive condition and all pairs have been typed ∆F508 homozygous.
Consequently, unless recombination events have taken place, both siblings will have identical
sequences at loci near CFTR as well. Hence, an observed allelic association can only be mediated by
a sequence close to the marker typed – i.e. by an element encoded in cis – if the association is
observed for pairs ranked concordant (allele MetH-1 associated with "concordant / mild disease" (I),
allele D7S495-10 associated with "concordant / mild disease" (III)and allele D7S495-14 associated with
"concordant / severe disease" (III)).
However, at two loci located further towards telomer than CFTR, an association of an allele
with the phenotype discordant has been detected (allele J3.11-1 associated with "discordant" (II) and
allele D7S495-15 associated with "discordant" (III)). At J3.11, no recombination event was observed
among the pairs typed (table 2323). At D7S495, with an observed recombination frequency 1/3,
discordant sibs shared the allele D7S495-15 which was observed predominantly for pairs ranked
discordant in absence of evidence for a recombination event between CFTR and D7S495 (table 23).
As this allelic association cannot be related to either a recombination event or an element encoded in
23  Table 23 is shown in chapter 3.2.3.5.2.4 on page 111.
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cis, the modulating effect has to be located outside the CFTR linkage group, probably on another
chromosome. In conclusion, an allelic association with the phenotype discordant observed at loci
linked to CFTR indicates a modulating factor encoded in trans acting on a sequence close to the
locus studied.
28
TABLE 28: MODULATION OF WFH% AND FEVPerc AT LOCI NEAR CFTR
ALLELE
ALLELIC
IMBALANCE
OBSERVED FOR
PAIRS RANKED
+: strong allelic
association
(+): faint allelic
association
EFFECT ON
PHENOTYPE
OBSERVED FOR
PAIRS
ANALYSED *
D7S525-9 CON+ (+) ΣRANKwfh% CON+, CON- p > 0.05 +
MetH-1 CON+ + ΣRANKwfh% CON+, CON- p < 0.01 +
J3.11-1 DIS + ∆RANKFEVPerc DIS p < 0.01 +
D7S514-11 CON+ (+) ΣRANKDfO CON+, CON- p > 0.05 +
D7S514-12 DIS (+) — DIS —
D7S495-10 CON+ + ΣRANKwfh% CON+, CON- p < 0.01 +
D7S495-14 CON- + ΣRANKwfh% CON+, CON- p < 0.01 +
D7S495-15 DIS + — DIS —
D7S495 Analysis of IBS at D7S495 shows decreasing intrapair rank number
difference in wfh% with increasing number of shared alleles.
all pairs p > 0.05 +
*
: quantitative influence of allele on clinical parameter judged by Mann-Whitney rank test of
values shown in figures 37 (a), 37 (b), 38 (b), 38 (c), 39 (a), 39 (d)
         — : no quantitative influence observed
p > 0.05 : quantitative influence observed, but not statistically significant
p < 0.01 : statistically significant quantitative influence detected
3.2.3.8.2.1    Selected genes mapped near CFTR
Figure 43 shows a map of the investigated 40 cM region encompassing the CFTR gene, displays the
effects observed and gives the position of some selected candidate genes. Based on the known
functions of the gene products, the candidate genes were classified with respect to their roles:
A) Involved in energy metabolism and/or bioenergetics
PRKAR2B (protein kinase, cAMP-dependent, type II, beta)
PRKAR2B knock-out mice have been described as "healthy, lean and protected against developing
dietary induced obesity and fatty livers" with reduced leptin mRNA and plasma levels (Cummings et
al. 1996). PRKAR2B was mapped to 7q22 near MET (Solberg et al. 1992) and located on a
physical map 600 Mb further towards the centromer than DRA (Höglung et al. 1995).
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LEP/OB (leptin; human homologue of murine obese)
The human homologue of the murine obese gene LEP was physically mapped at 7q31.3 (Green et al.
1995). The involvement of leptin in the long term regulation of energy balance has been
characterised (reviewed by Woodsa et al. 1998): the gene product leptin is secreted in proportion to
the  adipose tissue. Low plasma leptin levels result in increased food intake and weight gain.
PEG1/MEST (paternally expressed gene 1; mesoderm specific transcript)
PEG1/MEST was identified as an imprinted gene near D7S649 (Kobayashi et al. 1997) with
homology to a gene known to be imprinted in mice. Imprinting was verified by demonstrating that
the paternal allele of PEG1 was expressed. A role of PEG1 in energy metabolism is inferred based on
the observation that maternal isodisomy 7 leads to growth retardation (Spence et al. 1988, Voss et
al. 1989, Spotila et al. 1992, Eggerding et al. 1994) while paternal isodisomy 7 does not (Höglund
et al. 1994).
NRF1 (nuclar respiratory factor 1)
NRF1 has been identified as a transcription factor for mitochondrial proteins (Gopalakrishnan and
Scarpulla 1995). The genes responsive to NRF1 have been identified as components of the oxidative
chain. The gene was mapped to 7q32.
B) Tissue differentiation, integrity and development
MET/HGFR (met proto oncogene; hepatocyte growth factor receptor)
The proto oncogene MET encodes for a receptor tyrosine kinase (Dean et al. 1985). The ligand of
MET is the hepatocyte growth factor HGF (Bottaro et al. 1991). MET and HGF are involved in the
mediation of motility, invasiveness and proliferation of target cells (reviewed by Weidner 1993). 
PAX4 (paired box homeotic gene 4)
The PAX4 gene product was described as a regulator for the differentiation of pancreatic cells
(Sosa-Pineda et al. 1994). It has been localised between  CFTR and LEP (Green et al. 1995).
CASP2/NEDD2 (caspase 2; apoptosis related cysteine protease)
Caspase-2 deficient mice have been demonstrated as exhibiting a dual apoptosis defect: while some
CASP2 deficient cells – such as motor neurons – showed an accelerated cell death, other CASP2
deficient cell types – such as B lymphoblasts – demonstrated resistance against apoptosis signals
(Bergeron et al. 1998). CASP2 was mapped to 7q35 (Tiso et al. 1996).
C) Involved in host defence, modulation of infection or inflammation
NM (neutrophil migration)
NM, presumed to encode for the surface glycoprotein GP130 was mapped to 7q22-7qter (de la
Chapelle et al. 1979). Granulocytes that are defective in locomotion, chemotaxis and chemokinesis
were shown to express reduced amounts of GP130 (de la Chapelle et al. 1982). Thus, NM is most
likely to be involved in general host defence.
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FIGURE 43: INTEGRATED MAP OF SELECTED GENES NEAR CFTR
The relative positions of the map elements are consistent with Tsui 1985, Rommens 1989, Green 1995, Höglund 1995,
Bouffard 1997, Fisher 1998, Li 1998. Positions in cM are given as published by Bouffard 1997.
MARKER: of the displayed markers, all but D7S496 and  D7S649 have been typed.
MODULATION OF PHENOTYPE: representation of observed effects as summarised on page 126: association of
alleles at METH, J3.11, D7S514 and D7S495 with disease severity. CIS designates an effect disclosed for pairs
ranked concordant while TRANS refers to an effect observed for pairs ranked discordant.  
SELECTED GENES: the genes displayed are abbreviated according to the HUGO/GDB approved nomenclature.
Map positions are inferred from cytogenetic localisation using PON2 at 7q21.3, DRA/CLD at 7q22-7q31.1 (mapped
near D7S496), LEP at 7q31.3 (mapped near  D7S514) and D7S495 at 7q32-7q33 as reference points.
Role of gene product ‡ Symbol Localisation
C NM neutrophil migration 7q22-qter
D MUC3 mucin 3 7q22
C AZGP1 alpha-2-glycoprotein 1, zinc 7q22.1
C CYP3A4 cytochromeP450, subfamily IIIA, polypeptide 4 7q22.1
A PRKAR2B protein-kinase, cAMP-dependent, type II, beta 7q22
C PDS pendred syndrome (prostaglandin-h2 d-isomerase precursor) 7q31
E CLD/DRA congenital chloride diarrhoea /down-regulated in adenoma 7q22-7q31.1
B MET met proto oncogene (hepatocyte growth factor receptor) 7q31
B PAX4 paired box homeotic gene 4 7q22-qter
A LEP leptin (murine obesity homolog) 7q31.3
A PEG1 paternally expressed gene 1 (mesoderm specific transcript) 7q32
C ABP1 amiloride-binding protein 1 7q31-7q32
A NRF1 nuclear respiratory factor 1 7q32
D PIP prolactin-induced protein 7q32-q36
B CASP2 caspase 2 (apoptosis related cysteine protease) 7q35
      ‡      Functional classification of gene products (details see chapter 3.2.3.8.2.1):
, A role in energy metabolism and/or bioenergetics
, B role in tissue differentiation, integrity and development
, C involved in host defence, modulation of infection or inflammation
, D CFTR-like expression pattern or relation to CF pathophysiology
, E basic defect: ion transport
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AZGP1 (alpha-2-glycorotein-1, zinc)
AZGP1 was localised to 7q22.1 (Ueyama et al. 1993) and shown to encode for a soluble
glycoprotein. AZGP1 is partly homologous to class I MHC genes and an involvement in intracellular
recognition processes  has been proposed for the AZGP1 gene product (Freije  et al. 1993).
PDS/PGHD (pendred syndrome; prostaglandin-h2 d-isomerase precursor)
PDS was identified as a gene causing pendred syndrome and mapped in a location 300kb further
towards the centromer than DRA (Coyle et al. 1998). PDS was identified as prostaglandin
isomerase. 
CYP3A4 (cytochrome P450, subfamily IIIA, polypeptide 4; nifedipine oxidase)
CYP3A4 encodes for a member of the cytochrome P450 family (reviewed by Wrighton and Stevens
1992) and was mapped to 7q22.1 (Inoue et al. 1992). CF patients and their parents were described
as poor metabolisers for the CYP3A4 substrate nifedipine compared to non-CF adults (Daly et al.
1992).
ABP1 (amiloride binding protein)
ABP1 encodes for a diamine oxidase (Novotny et al. 1994) and was mapped to 7q34-36 (Barbry et
al. 1990).
D) CFTR like expression pattern or relation to CF pathophysiology
MUC3 (mucin 3)
MUC3 was described by Gum et al. (1990) as an intestinal mucin. The gene has been localised to
7q22 (Fox et al. 1992). The pathophysiology of CF makes a modulation of intestinal disease through
MUC3 plausible.
PIP (prolactin induced protein)
The PIP gene product is expressed in several exocrine organs and was mapped to 7q32-7q36 (Myal
et al. 1989).
E) Basic defect: ion transport
CLD/DRA (congenital chloride diarrhoea; down-regulated in adenoma)
The gene transmitting congenital chloride diarrhoea (CLD) was mapped near D7S496 (Höglund et
al. 1995). DRA (down regulated in adenoma), located at a distance of 230 kb to D7S496 (Höglund
et al. 1996a) was identified as the gene responsible for CLD (Höglund et al. 1996b). CLD was
described as a disease with impaired electrolyte transport and hence, DRA qualifies as a candidate
gene for the modulation of CF disease.
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3.2.3.8.2.2    Hypothesis: modulation of pulmonary status by CFTR linked loci
Regulation of CFTR transcription near J3.11: a trans effect
The existence of a modifier gene near J3.11 for the severity of CF lung disease was noticed before in
a group of unrelated patients (Santis et al. 1990b) where allele J3.11-2 was found to be associated
with mild lung disease. Within this thesis, an allelic association of J3.11-1 with the phenotype
"discordant" has been identified. ∆F508 homozygous patient pairs homozygous for J3.11-1 were
significantly more discordant in FEVPerc than pairs with other J3.11 genotypes. As both siblings,
though discordant, must share the same sequence at J3.11, an effect mediated by a gene located
elsewhere – i.e. in trans – has to be assumed.
A variety of genes located within the CFTR linkage group have been mapped (chapter
3.2.3.8.2.1). However, no clear evidence for a modulation of lung disease by a gene located near
J3.11 was found. Generally, all gene products participating in host defence, modulation of
inflammation or immunology – as NM, CYP3A4, AZGP1, PDS and ABP1 – can be considered
capable of modulating respiratory illness. Nevertheless, the only gene located in the region of interest
with a known role in respiratory disease is the CFTR gene itself (figure 43). The role of CFTR
mutations as a risk factor for lung disease conditions are well established (Dumur et al. 1990, Miller
et al. 1996, Pignatti et al. 1996, Friedman et al. 1997, Dahl et al. 1998) and hence, the most
plausible explanation for the effect observed at J3.11 is a modulation of CFTR expression by a
transcription factor that is acting on a regulatory sequence linked to J3.11. Intrapair-discordance
could then arise if both siblings have inherited different alleles for the transcription factor, which
consequently act differently on a responsive element near the CFTR gene. It has to be postulated that
this responsive element occurs in different allelic variations whereby the allele associated with J3.11-1
might depend most on the allelic variation of the transcription factor, hence resulting in a discordant
phenotype when siblings are homozygous for  J3.11-1.
3.2.3.8.2.3    Hypothesis: modulation of nutritional status by CFTR linked loci
Involvement of LEP in the inheritance of obesity
Obesity is presumed to be 40-70% inheritable and is considered to be a multigenic trait. 17 genes
with homologies to murine obesity loci have been identified so far (reviewed by Comuzzie 1998).
Linkage analysis and some association studies have provided evidence for an involvement of the LEP
gene region in obesity related traits (Duggirala et al. 1996, Clement et al. 1996, Reed et al. 1996,
Oksanen et al. 1997), but two research groups found no evidence for a role of LEP in obesity
(Norman et al. 1996, Bray et al. 1996). Nevertheless, a compilation of 5 studies has provided
evidence for strong association of the body mass index to markers within the LEP gene region
(Allison et al. 1998). Mutations within the LEP gene have been identified in patients suffering from
morbid obesity (Montague et al. 1997, Strobel et al. 1998), thus sustaining the involvement of leptin
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in obesity. Other genes suspected of being involved in the inheritance of obesity have been
investigated in obese patients and mutations have been described for the leptin receptor (Clement et
al. 1998).
Growth retardation caused by an imprinted gene on chromosome 7
Growth retardation has been described in patients with maternal isodisomy 7 (Spence et al. 1988,
Voss et al. 1989, Spotila et al. 1992). In contrast, paternal isodisomy 7 was reported to be
compatible with normal growth and development (Höglund et al. 1994). The imprinted gene was
presumed to be localised on 7q as a patient with partial paternal isodisomy 7p and partial maternal
isodisomy 7q was growth retarded (Eggerding et al. 1994). In addition, maternal isodisomy has been
reported for 3 out of 25 patients with Silver-Russel-syndrome and for 1 out of 10 patients with
primordial growth retardation (Kotzot et al. 1995). PEG1, a paternally imprinted gene, was mapped
to 7q32 (Kobayashi et al. 1997). PEG1 is regarded as a candidate gene for the growth retardation
caused by paternal isodisomy 7.
Obesity related traits and chromosome 7: evidence for more than one locus involved
Several approaches towards unravelling the role of the LEP gene region have investigated a
subportion of chromosome 7. Interestingly, some results point to the existence of more than one
locus on chromosome 7q determining obesity or obesity related traits (see table 29):
Stirling et al. (1995) investigated patient pairs with non-insulin dependent diabetes mellitus
(NIDDM) with respect to allele sharing at marker loci spanning a 4 cM region. While not
statistically significant, a surplus of allele sharing was detected at S7S480 and D7S635, but not
at the two tested markers localised in between.
Duggirala et al. (1996) has found linkage of three different obesity-related traits to three
different regions on chromosome 7 upon analysis of 15 markers spanning the whole
chromosome: variation in extremity skinfolds were linked to D7S514, fasting 32,33-split
proinsulin levels were linked to D7S530 and D7S479, waist circumference was linked to
D7S495.
Clement et al. (1996) has investigated sib pairs with respect to the sharing of alleles near LEP.
In obese/obese pairs linkage to D7S651 and neighbouring markers D7S680, D7S514 and
D7S530 was reported. In obese/lean pairs, an excess of sharing was found at D7S530 and
D7S640.
Oksanen et al. (1997) has studied association of serum leptin levels and response to a very-
low-calory dietary program (VLCD) to markers flanking LEP in a group of patients suffering
from morbid obesity. Weak association of an allele at D7S649 with response to VLCD and
significant association of an allele at D7S530 with serum leptin levels was detected.
In conclusion, markers associated with obesity related traits have been identified at 7q21 and at
7q31-33. Among the candidate genes discussed within this thesis, LEP and PEG1 – both within the
region 7q31-7q33 – can be considered to be involved in weight regulation and growth development.
Analysing ∆F508 homozygous CF twins and sibling pairs, a significant association of MetH and
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D7S495 genotypes with wfh% was noticed (figures 3724 and 3825). While D7S495 is localised near the
obesity-linked region containing LEP and PEG1, MET does not match the position of the obesity
related locus at 7q21. Hence, the modulating effect on wfh% observed with markers located further
towards 7qtel than CFTR can be related to LEP and/or PEG1 while, for the effect observed at
MetH, a modifier which has not been identified in previous previous studies of the LEP region has to
be considered.
29
TABLE 29: HYPOTHESIS: TWO LOCI DETERMINING OBESITY ON 7q
Abbreviations used in the table (details see text): ex shar = surplus of shared alleles in NIDDM sib pairs (Stirling et
al. 1995), FSPL = fasting 32,33-split proinsulin levels, extr skflds = extremity skinfolds, wst circ = waist
circumference (Duggirala et al. 1996), ob/ob = obese/obese sib pair, ob/l = obese/lean sib pair (Clement et al.
1996), VLCD resp = response to very-low-calorie-diet, lep lev = serum leptin levels (Oksanen et al. 1997), CON =
concordant CF sib pair, DIS = discordant CF sib pair (this work).
All marker positions are given based on the chromosome 7 physical map (Bouffard et al. 1997). On this map, PON2
is localised at 124 cM, CFTR is localised at 145 cM, LEP is localised at 153 cM and PEG1 is localised at 158 cM.
POSITION: near PON2 7q22-31 near CFTR near LEP near PEG1 7q32-33
Stirling et al. 1995
markers investigated: — —
D7S480
(147 cM)
D7S635
(153 cM)
D7S530
(157 cM) —
obesity associated: ex shar — ex shar
Duggirala et al. 1996
markers investigated:
D7S479
(125 cM)
D7S471
(135 cM)
D7S466
(144 cM)
D7S514
(153 cM)
D7S530
(157 cM)
D7S495
(166 cM)
obesity associated: FSPL — — extr skflds FSPL wst circ
Clement et al. 1996
markers investigated:
D7S651
(128 cM)
D7S692
(140 cM)
D7S677
(144 cM)
D7S514
(153 cM)
D7S640
(159 cM)
D7S509
(165 cM)
obesity associated: ob/ob — — ob/ob and ob/l ob/l —
Oksanen et al. 1997
markers investigated: — — —
D7S514
(153 cM)
D7S649
(158 cM) —
obesity associated: VLCD res lep lev
This work
markers investigated: —
D7S525
(141 cM)
MetH
(145 cM)
D7S514
(153 cM) —
D7S495
(166 cM)
wfh% modulation:
— CON — CON and DIS
Modulation of wfh% near MetH: a cis effect
The putative modifier of CF disease detected through an association of MetH-1 alleles with the
phenotype "concordant/mild disease" (table 1926) can be considered to be distinct from the candidate
genes PRKAR2B, PDS and DRA as the significant association of wfh% with MetH genotypes was
not seen at D7S525 (figure 3727), located within a 4 cM distance to MetH between MET and
PRKAR2B, PDS and DRA (figure 43). Thus, the modulation of the CF phenotype might be related
24  Figure 37 is shown in chapter 3.2.3.7.2.1 on page 116.
25  Figure 38 is shown in chapter 3.2.3.7.2.1 on page 117.
26  Table 19 is shown in chapter 3.2.3.5.2.1 on page 107.
27  Figure 37 is shown in chapter 3.2.3.7.2.1 on page 116.
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to MET itself. A possible mechanism for the influence of the nutritional status by MET relies on the
signal transduction pathways controlled by this receptor tyrosine kinase: the ligand of MET, the
hepatocyte growth factor, was shown to be involved in the mediation of motility and proliferation of
various cell types (reviewed by Weidner 1993). As coordinated cell growth and cell differentiation
are obligatory for tissues with rapid proliferation – as, for example, for the intestinal epithelium – a
modulation of the respective signal transduction pathway might influence the integrity of the organ
and hence modulate the nutritional status of the patient.
Modulation of wfh% by POMC: a trans effect mediated through leptin expression
Within this thesis, an association of alleles D7S514-12 and D7S495-15 with the phenotype "discordant"
was observed (figures 3328and 3429). As both siblings share not only their CFTR genotype, but also
flanking sequences unless recombination as occurred, the discordance has to be attributed to
sequences which are not located at D7S514 or D7S495 but elsewhere in the genome, thereby
facilitating the inheritance of different alleles to both siblings. A modulation of the phenotype by a
modifier acting in trans will then be detectable through D7S514 and D7S495 if the modifying factor is
interacting with a sequence near the marker loci , e.g. by modulating the expression of a gene
through binding to a regulatory element. Discordance might then occur even if both siblings share
their sequences at the regulatory element when they have inherited different alleles for the trans
acting factor, thereby resulting in different expression of the target gene. An association of alleles
D7S514-12 and D7S495-15 with the phenotypic trait "discordance" will then be noticed if the
respective allele at the marker locus is linked to an allele of the regulatory element that is sensitive to
the allelic heterogeneity of the trans acting factor. The two candidate genes LEP and PEG1 are
located near D7S514 and D7S495. However, only for LEP has the regulation of gene expression been
studied in detail.
It has been demonstrated that plasma leptin levels and the body mass index correlate to a
certain degree (Oksanen et al. 1997). The expression of the murine OB gene was shown to be
inducible by corticosteroids (de Vos et al. 1995). For humans, a genome wide linkage scan
demonstrated linkage of D2S1788 to serum leptin levels (Comuzzie et al. 1997). D2S1788 is
localised near POMC. The gene product of POMC is a precursor for the adrenocorticotropic
hormone which induces glucocorticoid production of the adrenal glands. Hence, a modulation of
LEP expression by POMC can be presumed. Recently, a mutation in the POMC gene was described
for two patients suffering from early-onset obesity (Krude et al. 1998).
D2S1788 was typed in order to assess the role of leptin expression in CF disease severity. At
D2S1788, a significant decrease of intrapair discordance in wfh% with the number of shared alleles
at D2S1788 was found (figure 4230). Thus, modulation of leptin expression by POMC might play a
role in the modulation of CF disease severity.
28  Figure 33 is shown in chapter 3.2.3.5.2.1 on page 108.
29  Figure 34 is shown in chapter 3.2.3.5.2.3 on page 110.
30  Figure 42 is shown in chapter 3.2.3.7.3 on page 124.
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4.1    CFTR genotype – the basis of CF disease phenotype?
4.1.1    Determination of CF disease features by the CFTR genotype
Genetic determination was inferred for the pancreatic status based on high familial concordance
(Corey et al. 1989). Mutations associated with pancreatic sufficiency were classified as "mild" while
those conveying pancreatic insufficiency were termed "severe" (Kristidis et al. 1992). A direct
correlation of CFTR genotype and phenotype might be expected for the sweat gland as this is the
only organ where the condition "CF carrier" can be distinguished from the condition "two wild type
CFTR alleles" (Behm et al. 1987). Consistent with the theory, elevated sweat chloride
concentrations were observed for patients carrying mutations surmised to yield no or only non-
functional CFTR protein while lower sweat chloride concentrations were observed for patients
carrying a CFTR allele associated with reduced chloride channel function (Wilschanski et al. 1995).
Inconsistent with the theory, mutations shown to produce low levels of wild type protein were not
associated with a lower sweat chloride concentration (Wilschanski et al. 1995). No tight correlation
between CFTR genotype and CF disease phenotype was noticed for the pulmonary status as
pulmonary disease was described as being variable among patients carrying the same CFTR mutation
genotype (Kerem et al. 1990, Johannsen et al. 1991, Gasparini et al. 1992, Shoshani et al. 1992,
Highsmith et al. 1994). However, the risk for colonisation of the airways with Pseudomonas
aeruginosa could be related to the CFTR genotype (Kubesch et al. 1993) whereby nonsense
mutations were associated with the highest risk. For adult CF patient pairs, concordance among
siblings in pulmonary parameters has been reported (Santis et al. 1990a). For a group of adult
patients, the severity of lung disease was associated with the CFTR mutation genotype (Hubert et al.
1996).
In summary, the pancreatic status was correlated with the CFTR genotype. The sweat chloride
concentration was mostly, but not always, deducible from the functional defect expected for the
CFTR mutation. A high degree of variability was described for the pulmonary phenotype whereby
correlation of genotype and phenotype seemed to be closer for adult patients.
4.1.2    Disease severity of patients homozygous for non-∆F508 genotypes 
Atypical CF has been described as "Pseudomonas bronchitis, associated with low sweat chloride
concentrations and pancreatic sufficiency" before the CFTR gene was identified (Stern et al. 1978).
Expression of symptoms restricted to only one of the many organs typically affected in CF has been
disclosed for patients homozygous for G551S (normal sweat chloride concentrations, Strong et al.
1991), R117H (only male infertility, Bienvenue et al. 1993) and T338I (isolated hypotonic
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dehydration, Leoni et al. 1995). Homozygosity for 3849+10 kb C - T has been associated with
normal sweat chloride concentrations and pancreatic sufficiency (Highsmith et al. 1994, Gilbert et
al. 1995) and a case of male fertility has been reported (Dreyfuß et al. 1996). Pancreatic sufficiency
has been described for patients homozygous for G85E, both cases associated with mild lung disease
and highly elevated sweat chloride concentrations (Chalkey and Harris 1991, Vasques et al. 1996).
Pancreatic insufficiency and elevated sweat chloride concentrations have been shown for patients
homozygous for 621+1 G - T – associated with normal pulmonary function – and 2183 AA - G –
associated with moderate lung disease. All patients carrying two nonsense mutations have been
reported as pancreatic insufficient (Cuppens et al. 1990, Cutting et al. 1990, Bal et al. 1991, Cheadle
et al. 1992, Gasparini et al. 1992, Shoshani et al. 1992, Castaldo et al. 1996, Castaldo et al. 1997).
Pancreatic insufficiency was described for patients homozygous for R1162X – associated with wild
type mRNA levels (Rolfini et al. 1993) – and likewise for patients homozygous for R553X or
G542X – associated with reduced mRNA levels (Hull et al. 1994b, Will et al. 1995). In all cases,
elevated sweat chloride concentrations were associated with homozygosity for two nonsense
mutations. Pulmonary disease varied from mildly affected to severely impaired among these patients.
Within this thesis, patients homozygous for R553X, CFTRdelEx2,3 , E92K, CFTRdelEx2,
3849+10kb C - T and 1898+3 A - G have been investigated during the study "rare genotypes and
atypical CF"31. The clinical picture of these patients was consistent with similar cases described in
the literature: the patient homozygous for R553X and two patients compound heterozygous for two
stop mutations were all pancreatic insufficient and had an elevated sweat chloride concentration as
reported for all other cases with two nonsense mutations. The moderate to severe pulmonary
impairment among these three patients likewise reflects the results of variable lung impairment
published by other authors. The E92K homozygous patient was comparable to the cases of G85E
homozygosity: patients homozygous for these genotypes had a highly elevated sweat test, pancreatic
sufficiency and little pulmonary disease in common (Chalkey and Harris 1991, Vasques et al. 1996).
The patients homozygous for 3849+10 kb C - T were, as described for other cases with this
mutation, presenting atypical normal sweat chloride levels and were pancreatic sufficient (Highsmith
et al. 1994, Gilbert et al. 1995).
Three cases investigated carried genotypes in the homozygous condition not described in the
literature: mutations 1898+3 A - G, CFTRdelEx2 and CFTRdelEx2,3 .The patient homozygous for
1898+3 A - G was pancreatic sufficient as were patients with 3849+10kbC - T or 2789+5G - A
(Highsmith et al. 1994, Highsmith et al. 1997). The index case homozygous for 1898+3 A - G was
investigated at 3 years of age and hence, prognosis for pulmonary disease and pancreatic status
cannot be given at this point. CFTRdelEx2,3 was detected in a pancreatic insufficient patient with an
impaired lung function and highly elevated sweat electrolytes. Based on the genotype, a condition as
observed for patients carrying two nonsense mutations was expected for the out-of-frame deletion
CFTRdelEx2,3 and the clinical findings are consistent with this hypothesis. CFTRdelEx2 was found
31  See chapter 3.1.2 for results and chapters 3.1.3.1, 3.1.3.2 and 3.1.2.3 for discussion.
— 124 —
CFTR GENOTYPE – THE BASIS OF CF DISEASE PHENOTYPE?
in a pancreatic insufficient patient with a normal lung function. This in-frame deletion might
theoretically give rise to functional CFTR. However, homozygotes for E92K and G85E, associated
with CFTR proteins of an altered function, were described as pancreatic sufficient (Nunes et al.
1993, Chalkey and Harris 1991, Vasques et al. 1996). Thus, CFTRdelEx2 should be considered as a
severe mutation.
4.1.3    Variability of CF lung disease– modulating factors or
functional diversity of CFTR?
The manifestation of pulmonary disease is variable among (a) patients without CFTR, e.g.
homozygotes for two nonsense mutations associated with mRNA reduction (Cuppens et al. 1990,
Cutting et al. 1990, Bal et al. 1991, Cheadle et al. 1992, Shoshani et al. 1992, Castaldo et al. 1996,
Castaldo et al. 1997) (b) patients with reduced wild type levels of CFTR, e.g. homozygotes for
3849+10 kb C . T (Highsmith et al. 1994, Gilbert et al. 1995, Dreyfuß et al. 1996, this work) and (c)
patients carrying only one defective CFTR allele while suffering from pulmonary disease such as
chronic bronchial hypersecretion, atypical sinopulmonary disease or disseminated bronchiectasis
(Dumur et al. 1990a, Poller et al. 1991, Pignatti et al. 1995, Pignatti et al. 1996, Friedman et al.
1997). Thus, while CFTR mutations predispose to disease conditions in the lung, the severity of
pulmonary disease in an individual cannot be predicted since for all groups of patients carrying the
same CFTR mutation genotype both exceptionally mild and exceptionally severe cases of lung
disease have been described. The pulmonary phenotypes displayed by the groups (a) "CFTR absent",
(b) "CFTR reduced" or (c) "CF carrier status" overlap. In conclusion, the variability of lung disease
is independent of the CFTR mediated risk. While this might indicate an involvement of factors
distinct from CFTR modulating lung disease in general, a functional diversity of CFTR itself is an
alternative to be considered.
Lung disease in CF was related to the CFTR transmitted defect of impaired chloride
conductance by inferring an elevated NaCl concentration of the airway surface fluid, which in turn
was thought to alter the defence against bacteria mediated by epithelial β-defensin-1 (Smith et al.
1996, Goldmann et al. 1997). However, the ionic composition of the airway surface fluid was also
reported to be normal (Knowles et al. 1997) and no β-defensin-1, but neutrophil defensins were
detected in bronchioalveolar lavage fluid (Schnapp and Harris 1998). Apart from chloride
conductance, other roles of CFTR in lung disease have been suggested: Lallemand et al (1997)
inferred a role of CFTR in the export of glutathione conjugated substrates, including leukotrienes
which act as inflammatory agents. Lindsdell and Hanrahan (1998) demonstrated that CFTR mediates
glutathione transport. Thus, apart from conducting chloride, CFTR seems to transport other
substances as is known for other members of the ABC transporter family (reviewed by Higgins
1995).
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In conclusion, CFTR has been shown to act as a chloride channel, to regulate the function of other
ion channels (Egan et al. 1992, Gabriel et al. 1993, Ismailov et al. 1996, Loussouarn et al. 1996,
Stutts et al. 1997, McNicholas et al. 1997) and might act as a transporter of glutathione and
derivatives thereof. Thus, CFTR can be considered to perform roles typical for other ABC
transporters.
4.1.4    Influence of intragenetic and extragenetic background on the
basic defect
The lack of correlation between CFTR genotype and CF disease phenotype has been attributed to
frequent polymorphisms within the CFTR gene that modulate the expression of the CFTR disease-
causing lesion (Kiesewetter et al. 1993, Cuppens et al. 1998) or to rare polymorphisms directly
compensating the disease-causing lesion (Dörk et al. 1991). Both mechanisms can be summarised as
"intragenetic background". Modulation of the effect of a disease-causing CFTR sequence variation
can only be expected if the sequence alteration occurs in combination with more than one
intragenetic background, i.e. more than one haplotype has to be associated with a disease-causing
lesion. In contrast, all CFTR alleles will occur in combinations with more than one allele at loci
distinct from CFTR and thus, this "extragenetic background" might modulate the CF phenotype (as
will be discussed in detail in chapter 4.2).
Within the study "rare genotypes and atypical cystic fibrosis", three ∆F508 homozygous
patients with a second sequence alteration on one ∆F508 allele have been characterised with respect
to the basic defect of impaired chloride conductance32. In these three cases, residual chloride channel
activity was detected. However, residual chloride conductance was also measured in ∆F508
homozygous patients without a second sequence alteration on any ∆F508 allele33. Additionally, in
two siblings carrying the genotype ∆F508/∆F508-V1212I, the residual conductance was DIDS-
sensitive indicating a non-CFTR origin. Hence, the second sequence alteration V1212I probably
does not have a functional effect on the ∆F508 allele. In contrast, the polymorphism M470V was
shown to influence the chloride conductance of mutant CFTR channels (Cuppens et al. 1998).
Finally, the diversity of ion conductances displayed by ∆F508 homozygous patient pairs34 – having an
identical intragenetic background but not an identical extragenetic background – indicates that the
expression of the basic defect among ∆F508 homozygous patients is not modulated by the CFTR
gene itself.
Modulation of residual chloride conductance among CF patients can either be mediated by an
influence on the expression and/or function of the mutant CFTR protein or by the presence of
alternative channels. Within this thesis, three chloride conductances differing in their sensitivity to
32  See chapter 3.1.2 for results.
33  See chapter 3.2.2 for results.
34  See figure 25, shown in chapter  3.2.2 on page 95.
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DIDS and cAMP have been described35. Thus, more than one alternative pathway for chloride
conductance exists among CF patients. However, when analysing the relation of residual chloride
channel activity in relation to the pancreatic status, any residual chloride conductance displayed by
pancreatic insufficient patients was sensitive to DIDS (i.e. indicative of non-CFTR mediated chloride
conductance) while the residual chloride conductance displayed by pancreatic sufficient patients was
sensitive to cAMP (i.e. indicative of CFTR mediated chloride conductance)36. Thus, concordant with
the literature published on a close correlation of CFTR genotype and pancreatic status (Corey et al.
1989, Kristidis et al. 1992), the pancreatic status appears to be determined by CFTR mediated
residual chloride conductance. Recently it was demonstrated that the DIDS sensitive chloride
channel is not expressed in pancreatic tissue (Gruber et al. 1998b) and consequently cannot
compensate for defective CFTR in the pancreas. In agreement with these findings, an elevated
frequency of mutant CFTR alleles was found among patients with chronic pancreatitis (Sharer et al.
1998), thus emphasising the importance of CFTR for the pancreatic status.
4.2    CF disease variability – the influence of non-CFTR genetics?
4.2.1    Genotype-phenotype correlation for ∆F508
∆F508 was classified as a "severe" mutation associated with pancreatic insufficiency in most, but not
all, cases (Santis et al. 1990a, Kristidis et al. 1992). However, a broad variability of lung disease
severity was noted among ∆F508 homozygotes (Kerem et al. 1990, Johannsen et al. 1991). When
∆F508 homozygotes were compared to ∆F508 compound heterozygotes, pulmonary disease was
reported to be similar for ∆F508 homozygous patients and patients carrying G551D/∆F508 (Hamosh
et al. 1992a) or ∆F508 compound heterozygous patients with various mutations (Al Jader et al.
1992). A higher risk of meconium ileus of ∆F508 homozygous patients compared to patients
carrying G551D/∆F508 was observed (Hamosh et al. 1992a). The disease severity of ∆F508
homozygotes and ∆F508 compound heterozygotes was reported to be identical in an ethnically
diverse population (Lester et al. 1994). When Caucasian and Afro-American ∆F508 homozygous CF
patients were compared, the patient groups were found identical except for lower height and weight
percentiles of the Afro-American patients (Hamosh et al. 1998). As the Afro-American CF patients
were diagnosed at a younger age than the Caucasian patients and the poorer nutritional status was
already detected at the age of diagnosis, it was concluded by the authors that the dissimilarities
observed "may extend beyond socioeconomic differences".
In summary, as described for patients homozygous for non-∆F508 genotypes (chapter 4.1),
variability of disease severity was noted among patients homozygous for the most frequent CFTR
disease-causing lesion.
35  See figure 18, shown in chapter 3.1.2.5 on page 68.
36  See chapter  3.1.3.2.3.2 for detailed discussion.
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4.2.2    The molecular phenotype of ∆F508 CFTR might be variable
Does the variability of CF disease severity among ∆F508 homozygotes reflect a variable molecular
phenotype of ∆F508-CFTR? Common pathways, consisting of several cell compartments and
multiple proteins, have been shown to contribute to CFTR processing (Jensen et al. 1995, Ward et
al. 1995). Degradation of CFTR in intracellular compartments was shown for wild type CFTR in
heterologous expression systems (Ward et al. 1994) as well as immortalised airway cells (Wei et al.
1996). However, the ∆F508-CFTR protein was characterised by a reduced stability within all
systems investigated (Lukacs et al. 1993, Ward et al. 1994, Jensen et al. 1995). The equilibrium
between processed and degraded CFTR was reported to be influenced by a variety of factors,
ranging from general biophysical properties such as the temperature (Denning et al. 1992b) to
chaperones interacting specifically with CFTR (Yang et al. 1993, Pind et al. 1994, Loo et al. 1998).
In conclusion, the maturation of CFTR – wild type as well as ∆F508 protein – can be considered as a
dynamic system and thus provides opportunities for variation in the expression of the maturation
defect between different cell types or individual patients.
4.2.3    The basis of clinical concordance
In general, the variability of CF disease can be attributed to three different factors:
The  CFTR mutation genotype, as the CFTR gene is characterised by allelic heterogeneity and
correlation of CFTR genotype and some aspects of the disease phenotype – i.e. pancreatic
status – are known;
Epigenetic factors, such as the socioeconomic status, therapeutic measures and the patient's
compliance, but also the exposure to chemicals and/or bacterial and viral lung pathogens;
The genetic background, i.e. inherited factors other than the CFTR gene itself.
The analysis of the clinical data collected on patients participating in the "European CF twin and
sibling study" has provided evidence of the influence of the genetic background on the disease
severity 37. CF twins and siblings have the same CFTR mutation genotype, they share several
environmental factors and their genetic background. Surprisingly, the disease variability between two
siblings of a pair (intrapair variance) was independent of the CFTR mutation genotype: ∆F508
homozygous patient pairs were comparable to all other patient pairs – displaying all other CFTR
mutation genotypes – with respect to their intrapair variance in wfh%38, representing the nutritional
status, and FEVPerc39, representing the pulmonary status. Likewise, the intrapair variance was
identical for pairs composed of two pancreatic insufficient patients (associated with severe CFTR
mutation genotypes) compared to pairs composed of two pancreatic sufficient patients (associated
with mild CFTR mutation genotypes). In contrast, the influence of an identical extragenetic
37  For detailed results see chapter 3.2.1.
38  Defined in chapter 2.2.1.2 on page 47.
39  Defined in chapter 2.2.1.2 on page 47.
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background had a significant influence on the intrapair variation of disease severity: monozygous
twins were significantly more concordant than dizygous patient pairs, even though a group of
monozygous twin pairs is heterogeneous with respect to the CFTR mutation genotype. In
conclusion, the extragenetic background determined the concordance of CF patient pairs and thus
the disease severity must be modulated by inherited factors other than the CFTR gene itself.
4.2.4    Non-CFTR genetics (I): analysis of ENaC as modifier of CF disease
Within this thesis, the influence of the epithelial amiloride sensitive Na+ channel ENaC on the disease
severity of selected ∆F508 homozygous patient pairs with extreme phenotypes was assessed using
polymorphic markers near genes encoding for the three subunits of the ENaC. An association of an
allele at D12S889, localised near SCNN1A encoding for the α subunit of the ENaC (Baens et al.
1995), with a mild disease phenotype was noticed40. Patients carrying one or two D12S889-10 alleles
had a significantly better nutritional and pulmonary status than patients with other D12S889
genotypes41. Thus, disease severity among ∆F508 homozygotes is modulated by a gene linked to
D12S889, presumably the α subunit of the ENaC itself.
The ENaC is related to CF on the molecular level and in terms of the disease phenotype. A
direct modulation of the ENaC by CFTR has been demonstrated (Ismailov et al. 1996, Stutts et al.
1997). In addition, mutations within the genes encoding for ENaC subunits have been shown to
cause pseudohypoaldosteronism type I (Chang et al. 1996, Strautnieks et al. 1996a) which in turn
was reported to display symptoms known for CF disease (Hanakoglu et al. 1994, Marthinsen et al.
1998). Thus, as discussed detail in chapter 3.2.3.8.1, the ENaC most probably modulates the CF
disease severity. Furthermore, the ENaC appears to be one of the factors determining the severity of
lung disease among CF patients: the association of D12S889-10 alleles with a mild phenotype was
more pronounced for the parameter FEVPerc than for wfh% and a patient suffering from
pseudohypoaldosteronism type I was reported to be colonised with Pseudomonas aeruginosa
(Marthinsen et al. 1998), a condition typical for CF lung disease.
4.2.5    Non-CFTR genetics (II): other modifiers
Within the last few years, modulation of CF disease by genes other than CFTR has been reported for
the antiprotease α1-antitrypsin (Döring et al. 1994), immunglobulin G allotypes (Ciofu et al. 1997),
the glutathione-S-transferase (Becker et al. 1997) and the low molecular weight protein 2 (Becker et
al. 1997, Mekus et al. 1998). A modifier of CF disease severity in CF mice was mapped to mouse
chromosome 7 (Rozmahel et al. 1996) and the homologous gene CFM1, reported to convey a risk
for meconium ileus, was localised to human chromosome 19q13 (Zielenski et al. 1998).
40  See figure 30 shown in chapter 3.2.3.4 on page 103.
41  See figure 36 shown in chapter 3.2.3.7.1 on page 115.
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Apart from these genetic approaches, an influence of residual chloride secretion on CF disease
severity has been shown for intestinal tissue (Veeze et al. 1994). Among the genes encoding for non-
CFTR chloride channels, CACLN1 – coding for the Ca2+ activated chloride channel – has recently
been cloned. The presence of alternative chloride channels in patients investigated within the study
"Rare genotypes and atypical cystic fibrosis" and the "European CF twin and sibling study" has
demonstrated the existence of DIDS-sensitive residual chloride currents among CF patients42.
Furthermore, ∆F508 homozygous patients have shown various combinations of DIDS-sensitive,
alternative residual chloride secretion and DIDS-insensitive residual chloride secretion indicating a
variable expression of the basic defect among patients with the same CFTR mutation genotype.
4.3    Advantage of CF carriers – none, CFTR transmitted or
hitchhiking genes?
4.3.1    Allele frequency, allelic heterogeneity and heterozygote advantage
A high frequency of mutant alleles, conveying lethality in the homozygous state, has been attributed
to a selective advantage of the heterozygous condition. It has been proposed that the carrier
advantage is one of several reasons for the dominance of the diploid phase in higher plants and
animals (Goldstein 1992). Examples for a heterozygote advantage have been suggested for
thalassaemia traits and glucose-6-phosphate-deficiency, both resulting in an increased resistance to
the malaria parasite due to the altered erythrocyte metabolism (reviewed by Friedman and Träger
1981). The high frequency of mutant CFTR alleles has been related to an advantage of the carrier
state. However, the question remains unresolved as to whether an advantage is transmitted by the
CFTR gene itself or is due to the action of other genes inherited in linkage to CFTR. Apart from the
allele frequency, the diversity of mutant CFTR alleles is noteworthy. Clark (1998) has speculated on
the mechanisms causing and leading to maintenance of allelic heterogeneity. The author concluded
that systems in which complementation of alleles occurs favour a higher number of alleles. Strictly
speaking, this mechanism is referring again to a group of linked genes and not to an isolated
sequence.
4.3.2    A balance: carrier risk and carrier advantage
The carrier status of CF was recognised by a reduced β-adrenergically stimulated response of sweat
glands (Behm et al. 1987). An elevated frequency of mutant CFTR alleles has been found in several
disease conditions, predominantly but not exclusively for pulmonary diseases (Warner 1976, Dumur
et al. 1990a, Dumur et al. 1990b, Poller et al. 1991, Chillon et al. 1995, Pignatti et al. 1995, Pignatti
42  See chapter 3.1.2 and 3.2.2 for results.
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et al. 1996, Dahl et al. 1998b, Sharer et al. 1998; table 30). In parallel, hypotheses regarding the
advantage of the heterozygous state have been made, mostly suggesting an enhanced resistance
against viral and bacterial pathogens (Stuart and Burdon 1974, Quinton 1982, Hollander 1982,
Cassano 1985, Rodman and Zamundio. 1991, Gabriel et al. 1994, Meindl 1987, Pier et al. 1998;
table 30).
30
TABLE 30: RISK AND ADVANTAGE OF CF CARRIER STATUS
—————————— CARRIER RISK —————————— REFERENCE
symptoms of allergy more frequent among CF carriers Warner (1976)
elevated frequency of ∆F508 heterozygotes among adults with chronic
bronchial hypersecretion
Dumur et al. (1990a)
elevated frequency of ∆F508 heterozygotes among azoospermic men
with congenital aplasia of epididymis and vas deferens
Dumur et al. (1990b)
mutant CFTR alleles among patients with disseminated bronchiectatic
lung disease Poller et al. (1991)
elevated frequency of mutant CFTR alleles among CBAVD patients Chillon et al. (1995)
elevated frequency of mutant CFTR alleles among patients with
disseminated bronchiectasis
Pignatti et al. (1995),
Pignatti et al. (1996)
CFTR is Pseudomonas receptor and thus non-functional CFTR
enhances risk of infection Pier et al. (1997)
elevated frequency of IVS8-5T alleles among patients with atypical
sinopulmonary disease Friedman et al. (1997)
reproductive disadvantage for smoking ∆F508 heterozygotes Dahl et al. (1998a)
elevated frequency of ∆F508 heterozygotes among patients suffering
from asthma
Dahl et al. (1998b)
elevated frequency of mutant CFTR alleles among patients with
chronic pancreatitis Sharer et al. (1998) 
———————— CARRIER ADVANTAGE ———————— REFERENCE
resistance to typhus Stuart and Burton (1974)
resistance to diarrhoea Quinton (1982),Baxter et al. (1988)
resistance to venereal syphillis Hollander (1982)
resistance to bubonic plague Cassano (1985)
resistance to tuberculosis Meindl et al. (1987)
resistance to cholera Rodman and Zamundio (1991)
CF mice heterozygotes are resistant to cholera toxin Gabriel et al. (1994)
family size related to carrier status de Vries et al. (1997)
reproductive advantage for non-smoking ∆F508 heterozygotes Dahl et al. (1998a)
resistance to Salmonella typhi Pier et al. (1998)
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In order to result in an elevated reproductive fitness, the carrier advantage has to outweigh the
disadvantages resulting from the elevated vulnerability of CF carriers to other diseases. A
reproductive advantage of CF carriership was detected by de Vries et al (1997). However, the
authors concluded that the observed effect was too complex to be attributed to a heterozygote
advantage alone. Dahl et al (1998) have reported an interrelationship of ∆F508 heterozygosity and
smoking on the family size: while the family size of smoking ∆F508 heterozygotes was lower, an
increase in family size among non-smoking ∆F508 heterozygotes was noticed. As smoking primarily
affects the lung, it is tempting to speculate whether this finding reflects the balance of CFTR
mediated risk – e.g. for lung disease – and CFTR mediated advantage – i.e. enhanced longevity due
to defence against viral and bacterial pathogens.
4.3.3    Hitchhiking genes near CFTR
The discussion of risk and advantage of the CF carrier status is focussed on pulmonary disease or
resistance to viral and bacterial pathogens in general. However, in terms of hitchhiking genes an
influence on the nutritional status can be inferred as LEP, the human homologue to the murine
obesity gene, is localised close to CFTR (Green et al. 1995). An influence of the haplotype at MetH
and J3.11, both markers flanking the CFTR gene (see figure 3143), on growth parameters has been
described (Tümmler et al. 1990). Furthermore, an interrelation of the pulmonary status and the J3.11
genotype was noticed (Santis et al. 1990b) and an association of postnatal female survival with the
CS.7 genotype was detected (Macek et al. 1997).
The polymorphisms near the CFTR locus are in a pronounced linkage disequilibrium with the
gene (Kerem et al. 1989a, Dörk et al. 1992, Cuppens et al. 1994), i.e. the "normal" CFTR allele is
associated with other genotypes at the flanking polymorphisms compared to disease-causing CFTR
alleles. The following two observations provide evidence for a selective advantage of the
chromosomal background associated with most mutant CFTR alleles:
(a) The number of mutations associated with an intragenic haplotype was shown to be proportional
to the frequency of the haplotype among non-CF chromosomes, indicating that mutations occur
on each chromosomal background with the same probability (Morral et al. 1996). However, the
most frequent CFTR mutations which have been caused by unrelated mutation events are found
on the same intragenic dimorphic marker haplotype (Dörk et al. 1992, Cuppens et al. 1994,
Morral et al. 1996). Consequently, mutations which must have occurred on other chromosomal
backgrounds than the haplotype found on most CF chromosomes did not persist within the
population.
43  Figure 31 is shown in chapter 3.2.3.5 on page 105.
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(b) The most common mutation has been analysed at three intragenic microsatellite markers and
several intra- and extragenic dimorphic markers (Dörk et al. 1992, Morral et al. 1996).
Recombination between the two dimorphic markers KM.19 and TUB20, located in a 1 Mb
distance to each other, is considered to be more frequent than a mutation event at a microsatellite
locus (Morral et al. 1996). Thus, it is expected that each microsatellite haplotype is associated
with several dimorphic marker haplotypes. For ∆F508 chromosomes, the opposite has been
observed: ∆F508 is associated with several haplotypes at three intragenic dinucleotide
polymorphism (Morral et al. 1994). In contrast, ∆F508 occurs nearly exclusively on one
dimorphic marker haplotype spanning markers between KM.19 and TUB20. Consequently, other
dimorphic haplotypes which must have been generated by recombination events did not persist
within the population.
Hence, the chromosomal background associated with most CFTR mutations is suspected to transmit
a selective advantage compared to the other haplotypes which must have existed on CF
chromosomes but did not remain within the gene pool.
In this thesis, the hypothesis of hitchhiking genes within the CFTR linkage group was tested by
analysing polymorphisms in a 40 cM region encompassing the CFTR gene. Allele frequencies were
than compared among ∆F508 homozygous CF twins and siblings with extreme disease phenotypes.
Patient pairs were classified as "concordant/mild disease" (CON+), "concordant/severe disease"
(CON-) and "discordant" (DIS) based on their pulmonary function, their growth parameters and the
intrapair variation thereof (for details see chapters 2.2.1.3 and 2.2.1.4 and figures 27, 28 and 2944).
An association of an allele at a marker locus with the phenotype CON+, CON- or DIS was
considered as indicative for a modulation of the disease phenotype by a gene linked to the marker
locus studied. As all patient pairs investigated were ∆F508 homozygous and hence the CFTR
disease-causing lesion was identical for all patients studied, the phenotype – CON+, CON- or DIS –
cannot be caused by the CFTR gene itself.
Published results and results obtained within this work on flanking markers localised within
1iMb distance to the CFTR gene (see figure 3145) are summarised in table 31. A benign phenotype –
better growth (Tümmler et al. 1990), survival (Macek et al. 1997) and an overall mild disease (this
work)– was found to be associated with alleles composing the flanking marker haplotype. Thus, the
compiled data support the hypothesis of a selective advantage transmitted by the chromosomes
carrying the CF haplotype.
44 Figure 27 is shown in chapter 3.2.3.1 on page 97, figure 28 is displayed in chapter 3.2.3.2 on page 99 and figure
29 is shown in chapter  3.2.3.2 on page 100.
45 Figure 31 is shown in chapter  3.2.3.5 on page 105.
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31
TABLE 31: ASSOCIATION OF ALLELES AT CFTR FLANKING LOCI WITH PHENOTYPE
Allele frequencies are given for European populations (Estivill  et al. 1987, Schmidke et al. 1987).
Published results: Tümmler et al. 1990: haplotype 1-1-2-1 associated with better growth, Santis et al. 1990a: allele
J3.11-2 associated with mild lung disease, Macek et al. 1997: allele KM.19-2 associated with postnatal female
survival.
ALLELE FREQUENCIES
MetH XV-2c KM.19 J3.11
non-CF chromosomes Allele 1 54 45 73 43
Allele 2 45 55 27 57
CF- chromosomes Allele 1 70 89 12 60
Allele 2 30 11 88 40
"CF-haplotype" 1 1 2 1
ASSOCIATION OF ALLELE AND PHENOTYPE
MetH XV-2c KM.19 J3.11
Tümmler (1990): better growth 1 1 2 1
Santis (1990a): mild lung disease 2
Macek (1997): female survival 2
This work: associated with CON+ 1 — — —
This work: associated with DIS — — — 1
In addition to markers located within 1 Mb distance to CFTR, polymorphic loci within a 40icM
region encompassing the CFTR gene have been investigated within this thesis. As discussed in detail
before46, more than one modulating element had to be assumed to account for all effects observed.
Figure 44 summarises the hypothesis, based on the known genes within the region investigated (see
figure 4347 for an overview of genes mapped near CFTR).
46 RESULTS: allelic association: For results on the association of alleles at marker loci near CFTR with the
phenotypes CON+, CON- and DIS see chapter 3.2.3.5. Results on allelic association of D2S1788 alleles with the
phenotype of the investigated patient pairs are shown in chapter 3.2.3.6.
RESULTS: correlation of genotype and clinical data: For loci near CFTR, results are displayed in chapter
3.2.3.7.2. For D2S1788, results are shown in chapter 3.2.3.7.3.
The effect are summarised in chapter 3.2.3.8.2.
DISCUSSION: Modulation of the pulmonary status is discussed in chapter 3.2.3.8.2.2. Influence of genes near
CFTR and at D2S1788 on the nutritional status is dissected in chapter 3.2.3.8.2.3.
47 Figure 43 is shown in chapter 3.2.3.8.2.1 on page 129.
— 134 —
ADVANTAGE OF CF CARRIERS – NONE, CFTR TRANSMITTED OR HITCHHIKING GENES?
44
FIGURE 44: SUMMARY OF HYPOTHESES: HITCHHIKING GENES NEAR CFTR
(a) Map of investigated region, all typed markers, candidate genes on 7q31 and summary of observed effects.
(b) - (f) Hypotheses to explain observed allelic associations. For detailed discussion see text (page 148).
(b) - (d) Allelic association observed for concordant pairs (modulation in CIS).
(e) - (f)  Allelic association observed for discordant pairs (modulation in TRANS).
Alleles at polymorphic loci: locus name - allele name, observed associated with phenotype  CON+ , CON –  or  DIS
Alleles at gene loci: gene name /  CON+, this allele causes phenotype CON+
gene name /  CON– , this allele causes phenotype CON-
gene name , printed in orange box: allelic diversity at this locus causes phenotype DIS
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Figure 44 (b) MetH-1 was observed associated with the phenotype "concordant/mild disease"
(figure 32). Patient pairs homozygous for MetH-1 had a significant better wfh% than patient pairs
heterozygous at MetH (figure 37(b), p < 0.01). The most plausible mediator for this effect is the gene
MET (discussed detailed in chapter 3.2.3.8.2.3).
Figure 44 (c) At D7S495, an association of the allele D7S495-10 with the phenotype
"concordant/mild disease" was seen (figure 34). Pairs with siblings carrying each one or two alleles
D7S495-10 had a significantly better wfh% than pairs with other D7S495 genotypes (figure 38(b),
p < 0.01). This effect might be mediated by LEP, by PEG1 or both (discussed in detail in chapter
3.2.3.8.2.3).
Figure 44 (d) The allele D7S495-14 was found predominantly on pairs with a "concordant/severe
disease" phenotype (figure 34) Pairs where each sibling carried one or more alleles D7S495-14 had a
significantly worse wfh% than pairs with other D7S495 genotypes (figure 38(c), p < 0.01). Again, this
effect might be mediated by LEP, by PEG1 or both (discussed in detail in chapter 3.2.3.8.2.3).
Figure 44 (e) Located further towards the telomer than CFTR, a modulation of the nutritional
status by a factor acting in trans was inferred: alleles at J3.11, D7S514 and D7S495 were found
associated with the phenotype "discordant" (figures 32, 33 and 34). As described before, an
association of the phenotype "discordant" with an allele linked to CFTR indicates a modulation
mediated by a gene encoded in trans, i.e. not within the CFTR linkage group: two siblings with CF
have the identical CFTR gene and identical flanking sequences unless a recombination has occurred.
Hence, discordance within such a sib pair has to be caused by a sequence located elsewhere in the
genome. LEP, considered as a candidate for the modulation of the nutritional status, is localised
between D7S514 and D7S495. Serum leptin levels were shown to be linked to D2S1788
(Commuzzie et al. 1997), and thus, an influence in trans on LEP can be assumed. D2S1788 was
investigated in the selected panel of CF twins and siblings. Patient pairs sharing one or two alleles at
D2S1788 were significantly more concordant in wfh% than pairs with no identical allele at D2S1788
(figure 42, p < 0.01). The most likely candidate gene near D2S1788 to mediate this effect is POMC
(discussed in detail in chapter 3.2.3.8.2.3).
Figure 44 (f) At J3.11, an association of the phenotype "discordant" with the allele J3.11-1 was
detected (figure 32). Pairs homozygous for J3.11-1 were significantly more concordant in FEVPerc
than pairs heterozygous at J3.11 (figure 39(a), p < 0.01). As the CFTR genes and flanking sequences
of two CF affected siblings are identical by descent, the discordance cannot be caused by a sequence
linked to J3.11 itself: a gene encoded elsewhere, i.e. in trans, expressing allelic diversity, has to
mediate the effect. Most likely, a regulatory factor acts on the CFTR expression via a responsive
element liked to J3.11. The observed association of allele J3.11-1 with the phenotype "discordant"
will occur if the allele of the responsive element linked to J3.11-1 is most susceptible to the allelic
diversity of the regulatory factor (discussed in detail in chapter 3.2.3.8.2.2).
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Figure  44 (c), (d) and (f): three pairs sharing no allele at D7S495 were ranked discordant. This
condition was not seen on any pair with a concordant phenotype (table 22). Discordance in siblings
sharing no allele at D7S495 could be caused by different alleles at the candidate gene loci LEP
and/or PEG1 and/or the regulatory element controlling the expression of LEP, with a probable
enhancing effect of an allelic diversity at POMC near D2S1788. Two out of the three pairs ranked
discordant and sharing no allele at D7S495 likewise did not share an allele at D2S1788.
In conclusion, hitchhiking genes within the CFTR linkage group have a modulating effect on the CF
disease phenotype. Whether the genes identified so far within the region investigated are responsible
for the effect observed or whether other genes, not identified or mapped till today, are causing the
modulation of the CF disease phenotype, will have to be clarified by further investigation of
polymorphisms surmised to exist within the candidate genes.
4.4    Cystic fibrosis – monogenic disease or complex trait?
4.4.1    CF disease condition without two mutant CFTR alleles
Within this thesis, for three patients, presenting symptoms compatible with CF, evidence for the
absence of CFTR disease-causing lesions on at least one allele was provided (see chapter 3.1.2.5 for
results and chapter 3.1.3.2.2.4 for discussion). In these three cases – patient Q, R and S – only the
lack of two CFTR disease-causing lesions has hindered he unequivocal diagnosis of CF. For patients
Q, R and S, all CFTR exons and flanking intron sequences have been investigated for sequence
alterations by SSCP and subsequent sequencing. The promoter region – extended to a 4 kb segment
– has been screened for polymorphisms by SSCP in patients Q and R. Large genomic rearrangements
have been searched for by pulsed field gel electrophoresis and southern blotting in patients Q and R.
The only disease-causing lesion detected in patients Q, R and S was a splice site consensus transition
preceding exon 12 in patient Q. The carrier status of patient Q was sustained by the familial history:
a sibling was reported to have died from meconium ileus and thus, CF alleles within the family of
patient Q are most likely associated with pancreatic insufficiency while patient Q is pancreatic
sufficient. Patient S has a healthy sister, carrying the same alleles within a 30 cM region
encompassing the CFTR gene locus (figure 19) and putative modifiers loci suspected within the
linkage group (figure 44). Hence, unless at least one de novo mutation has occurred in patient S, he
carries at least one wild type CFTR allele.
In conclusion, for all three patients the expression of the CF typical basic defect has been
detected in at least one tissue. Due to the inheritance of CFTR alleles within the family, patient S
cannot carry two CFTR disease-causing lesions. The carrier status of patient Q is sustained by he
family history. For patient R, the absence of two disease-causing lesions can only be inferred based
on the genetic analysis performed.
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The basic defect of impaired chloride conductance has been investigated in the sweat gland, the nasal
tissue and the rectal tissue of these patients. For patient R, evidence for dysfunctional CFTR was
found in all three tissues investigated. Patient Q showed an impaired chloride conductance with the
respiratory epithelium, but not within the sweat gland or the rectal tissue. In patient S, highly
elevated sweat chloride concentrations were detected repetitively, but the nasal and rectal tissue
displayed the non-CF condition. These results are summarised in table 32.
32
TABLE 32: CF WITHOUT TWO DISEASE-CAUSING LESIONS IN THE CFTR GENE
All patients present symptoms compatible with CF and have been screened for disease-causing lesions within all
CFTR exons and flanking intron sites. For patient Q, 1898+3A
1
G has been identified on one chromosome. Patient S
has a healthy sister carrying the same CFTR alleles and consequently cannot have two disease-causing lesions within
the CFTR gene. The carrier status of patient Q is sustained by the familial history (see text  for details).
number of CFTR
disease-causing lesions pathological sweat test?
pathological nasal
potential difference?
pathological ion currents
in rectal tissue?
Patient Q one no yes no
Patient R (none) yes yes yes
Patient S none yes no no
Given the diagnosis of CF in patients Q, R and S – sustained by the pathological condition, due to
the impaired chloride conductance typical for CF, which was detected in at least one tissue in each of
these patients – other genes than CFTR alone must be considered in order to explain the disease
condition in these patients. In patient R, a defective factor controlling the CFTR expression or the
CFTR function might be responsible as an altered CFTR function was demonstrated in all tissues
examined. For patient Q, the CF typical picture of defective chloride conductance was revealed
exclusively in the nasal tissue and hence, elements of the genetic background involved in the tissue
specific expression are likely to be involved. For patient S, pseudohypoaldosteronism type 1 –
reported to be associated with CF-like symptoms and elevated sweat electrolytes (Hanokoglu et al.
1994, Marthinsen et al. 1998) – was excluded by differential diagnosis. It was demonstrated that
pseudohypoaldosteronism type 1 can be caused by mutations within the genes encoding for the
subunits of the epithelial sodium channel ENaC (Chang et al. 1996, Strautnieks et al. 1996a). In
addition, an involvement of the SCNN1A gene in modulation of the CF phenotype was indicated
(see chapter 3.2.3.8.1 for discussion). Thus, the ENaC subunits remain a plausible candidate gene to
explain the disease symptoms in patient S as this index case and his healthy sister share only one
allele at two polymorphic loci located near genes encoding for ENaC subunits and consequently, the
discordance in this sib pair might be caused by different ENaC alleles.
Summarising these findings, the extensive analysis of the CFTR alleles from 350 patients (Dörk
et al. 1994c, this work) has disclosed three index cases of CF-like disease without two defective
CFTR alleles.
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4.4.2    On the role of the CFTR gene, hitchhiking sequences and the
extragenetic background in nutritional status and pulmonary
disease
As discussed in chapter 4.3.3, modulating genes within the CFTR linkage group have been detected
due to their influence on the nutritional status of CF twins and siblings. Thus, the selective advantage
associated with CF carriership is most likely mediated by genes linked to CFTR which act on the
nutritional status – and not by CFTR itself. In contrast, the risk associated with CF carriership
appears to be directed to pulmonary disorders being most likely caused by the CFTR gene itself – not
by flanking sequences. In conclusion, the balance between CF carrier risk and CF carrier advantage
appears to be based on the genetic linkage between CFTR as a risk factor for lung disease and
hitchhiking sequences providing an advantage with respect to the nutritional status.
The prominent role of the CFTR gene in determining the course of CF lung disease is not
contradicted by the variability of pulmonary disease severity among patients carrying the same CFTR
mutation genotype: statistical analysis of CF twins and siblings has provided evidence for multiple
factors modulating CF lung disease while the nutritional status was shown to be determined by few
inherited genes besides CFTR (see chapter 3.2.1.2 for details). As introduced in chapter 1.4, the
number of loci involved in shaping a phenotypic trait and the impact of each gene determines
whether the inheritance is perceived as monogenic or polygenic. Thus, the appearance of the trait
"CF-nutritional status" resembles more the condition of a monogenic disease than "CF-pulmonary
status" which has the appearance of a genetically complex trait.
45
FIGURE 45: CF: MONOGENIC DISEASE OR COMPLEX TRAIT ?
The number of loci involved and the impact of each locus on the phenotype determines whether a trait is perceived as
monogenic, influenced by genetic background or polygenic (see chapter 1.4). For CF, wfh% (representing the
nutritional status) was shown to be modified by few inherited factors besides the CFTR gene itself. The pulmonary
status (expressed as FEVPerc) was demonstrated to be modulated by many inherited and environmental factors.
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Cystic fibrosis (CF) is the most frequent disease inherited in an autosomal recessive fashion within the
Caucasian population. Though CF is considered to be a monogenic disorder transmitted by lesions in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene, the disease severity is characterised by a
high degree of variability. This thesis reports on two studies addressing the relative impact of the CFTR
mutation genotype and other inherited factors on the course of CF disease.
Patients participating in the study "rare genotypes and atypical CF" were recruited from the Hannover clinic.
A total of 19 patients were investigated by intestinal current measurements (ICM), nasal potential difference
measurement (NPD) and a pilocarpine iontophoresis sweat test to assess the basic defect, being defined as an
impaired CFTR transmitted Cl
¯
conductance. Mutation analysis of the CFTR gene was done by single strand
conformation polymorphism analysis, direct sequencing and Southern blotting. The two deletions
CFTRdelEx2 and CFTRdelEx2,3 were identified by analysis of genomic DNA. Different residual Cl
¯
conductances, distinguishable by their sensitivity to DIDS and cAMP, were seen by ICM in patients
participating in the study "rare genotypes and atypical CF" but pancreatic sufficiency was found to be
associated with a residual current indicative of CFTR mediated Cl
¯
conductance. The diagnosis of CF was
confirmed by investigation of the basic defect for three patients presenting CF symptoms but lacking evidence
for two CFTR disease causing lesions as judged by extensive mutation screening and, in two of these cases,
sustained by the family history or genetic analysis within the family.
In the "European CF twin and sibling study", disease severity and intrapair discordance for more than 300
patient pairs was quantified by combining nutritional (weight for height %, wfh%) and pulmonary
(FEV1%pred percentiles, FEVPerc) status. A significantly higher concordance of monozygous twins in wfh%
and FEVPerc compared to dizygous patient pairs indicated the impact of non-CFTR genetics on the CF
disease phenotype. 38 patient pairs, selected due to an extreme phenotype while being homozygous for the
most frequent CF causing allele ∆F508, were analysed at candidate gene loci. The typing of polymorphic
markers employing multiwell PCR reactions and continuous direct blotting electrophoresis was optimised.
Significant association of an allele at the marker locus D12S889 with a milder clinical phenotype was
detected. Hence, SCNN1A, encoding for the α-subunit of the amiloride-sensitive sodium channel (ENaC) and
located near D12S889, might modulate CF disease. The analysis of markers within the CFTR linkage group
pointed to the existence of hitchhiking genes which modulate the course of CF disease and thus might be
responsible for a heterozygote advantage among CF carriers. A significant influence on wfh% was detected at
MetH and at D7S495 due to an association of alleles at these loci with a milder phenotype. Candidate genes
for the modulation of the nutritional status located within the investigated region are the receptor tyrosine
kinase MET, the paternally imprinted gene PEG1 and the human homologue of the murine obesity gene LEP.
An association with the phenotype "discordance" in FEVPerc, indicative of a modulation mediated by a gene
encoded in trans, was seen at J3.11. This effect was attributed to a trans encoded factor acting on a responsive
element linked to J3.11, thereby regulating CFTR expression. At the loci D7S514 and D7S495, an association
of alleles with the phenotype "discordant" was seen in wfh%. As serum levels of leptin, encoded for by the
gene LEP located near D7S514 and D7S495, were shown to be in linkage to D2S1788, this marker was
analysed among CF twins and sibs. Sharing of alleles at D2S1788 was significantly associated with higher
concordance in wfh%. Summarising these findings gained by genetic analysis of ∆F508 homozygous CF twins
and siblings, evidence for a role of the ENaC and hitchhiking genes near CFTR in modulating CF disease
severity has been provided.
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6    ZUSAMMENFASSUNG      
Cystische Fibrose (CF) wird durch Mutationen im "Cystic Fibrosis Transmembrane Conductance Regulator"
(CFTR) Gen ausgelöst und ist die häufigste autosomal rezessiv vererbte Erkrankung in der kaukasischen
Bevölkerung. CF wird als monogene Erkrankung angesehen, obwohl der Schweregrad der CF durch eine hohe
Variabilität gekennzeichnet ist. Diese Dissertation beschreibt Ergebnisse zweier Studien, deren Ziel es ist, den
relativen Einfluß des CFTR Mutationsgenotypes neben weiteren vererbten Faktoren auf den Verlauf der
Erkrankung zu erfassen.
19 Patienten der CF Klinik in Hannover wurden im Rahmen der Studie "Seltene Genotypen und atypische
CF" mithilfe der Messung der intestinalen Leitfähigkeit (ICM), der Nasalpotentialdifferenzmessung (NPD)
und dem Pilocarpin-Iontophorese Schweißtest hinsichtlich ihres Basisdefektes untersucht, der sich als Störung
der CFTR vermittelten Chloridleitfähigkeit manifestiert. Mutationsanalyse des CFTR Gens wurde mithilfe der
Analyse von Einzelstrangkonformationspolymorphismen, Direktsequenzierung und Southern-Blot Verfahren
durchgeführt. Die Deletionen CFTRDelEx2 und CFTRDelEx2,3 wurden auf genomischer Ebene
nachgewiesen. Verschiedene Restleitfähigkeiten, die aufgrund ihrer Sensitivität gegenüber DIDS und cAMP
unterschieden werden konnten, wurden mit ICM im Rahmen der Studie "Seltene Genotypen und atypische
CF" beobachtet. Pankreassuffizienz war dabei mit CFTR vermittelter Restleitfähigkeit assoziiert. Durch die
Analyse des Basisdefektes wurde die Diagnose der CF bei drei Patienten bestätigt, für die eine Anwesenheit
von krankheitsauslösenden Läsionen auf beiden CFTR Allelen nach ausführlicher Mutationsanalyse
unwahrscheinlich schien. Für zwei dieser Patienten wurde der genetische Befund durch klinische oder
genetische Analyse der Familie unterstützt.
Im Rahmen der "Europäischen CF Zwillings-und Geschwisterstudie" wurde für mehr als 300 Patientenpaare
der Schweregrad der Erkankung und die Intrapaardiskordanz quantitativ durch einen aus dem
Ernährungsstatus (wfh%) und dem pulmonalen Status (FEVPerc) zusammengesetzten Parameter beschrieben.
Monozygote Zwillinge waren signifikant konkordanter in wfh% und FEVPerc als dizygote Patientenpaare, so
daß der Einfluß des genetischen Hintergrundes auf den Schweregrad der Erkrankung nachgewiesen werden
konnte. Aufgrund eines extremen klinischen Phänotyps wurden 38 Patientenpaare, die für das häufigste CF
verursachende Allel ∆F508 homozygot waren, zur Analyse von Kandidatengenorten ausgewählt. Die
Typisierung polymorpher Marker wurde mithilfe von Multiwell-PCR Reaktionen und kontinuierlicher "Direct
Blotting" Elektrophorese optimiert. Ein Allel des Marker Locus D12S889 war mit einem milden klinischen
Verlauf signifikant assoziiert. SCNN1A, das Gen welches für die α−Untereinheit des Amilorid-sensitiven
Natriumkanals codiert, liegt in der Nähe von D12S889 und könnte daher als Modulator der Erkrankung CF
eine Rolle spielen. Eine Analyse von Markern innerhalb der CFTR Kopplungsgruppe ergab Hinweise auf die
Existenz benachbarter Gene, die den Verlauf der CF beeinflussen und daher auch für den Heterozygotenvorteil
von CF Genträgern verantwortlich sein können. Eine Assoziation von Allelen der Loci MetH und D7S495 mit
einem milden Krankheitsbild konnte für wfh% beschrieben werden. Kandidatengene dieser Region mit einer
möglichen Funktion bei der Modulation des Ernährungsstatus sind MET, PEG1 und LEP. Mit dem Phänotyp
"diskordant" konnte eine Assoziation eines J3.11 Allels in FEVPerc gezeigt werden. Dieser Effekt stellt einen
Hinweis auf den Einfluß eines in trans kodierten Gens dar und wurde auf einen regulatorischen Faktor
zurückgeführt, der durch ein an J3.11 gekoppeltes Element die Expression des CFTR Gens beeinflußt. Eine
Assoziation von Allelen der Loci D7S514 und D7S495 mit dem Phänotyp "diskordant" wurde in wfh%
beobachtet. Da der Serumspiegel von Leptin – einem durch das zwischen D7S514 und D7S495 liegende Gen
LEP kodierten Peptid – mit dem Marker D2S1788 in genetischer Kopplung steht, wurde D2S1788 bei den
ausgewählten Patientenpaaren typisiert. Ein signifikanter Zusammenhang zwischen der Zahl gemeinsamer
D2S1788 Allele und der Konkordanz in wfh% wurde beobachtet. Zusammenfassend läßt sich aus den
Ergebnissen der Typisierung von ∆F508 homozygoten Zwillingen und Geschwistern ein modulierender Einfluß
des ENaC sowie mehrerer Gene aus der CFTR Kopplungsgruppe auf den Schweregrad der Erkrankung
ableiten.
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8.2    List of frequently used abbreviations
ARU arbitrary repeat units 
(for definition see figure 8 in chapter 2.1.2.2.4 on page 43)
CON+ concordant/mild disease 
(for definition see figure 12 in chapter 2.2.1.4 on page 53)
CON- concordant/severe disease 
(for definition see figure 12 in chapter 2.2.1.4 on page 53)
DELTA for definition see figure 10 in chapter 2.2.1.3 on page 48
DfO distance from origin 
(for definition see figure 10 in chapter 2.2.1.3 on page 48)
DIDS 4-4'-diisothiocyanostilbene-2,2'-disulfonic acid
DIS discordant 
(for definition see figure 12 in chapter 2.2.1.4 on page 53)
ENaC amiloride-sensitive epithelial sodium channel
FEV1 forced expiratory volume in 1 s
FEV1% FEV1 as % of predicted FEV1
FEVPerc percentiles for FEV1%pred 
(for definition see figure 10 in chapter 2.2.1.3 on page 48)
IBD identity by descent
IBS identity by state
ICM intestinal current measurement
NPD nasal potential difference
PCR polymerase chain reaction
RFLP restriction fragment length polymorphism
SNP single nucleotide polymorphism
SSCP single strand conformation polymorphism
wfh% weight as % of weight predicted for height centile 
(for definition see figure 10 in chapter 2.2.1.3 on page 48)
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8.3    Appendix to chapter 2
8.3.1    References for primer sequences
Chromosome 12 microsatellite locus near SCNN1A:
Marker locus                GDB accession number / reference                                     
D12889 363193
Chromosome 16 microsatellite locus near SCNN1B, SCNN1C:
Marker locus                GDB accession number / reference                                     
βENaCGT 434736
Chromosome 7 marker loci:
Marker locus                GDB accession number / reference                                     
D7S495 188164
D7S514 188404
D7S525 188521
PON2      — Adkins et al 1993 (modified)
5'-GGCACAAATGATCACTATTTTCTTGAC
5'-GAGTAAATCCACTACATTTCA
MetH Horn et al. 1989
XV-2c Rosenbloom et al. 1989
KM.19 Anwar et al. 1990
TUB20 Dörk et al. 1992
J3.11 Horn et al. 1989
4 kb sequence preceding CFTR exon 1:
    genomic sequence: M58478 (EMBL accession number)
and M58479 (EMBL accession number)
Primers used for amplification: 5'-CAAAGGAAAACATAAGATGCAATTCG
5'-CAAATCCTGAATATCATGTCGCAA
5'-TGTCCAGATGCACTAATTGCGA
5'-GACCCTTGCCTTAGATGTGTCG
5'-TGGCCTGATTTTATTGCCG
5'-TGAAAAAAAGTTTGGAGACAACGC
These primer sequences were chosen based on the algorithm of Griffais  et al (1991).
CFTR exons and flanking intron sequences:
Unless noted differently in Dörk et al. 1994b, the primers described by Zielenski et al. 1991 were
used for amplification of the CFTR exons and flanking intron sequences. For mutation screening of
patients D, I, P, Q, R and S, the CFTR exons 1, 2, 3, 5, 6a, 6b, 8, 12, 14a, 14b, 15, 16, 18, 23, 24
were analysed by SSCP (see tables 5 and 10 for details). The following primer sequences were used
to amplify the respective exons and flanking intron sites:
Exon          primer sequences                           
1 5'-GGTCTTTGGCATTAGGAGCTTG 5'-ACACGCCCTCCTCTTTCGTG
2 5'-CATAATTTTCCATATCGGAG 5'-TAGCCACCATACTTGGCTCC
3 5'-CTTGGGTTAATCTCCTTGG 5'-ATTCACCAGATTTCGTAGTC
5 5'-ATTTCTGCCTAGATGCTGGG 5'-AACTCCGCCTTTCCAGTTG
6a 5'-GTGCTCAGAACCACGAAGTG 5'-GGGATGACAGATCTAGACTC
6b 5'-GGAATGAGTCTGTACAGCG 5'-GAGGTGGAAGTCTACCATG
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8 5'-AAGATGTAGCACAATGAGAG 5'-GTGAGTGATCCTCCTTCCAG
12 5'-GTGAATCGATGTGGTGACCA 5'-CTGGTTTAGCATGAGGCGGT
14a 5'-AAAAGGTATGCCACTGTTAA 5'-GTATACATCCCCAAACTATCT
14b 5'-GAACACCTAGTACAGCTGC                5'-CACCTCACCCAACTAATGGTCATC
15 5'-GTGCATGCTCTTCTAATGC 5'-AAGGCACATGCCTCTGTGCA
16 5'-CAGAGAAATTGGTCGTTAC 5'-CTAAATGTGGGATTGCCTC
18 5'-GTAGATGCTGTGATGAACTG 5'-AGTGGCTACTCATGAGAAGG
23 5'-AGCTGATTGTGCGTAACGC 5'-TAAAGCTGGATGGCTGTATG
24 5'-GGACACAGCAGTTAAATGTG             5'-CCAATTCCATGAGGTGACTGTCCC
8.3.2    Common reagents
Common reagents:
SSC (20×) 3M NaCl, 0.3M NaCitrat
STE 50mM Tris-HCl pH 7.5, 100mM NaCl, 1mM Na2EDTA
TBE (10×) 0.9M Tris-HCl pH 8.3, 0.9M Boric acid, 0.02M Na 2EDTA
TE 10mM Tris-HCl pH 8.0, 1mM Na2EDTA
Meyler buffer 126.2 mM Na+, 114.3 mM Cl-, 20.2 mM HCO3-, 
0.3 mM HPO42-, 0.4 mM H2PO4-, 10 mM Hepes, pH7.4
Reagents provided by manufacturers:
TaqPolymerase reaction buffer (Invitek):
670mM Tris-HCl pH 8.8; 160 mM (NH4)2SO4, 0.1%Tween20
DapGoldstar TaqPolymerase reaction buffer (Eurogentec):
750mM Tris-HCl pH 9.0; 200mM (NH4)2SO4, 0.1%Tween20
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8.3.3    Regression formulas for height, weight and FEV1%pred
percentiles
All centiles were described by areas defined by a polynomial equation z = f(x,y). Censoring of data
was unavoidable for some patients with unusual combination of extreme values in age and pulmonary
function or weight and height, because the regression curves resulted in implausible percentiles of
larger than 100 or lower than 0. As negative values or values of more than 100 are not defined for
percentiles, these patients could not be described with the regression parameters employed and thus
were excluded from further analysis.
In detail, the following calculation parameters were used:
length centiles for females:
x = age [years], y = length [cm], area defines z= length centiles
z=a00+a01*y+a02*y^2+a03*y^3+a04*y^4+a05*y^5+a10*x+a11*x*y+a12*x*y^2+a13*x*y^3+a14*x*y^4+a15*x*y^
5+a20*x^2+a21*x^2*y+a22*x^2*y^2+a23*x^2*y^3+a24*x^2*y^4+a25*x^2*y^5+a30*x^3+a31*x^3*y+a32*x^3*y^
2+a33*x^3*y^3+a34*x^3*y^4+a35*x^3*y^5+a40*x^4+a41*x^4*y+a42*x^4*y^2+a43*x^4*y^3+a44*x^4*y^4+a45*
x^4*y^5+a50*x^5+a51*x^5*y+a52*x^5*y^2+a53*x^5*y^3+a54*x^5*y^4+a55*x^5*y^5
a00 = 48,3151
a01 = 0,34407
a02 = -0,0151914
a03 = 0,000340005
a04 = -0,00000346078
a05 = 0,0000000131611
a10 = 22,8933
a11 = 0,0867497
a12 = -0,00173392
a13 = 0,0000373274
a14 = -0,000000590913
a15 = 0,00000000343674
a20 = -4,20072
a21 = -0,00833215
a22 = -0,000819702
a23 = 0,0000290106
a24 = -0,000000306396
a25 = 0,000000000996832
a30 = 0,432829
a31 = 0,00350085
a32 = 0,00000752944
a33 = -0,00000214429
a34 = 0,0000000288737
a35 = -0,000000000105779
a40 = -0,020147
a41 = -0,000318564
a42 = 0,00000597415
a43 = -0,0000000189258
a44 = -0,000000000292056
a45 = 1,26083E-12
a50 = 0,000338875
a51 = 0,00000783121
a52 = -0,000000206802
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a53 = 0,00000000247261
a54 = -1,57831E-11
a55 = 5,64011E-14
length centiles for males:
x = age [years], y = length [cm], area defines z= length centiles
'z=a00+a01*y+a02*y^2+a03*y^3+a04*y^4+a10*x+a11*x*y+a12*x*y^2+a13*x*y^3+a14*x*y^4+a20*x^2+a21*x^2
*y+a22*x^2*y^2+a23*x^2*y^3+a24*x^2*y^4+a30*x^3+a31*x^3*y+a32*x^3*y^2+a33*x^3*y^3+a34*x^3*y^4+a40
*x^4+a41*x^4*y+a42*x^4*y^2+a43*x^4*y^3+a44*x^4*y^4+a50*x^5+a51*x^5*y+a52*x^5*y^2+a53*x^5*y^3+a54
*x^5*y^4
a00 = 50,4847
a01 = 0,185647
a02 = -0,00473329
a03 = 0,0000599715
a04 = -0,000000243954
a10 = 19,3204
a11 = 0,194157
a12 = -0,00197079
a13 = -0,0000144381
a14 = 0,000000229552
a20 = -2,44298
a21 = -0,0725234
a22 = 0,00102231
a23 = -0,0000000974229
a24 = -0,0000000532814
a30 = 0,169349
a31 = 0,00985
a32 = -0,000145367
a33 = 0,000000182424
a34 = 0,0000000062406
a40 = -0,00437449
a41 = -0,000522302
a42 = 0,00000731626
a43 = -0,00000000301641
a44 = -0,000000000371049
a50 = 0,0000160633
a51 = 0,00000933779
a52 = -0,000000114827
a53 = -0,000000000259881
a54 = 8,51463E-12
weight centiles for females:
x = age [years], y = length [cm], area defines z= weight centiles
z=a00 + a01 * y + a02 * y ^ 2 + a03 * y ^ 3 + a04 * y ^ 4 + a05 * y ^ 5 + a10 * x + a11 * x * y + a12 * x * y ^ 2 +
a13 * x * y ^ 3 + a14 * x * y ^ 4 + a15 * x * y ^ 5 + a20 * x ^ 2 + a21 * x ^ 2 * y + a22 * x ^ 2 * y ^ 2 + a23 * x ^ 2 *
y ^ 3 + a24 * x ^ 2 * y ^ 4 + a25 * x ^ 2 * y ^ 5 + a30 * x ^ 3 + a31 * x ^ 3 * y + a32 * x ^ 3 * y ^ 2 + a33 * x ^ 3 * y
^ 3 + a34 * x ^ 3 * y ^ 4 + a35 * x ^ 3 * y ^ 5 + a40 * x ^ 4 + a41 * x ^ 4 * y + a42 * x ^ 4 * y ^ 2 + a43 * x ^ 4 * y ^
3 + a44 * x ^ 4 * y ^ 4 + a45 * x ^ 4 * y ^ 5 + a50 * x ^ 5 + a51 * x ^ 5 * y + a52 * x ^ 5 * y ^ 2 + a53 * x ^ 5 * y ^ 3
+ a54 * x ^ 5 * y ^ 4 + a55 * x ^ 5 * y ^ 5
a00 = 2,71691
a01 = 0,103324
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a02 = -0,00521835
a03 = 0,000125116
a04 = -0,00000137348
a05 = 0,00000000560491
a10 = 5,26919
a11 = -0,0582872
a12 = 0,00646361
a13 = -0,000179684
a14 = 0,00000214365
a15 = -0,00000000909209
a20 = -1,13665
a21 = 0,0652821
a22 = -0,00510643
a23 = 0,000137522
a24 = -0,00000160224
a25 = 0,00000000667259
a30 = 0,132086
a31 = -0,012776
a32 = 0,000966179
a33 = -0,0000258209
a34 = 0,000000297988
a35 = -0,00000000122846
a40 = -0,00611844
a41 = 0,000943505
a42 = -0,0000687829
a43 = 0,0000018189
a44 = -0,0000000208099
a45 = 8,51988E-11
a50 = 0,0000971125
a51 = -0,0000230746
a52 = 0,00000162686
a53 = -0,0000000425435
a54 = 0,000000000482632
a55 = -1,96363E-12
weight centiles for males:
x = age [years], y = length [cm], area defines z= weight centiles
z= a00 + a01 * y + a02 * y ^ 2 + a03 * y ^ 3 + a04 * y ^ 4 + a05 * y ^ 5 + a10 * x + a11 * x * y + a12 * x * y ^ 2 +
a13 * x * y ^ 3 + a14 * x * y ^ 4 + a15 * x * y ^ 5 + a20 * x ^ 2 + a21 * x ^ 2 * y + a22 * x ^ 2 * y ^ 2 + a23 * x ^ 2 *
y ^ 3 + a24 * x ^ 2 * y ^ 4 + a25 * x ^ 2 * y ^ 5 + a30 * x ^ 3 + a31 * x ^ 3 * y + a32 * x ^ 3 * y ^ 2 + a33 * x ^ 3 * y
^ 3 + a34 * x ^ 3 * y ^ 4 + a35 * x ^ 3 * y ^ 5 + a40 * x ^ 4 + a41 * x ^ 4 * y + a42 * x ^ 4 * y ^ 2 + a43 * x ^ 4 * y ^
3 + a44 * x ^ 4 * y ^ 4 + a45 * x ^ 4 * y ^ 5 + a50 * x ^ 5 + a51 * x ^ 5 * y + a52 * x ^ 5 * y ^ 2 + a53 * x ^ 5 * y ^ 3
+ a54 * x ^ 5 * y ^ 4 + a55 * x ^ 5 * y ^ 5
a00 = 3,0688
a01 = 0,0999505
a02 = -0,00413342
a03 = 0,0000958518
a04 = -0,00000103228
a05 = 0,00000000408829
a10 = 4,4228
a11 = 0,011136
a12 = -0,000399856
a13 = 0,0000155581
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a14 = -0,000000254645
a15 = 0,00000000163697
a20 = -0,620168
a21 = 0,0304986
a22 = -0,0016539
a23 = 0,0000391129
a24 = -0,000000397227
a25 = 0,00000000133317
a30 = 0,0567971
a31 = -0,00793663
a32 = 0,000415316
a33 = -0,00000988668
a34 = 0,000000102572
a35 = -0,000000000363985
a40 = -0,00231202
a41 = 0,000684378
a42 = -0,0000334448
a43 = 0,000000776112
a44 = -0,00000000796942
a45 = 0,000000000028344
a50 = 0,0000421339
a51 = -0,0000184095
a52 = 0,000000839923
a53 = -0,0000000187932
a54 = 0,000000000188535
a55 = -6,58876E-13
FEVPerc – centiles for FEV1%pred:
x = FEV1%pred (defined by Knudson et al. 1983), y = age [years], area defines z=FEVPerc
z= 54,2282 - 6,48596 * y + 0,160673 * y ^ 2 - 5,79524 * x + 0,686198 * x * y - 0,0183229 * x * y ^ 2 + 0,229493 * x
^ 2 - 0,0267976 * x ^ 2 * y + 0,000755553 * x ^ 2 * y ^ 2 - 0,00399186 * x ^ 3 + 0,000423935 * x ^ 3 * y -
0,000010645 * x ^ 3 * y ^ 2 + 0,0000303584 * x ^ 4 - 0,00000261721 * x ^ 4 * y + 0,0000000507948 * x ^ 4 * y ^ 2 -
0,0000000785657 * x ^ 5 + 0,00000000480301 * x ^ 5 * y - 3,86546E-11 * x ^ 5 * y ^ 2
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